

(19) World Intellectual Property Organization  
International Bureau(43) International Publication Date  
29 May 2008 (29.05.2008)

PCT

(10) International Publication Number  
**WO 2008/061781 A1**

## (51) International Patent Classification:

C07D 285/08 (2006.01) A61P 25/16 (2006.01)  
A61K 31/433 (2006.01) A61P 25/28 (2006.01)

## (21) International Application Number:

PCT/EP2007/010192

## (22) International Filing Date:

22 November 2007 (22.11.2007)

## (25) Filing Language:

English

## (26) Publication Language:

English

## (30) Priority Data:

0623258.1 22 November 2006 (22.11.2006) GB

(71) Applicant (for all designated States except US): NV  
REMYND [BE/BE]; Gaston Geenslaan 1, B-3001 Leuven  
(BE).

## (72) Inventors; and

(75) Inventors/Applicants (for US only): GRIFFIOEN,  
Gerard [NL/BE]; Zandveldstraat 3, B-3210 Linden  
(BE). WERA, Stefaan [BE/BE]; Hoegaardsesteenweg  
78, B-3360 Bierbeek (BE). DUHAMEL, Hein, Roger  
[BE/BE]; Edeldzangerslaan 56 bus 10, B-3010 Kessel-Lo  
(BE). VAN DAMME, Niele [BE/BE]; Tiensevest 49 bus  
2, B-3010 Kessel-Lo (BE). GOMME, Ellen [BE/BE];  
Hoegaardsesteenweg 72, B-3360 Opvelp (BE).

(74) Agents: BIRD, William, E. et al.; Bird Goën & Co., Klein  
Dalenstraat 42A, B-3020 Winksele (BE).

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH,  
CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG,  
ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL,  
IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK,  
LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW,  
MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL,  
PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY,  
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA,  
ZM, ZW.

(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, GH,  
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,  
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,  
FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL,  
PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM,  
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


## Declaration under Rule 4.17:

— of inventorship (Rule 4.17(iv))

## Published:

— with international search report  
— before the expiration of the time limit for amending the  
claims and to be republished in the event of receipt of  
amendments

(54) Title: THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES



(57) Abstract: The invention provides novel 1,2,4-thiadiazole derivatives useful for preventing or treating an  $\alpha$ -synucleopathy such as Parkinson's disease, as well as pharmaceutical compositions including them as biologically active ingredients, and methods for manufacturing them.

WO 2008/061781 A1

## THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES

### FIELD OF THE INVENTION

5           The present invention relates to novel thiadiazole derivatives useful for treating certain neurological disorders characterised by cytotoxic  $\alpha$ -synuclein amyloidogenesis. The invention further relates to methods of treatment or prevention of such neurological disorders by the administration of a pharmaceutical composition, comprising one or more thiadiazole derivatives in an amount which alleviates or prevents the cytotoxic  
10           properties of  $\alpha$ -synuclein. The invention further relates to methods of preparing novel thiadiazole derivatives, as well as certain classes of intermediates useful in such preparation.

### BACKGROUND OF THE INVENTION

15            $\alpha$ -Synuclein is a neuronal protein which originally has been associated with neuronal plasticity during Zebra finch song learning. Although its role at the molecular level is at present largely elusive it appears to have lipid bi-layer (or membrane) binding properties important for preserving proper transport of neurotransmitter vesicles to the axonal ends of neurons presumably to ensure proper signalling at the synapse.

20           Apart from its physiological role in brain cells, human  $\alpha$ -synuclein also possesses pathological features that underlies a plethora of neurodegenerative diseases including Parkinson's disease, diffuse Lewy body disease, traumatic brain injury, amyotrophic lateral sclerosis, Niemann-Pick disease, Hallervorden-Spatz syndrome, Down syndrome, neuroaxonal dystrophy, multiple system atrophy and  
25           Alzheimer's disease. These neurological disorders are characterised by the presence of insoluble  $\alpha$ -synuclein polymers or aggregates usually residing within neuronal cells, although in the case of Alzheimer's disease  $\alpha$ -synuclein (or proteolytic fragments thereof) constitutes the non-amyloid component of extracellular " amyloid- $\beta$  plaques ". It is widely believed that the amyloidogenic properties  $\alpha$ -synuclein disrupt cellular  
30           integrity leading to dysfunctioning or death of affected neurons resulting in cognitive and/or motoric decline as it is found in patients suffering from such diseases. The aggregation of  $\alpha$ -synuclein is at present very poorly defined, but constitutes most likely a multi-step process wherein self-polymerization of  $\alpha$ -synuclein into insoluble aggregates is preceded by the formation of soluble protofibrils of  $\alpha$ -synuclein  
35           monomers. Self-association may be triggered by the formation of alternative conformations of  $\alpha$ -synuclein monomers with high propensity to polymerize. Several studies using neuronal cell lines or whole animals have shown that formation of

reactive oxygen species (hereinafter abbreviated as ROS) appear to stimulate noxious  $\alpha$ -synuclein amyloidogenesis. For instance paraquat (an agent stimulating ROS formation within the cell) has been recognized as a stimulator of  $\alpha$ -synuclein aggregation. Like in animals, exposure to paraquat is believed to induce the formation of synuclein inclusions, and consequently neurodegeneration, especially of dopaminergic neurons in humans. Dopaminergic neurons appear to be particularly sensitive because the concurrent dopamine metabolism may on the one hand contribute significantly to the oxidative stress load but may on the other hand result in kinetic stabilisation of highly toxic protofibrillar  $\alpha$ -synuclein species by dopamine (or its metabolic derivatives). Parkinson's disease is characterised by a selective loss of dopaminergic *substantia nigra* cells and therefore treatment of animals (or neuronal cells) with paraquat is a common well-accepted experimental set-up for studying synucleopathies, in particular Parkinson's disease.

Apart from ROS, mutations in the coding region of the  $\alpha$ -synuclein gene have also been identified as stimulators of self-polymerization resulting in early disease onset as it is observed in families afflicted by such mutations. Finally, increased expression of  $\alpha$ -synuclein also promotes early disease onset as evidenced by a duplication or triplication of the  $\alpha$ -synuclein gene in the genome of some individuals. The molecular mechanism by which  $\alpha$ -synuclein self-association triggers cellular degeneration is at present largely unknown. Although it has been speculated that insoluble aggregates affect cellular integrity, it has recently been suggested that soluble protofibrillar intermediates of the aggregation process are particularly toxic for the cell as opposed to mature insoluble fibrils which may be inert end-products or may even serve as cytoprotective reservoirs of otherwise harmful soluble species. Therapeutic attempts to inhibit formation of insoluble aggregates may therefore be conceptually wrong, possibly even promoting disease progress.

While the identification of pathological  $\alpha$ -synuclein mutations unequivocally revealed a causative factor of a plethora of neurodegenerative disorders, treatments ensuring suppression of toxic  $\alpha$ -synuclein amyloidogenesis are presently not available. Only symptomatic treatments of Parkinson's disease exist, which aim e.g. at increasing dopamine levels in order to replenish its lowered level due to degeneration of dopaminergic neurons, for instance by administering L-DOPA or inhibitors of dopamine breakdown. Although such treatments suppress disease symptoms to some extent, they are only temporarily effective and certainly do not slow down ongoing neuronal degeneration.

Thus there is a need in the art for designing new drugs for therapeutic treatments that target the underlying molecular mechanism of  $\alpha$ -synuclein related pathologies in order to reduce neuronal cell death and/or degeneration.


WO 99/51584 discloses 5-piperazinyl-1,2,4-thiadiazoles as inhibitors of proton pump  $H^+/K^+$ -ATPase and therefor useful in the treatment of peptic ulcer. However these compounds are not suggested for use in the prevention or treatment of neuro-degenerative disorders.

WO 2006/002981 teaches thiazole and thiadiazole derivatives including a propynoyl linker for use in the field of pain relief, through acting on the mGluR5-receptor regulation.


### SUMMARY OF THE INVENTION

The present invention relates to different classes of 1,2,4-thiadiazole derivatives that have been shown to effectively counteract or inhibit the toxic properties of  $\alpha$ -synuclein . Administration of these compounds to patients suffering from a neurodegenerative disease characterised by noxious  $\alpha$ -synuclein amyloidogenesis therefore constitutes an effective therapeutic and/or prophylactic method of treatment.

According to a first aspect, the present invention provides a first class of novel 1,2,4-thiadiazole derivatives having the structural formula (A):




or, more specifically, the structural formula (B):





wherein the divalent group schematically represented by the structural formula (A')



includes an optionally mono-substituted or poly-substituted, saturated or partly unsaturated heterocyclic ring with at least two nitrogen atoms in the said heterocyclic ring

5 and with a total of 5 to 7 atoms in the said heterocyclic ring,

and further wherein:

- each  $R_6$  is a substituent on a carbon atom of said heterocyclic ring and is independently selected from the group consisting of oxo, aryl and  $C_{1-4}$  alkyl, or two substituents  $R_6$  on the same carbon atom of said heterocyclic ring together form a heterocyclic or homocyclic ring system;
- $n$  is selected from the group consisting of 0, 1, 2 and 3;
- $R_1$ ,  $R_2$ ,  $R_3$ ,  $R_4$  and  $R_5$  are each independently selected from the group consisting of hydrogen,  $C_{1-4}$  alkyl,  $C_{1-4}$  alkoxy, aryl, aryloxy, aryl- $C_{1-4}$  alkyloxy, heteroaryloxy, benzenesulfonate, amino, hydroxy, nitro, trifluoromethyl, trifluoromethoxy and halogen, or any two adjacent substituents selected from the group consisting of  $R_1$ ,  $R_2$ ,  $R_3$ ,  $R_4$  and  $R_5$  form, together with the phenyl ring carbon atoms to which they are attached, a saturated or unsaturated ring fused to said phenyl ring and having from 5 to 7 ring members, said saturated or unsaturated ring optionally comprising one or two oxygen atoms and being optionally substituted with one or more halogen atoms;
- $R_7$ ,  $R_8$ ,  $R_9$ ,  $R_{10}$  and  $R_{11}$  are each independently selected from the group consisting of hydrogen,  $C_{1-10}$  alkyl,  $C_{1-6}$  alkoxy, aryl, hydroxy, acyl (in particular acetyl), nitro, trifluoromethyl, trifluoromethoxy, mono- $C_{1-6}$ alkylamino, di- $C_{1-6}$ alkyl-amino,  $C_{1-6}$  alkylcarbonyloxy,  $C_{1-6}$  alkylthio, cyano, heterocyclic, benzyloxy, dialkylaminosulfonyl and halogen; or any two adjacent substituents selected from the group consisting of  $R_7$ ,  $R_8$ ,  $R_9$ ,  $R_{10}$  and  $R_{11}$  form, together with the phenyl ring carbon atoms to which they are attached, a saturated or unsaturated ring fused to said phenyl ring and having from 5 to 7 ring members, said saturated or unsaturated ring optionally comprising one or two heteroatoms independently selected from the group consisting of oxygen, sulfur and


nitrogen; and each of said C<sub>1-6</sub> alkyl, C<sub>1-6</sub> alkoxy, aryl or fused ring is optionally substituted with one or more halogen atoms;

- R<sub>12</sub> and R<sub>13</sub> are each independently selected from the group consisting of hydrogen, C<sub>1-6</sub> alkyl, aryl-C<sub>1-4</sub> alkyl, aryl and N-containing heterocyclic rings, or R<sub>12</sub> and R<sub>13</sub> together form a C<sub>3-6</sub> cycloalkyl or heterocyclic group; and

- X is a linking moiety selected from the group consisting of a single bond; -C(=O)-; -S(=O)<sub>2</sub>-; divalent saturated, ethylenically unsaturated or acetylenically unsaturated non-cyclic hydrocarbon groups comprising from 1 to 8 atoms (preferably from 1 to 6 atoms) in the main chain, each of said atoms in the main chain being independently selected from the group consisting of carbon, nitrogen and sulfur, and each of said carbon atoms in the main chain being optionally substituted with one or more substituents independently selected from the group consisting of oxo, thioxo, C<sub>1-4</sub> alkyl and halogen, provided that the number of heteroatoms in the main chain of said divalent saturated or unsaturated non-cyclic hydrocarbon group is 0, 1 or 2; and divalent saturated or unsaturated heterocyclic groups comprising from 2 to 6 carbon atoms and from 1 to 3 heteroatoms independently selected from the group consisting of oxygen, sulfur and nitrogen in the said heterocyclic group; or X together with one of R<sub>7</sub> and R<sub>11</sub> forms a saturated or unsaturated ring having from 5 to 7 ring members and being fused to the phenyl ring bearing said one of R<sub>7</sub> and R<sub>11</sub>, said saturated or unsaturated ring optionally comprising one or two heteroatoms independently selected from the group consisting of oxygen, sulfur and nitrogen, and said saturated or unsaturated ring optionally comprising one or more substituents independently selected from the group consisting of C<sub>1-4</sub> alkyl and trifluoromethyl;

or a stereoisomer or solvate thereof, or a pharmaceutically acceptable salt thereof.

The present invention further provides a second class of novel 1,2,4-thiadiazole derivatives having the structural formula (C):




wherein X, R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub>, R<sub>7</sub>, R<sub>8</sub>, R<sub>9</sub>, R<sub>10</sub>, R<sub>11</sub>, R<sub>12</sub> and R<sub>13</sub> are as defined with respect to formulae (A) and (B), and further wherein:


- n is an integer from 0 to 11,
- R<sub>14</sub>, R<sub>15</sub>, R and R' are each independently selected from hydrogen and C<sub>1-4</sub> alkyl,

or a stereoisomer or a solvate thereof, or a pharmaceutically acceptable salt thereof.

The present invention further provides a third class of novel 1,2,4-thiadiazole derivatives having the structural formula (D):




or more specifically the structural formula (E):



wherein X, R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub>, R<sub>6</sub>, R<sub>12</sub> and R<sub>13</sub> and n are as defined with respect to formulae (A) and (B), and further wherein Het<sup>1</sup> is a heteroaryl group optionally substituted with one or more substituents independently selected from the group consisting of halogen, trifluoromethyl, nitro, cyano and C<sub>1-10</sub> alkyl.

The present invention further provides a fourth class of novel 1,2,4-thia-diazole derivatives having the structural formula (F):



wherein X, R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub>, R<sub>6</sub>, R<sub>12</sub>, R<sub>13</sub>, R, R', R<sub>14</sub>, R<sub>15</sub> and n are as defined with respect to formula (C), and further wherein Het<sup>1</sup> is a heteroaryl group.

Particular embodiments of the present invention relate to 1,2,4-thiadiazole derivatives belonging to the third class and fourth class defined above, wherein Het<sup>1</sup> is selected from the group consisting of furyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, isoxazolyl, isothiazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, pyranlyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, 1,2,3-triazinyl, 1,2,4-triazinyl, 1,3,5-triazinyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, tetrazolyl, thiadiazinyl, indolyl, isoindolyl, benzofuryl, benzothienyl, benzothiophenyl, indazolyl, benzimidazolyl, benzthiazolyl, benzisothiazolyl, benzisoxazolyl, purinyl, quinazolinyl, quinoliziny, quinoliny, isoquinoliny, quinoxaliny, naphthyridiny, pteridinyl, carbazolyl, azepiny, diazepiny, acridiny, pyrroliny, pyrazoliny, indoliny, pyrrolidinyl, piperidinyl, piperaziny, azepiny, diazepiny, morpholiny, thiomorpholiny, oxazolidiny, oxazoliny, oxazepiny, aziridinyl and tetrahydrofurany. Due to the limited number of heteroaryl compounds commercially or readily available for the production of 1,2,4-thiadiazole derivatives having the structural formulae (D), (E) and (F), Het<sup>1</sup> may be preferably selected from the group consisting of thienyl, furyl, pyrrolyl and pyridyl.

Compounds belonging to all classes (i.e. structural formulae A, B, C, D, E and F) of the 1,2,4-thiadiazole derivatives of the present invention are capable of inhibiting or significantly reducing  $\alpha$ -synuclein-instigated loss of neuronal cell integrity.

According to a second aspect, therefore the present invention provides each class of these compounds for use as active ingredients in the manufacture of medicaments, more particularly for use in the treatment of  $\alpha$ -synucleopathies in particular in humans. According to this second aspect, the invention also provides pharmaceutical compositions comprising an effective amount of one or more of such 1,2,4-thiadiazole derivatives, said pharmaceutical compositions being useful for the prevention and/or treatment of an  $\alpha$ -synucleopathy such as, but not limited to, Parkinson's disease, diffuse Lewy body disease, multiple system atrophy and Alzheimer's disease, preferably in humans. Accordingly, the present invention also

relates to the treatment and/or prevention of  $\alpha$ -synucleopathies, such as, but not limited to Parkinson's disease, diffuse Lewy body disease, multiple system atrophy and Alzheimer's disease by the administration, to a patient in need thereof, of a therapeutically effective amount of one or more of such 1,2,4-thiadiazole derivatives. In a third aspect, the present invention provides methods for preparing such 1,2,4-thiadiazole derivatives in good yield via synthetic routes including a limited number of steps and starting from commercially available materials or easily obtainable analogues thereof.

## 10 DEFINITIONS

As used herein with respect to a substituting group, and unless otherwise stated, the term "C<sub>1-4</sub> alkyl" means straight and branched chain saturated acyclic hydrocarbon monovalent groups having from 1 to 4 carbon atoms such as, for example, methyl, ethyl, propyl, n-butyl, 1-methylethyl (isopropyl), 2-methylpropyl (isobutyl) and 1,1-dimethylethyl (ter-butyl). By analogy, the term "C<sub>1-6</sub> alkyl" refers to such radicals having from 1 to 6 carbon atoms, including 2-methylbutyl, n-pentyl, dimethylpropyl, n-hexyl, 2-methylpentyl, 3-methylpentyl, and the like. By analogy, the term "C<sub>1-10</sub> alkyl" refers to such radicals having from 1 to 10 carbon atoms, including n-heptyl, n-octyl, n-nonyl, n-decyl and the like.

As used herein with respect to a linking group, and unless otherwise stated, the term "C<sub>1-6</sub> alkylene" means a divalent hydrocarbon radical corresponding to the above defined C<sub>1-6</sub> alkyl, such as methylene, bis(methylene), tris(methylene), tetramethylene, hexamethylene and the like.

As used herein with respect to a substituting group, and unless otherwise stated, the term "C<sub>3-6</sub> cycloalkyl" means a mono- or polycyclic saturated hydrocarbon monovalent group having from 3 to 6 carbon atoms, such as for instance cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and the like.

As used herein with respect to a substituting group, and unless otherwise stated, the term "aryl" designate any mono- or polycyclic aromatic monovalent hydrocarbon group having from 6 up to 30 carbon atoms such as but not limited to phenyl, naphthyl, anthracenyl, phenanthracenyl, fluoranthenyl, chrysenyl, pyrenyl, biphenyl, terphenyl, picenyl, indenyl, biphenyl, indacenyl, benzocyclobutenyl, benzocyclooctenyl and the like, including fused benzo-C<sub>4-8</sub> cycloalkyl groups such as, for instance, indanyl, tetrahydronaphthyl, fluorenyl and the like, all of the said radicals being optionally substituted with one or more substituents independently selected from the group consisting of halogen, amino, trifluoromethyl, hydroxyl, sulfhydryl and nitro, such as for instance 4-fluorophenyl, 4-chlorophenyl, 3,4-dichlorophenyl, 4-

cyanophenyl, 2,6-dichlorophenyl, 2-fluorophenyl, 3-chlorophenyl, 3,5-dichlorophenyl and the like.

As used herein with respect to a substituting group, and unless otherwise stated, the terms "C<sub>1-4</sub> alkoxy", "C<sub>1-6</sub> alkoxy" and "aryloxy", refer to substituents wherein a carbon atom of a C<sub>1-4</sub> alkyl, respectively a C<sub>1-6</sub> alkyl or an aryl group (each of them such as defined herein), is attached to an oxygen atom through a single bond such as, but not limited to, methoxy, ethoxy, propoxy, butoxy, pentoxy, isopropoxy, sec-butoxy, tert-butoxy, isopentoxy, phenoxy, and the like.

As used herein with respect to a substituting group, and unless otherwise stated, the terms "C<sub>1-6</sub> alkylthio", refer to substituents wherein a carbon atom of a C<sub>1-6</sub> alkyl group (such as defined herein), is attached to a sulfur atom through a single bond such as, but not limited to, methylthio or ethylthio.

As used herein with respect to a substituent, and unless otherwise stated, the term "acyl" broadly refers to a carbonyl (oxo) group being adjacent to a C<sub>1-6</sub> alkyl, aryl or heterocyclic group, all of them being such as herein defined; representative examples of acyl include, but are not limited to, acetyl, pivaloyl, benzoyl, naphthoyl and the like.

As used herein with respect to a substituent, and unless otherwise stated, the term "mono-C<sub>1-6</sub> alkylamino" means that one C<sub>1-6</sub> alkyl group (such as defined herein) is attached to a nitrogen atom through a single bond such as, but not limited to, methylamino, ethylamino, isopropylamino, *n*-butylamino and *tert*-butylamino. As used herein with respect to a substituent, and unless otherwise stated, the term "di-C<sub>1-6</sub> alkylamino" means that two C<sub>1-6</sub> alkyl groups (such as defined herein) are attached to a nitrogen atom through a single bond such as, but not limited to, dimethylamino, diethylamino, diisopropylamino, di-*n*-butylamino and di-*tert*-butylamino.

As used herein, e.g. with respect to a substituent or a combination of substituents, and unless otherwise stated, the term "homocyclic" means a mono- or polycyclic, saturated or mono-unsaturated or polyunsaturated hydrocarbon radical having from 4 up to 15 carbon atoms but including no heteroatom in the said ring.

As used herein with respect to a substituent, and unless otherwise stated, the term "heterocyclic" means a mono- or polycyclic, saturated or mono-unsaturated or polyunsaturated monovalent hydrocarbon radical having from 2 up to 15 carbon atoms and including one or more heteroatoms in one or more heterocyclic rings, each of said rings having from 3 to 10 atoms (and optionally further including one or more heteroatoms attached to one or more carbon atoms of said ring, for instance in the form of a carbonyl (oxo) or thiocarbonyl group, and/or to one or more heteroatoms of said ring, for instance in the form of a sulfone, sulfoxide, N-oxide, phosphate,

phosphonate or selenium oxide group), each of said heteroatoms being independently selected from the group consisting of nitrogen, oxygen, sulfur, selenium and phosphorus, also including radicals wherein a heterocyclic ring is fused to one or more aromatic hydrocarbon rings for instance in the form of benzo-fused, dibenzo-fused and naphtho-fused heterocyclic radicals; within this definition are included heterocyclic radicals such as, but not limited to, diazepinyl, oxadiazinyl, thiadiazinyl, dithiazinyl, triazolonyl, diazepinonyl, triazepinyl, triazepinonyl, tetrazepinonyl, benzoquinolonyl, benzothiazinyl, benzothiazinonyl, benzoxathiinyl, benzodioxinyl, benzodithiinyl, benzoxazepinyl, benzothiazepinyl, benzodiazepinyl, benzodioxepinyl, benzodithiepinyl, benzoxazocinyl, benzothiazocinyl, benzo-diazocinyl, benzoxathiocinyl, benzodioxocinyl, benzotrioxepinyl, benzoxathiazepinyl, benzoxadiazepinyl, benzothiadiazepinyl, benzotriazepinyl, benzoxathiepinyl, benzotriazinonyl, benzoxazolinonyl, azetidinonyl, azaspiroundecyl, dithiaspirodecyl, selenazinyl, selenazolyl, selenophenyl, hypoxanthinyl, azahypoxanthinyl, bipyrazinyl, bipyridinyl, oxazolidinyl, diselenopyrimidinyl, benzodioxocinyl, benzopyrenyl, benzopyranonyl, benzophenazinyl, benzoquinoliziny, dibenzocarbazolyl, dibenzoacridinyl, dibenzophenazinyl, dibenzothiepinyl, dibenzoxepinyl, dibenzopyranonyl, dibenzoquinoxaliny, dibenzothiazepinyl, dibenzisoquinoliny, tetraazaadamantyl, thiatetraazaadamantyl, oxauracil, oxazinyl, dibenzothiophenyl, dibenzofuranyl, oxazoliny, oxazolonyl, azaindolyl, azolonyl, thiazoliny, thiazolonyl, thiazolidinyl, thiazanyl, pyrimidonyl, thiopyrimidonyl, thiamorpholiny, azlactonyl, naphthindazolyl, naphthindolyl, naphthothiazolyl, naphthothioxolyl, naphthoxindolyl, naphtho-triazolyl, naphthopyranyl, oxabicycloheptyl, azabenzimidazolyl, azacycloheptyl, azacyclooctyl, azacyclononyl, azabicyclononyl, tetrahydrofuryl, tetrahydropyranyl, tetrahydro-pyronyl, tetrahydroquinoleinyl, tetrahydrothienyl and dioxide thereof, dihydrothienyl dioxide, dioxindolyl, dioxinyl, dioxenyl, dioxazinyl, thioxanyl, thioxolyl, thiourazolyl, thiotriazolyl, thiopyranyl, thiopyronyl, coumarinyl, quinoleinyl, oxyquinoleinyl, quinuclidinyl, xanthinyl, dihydropyranyl, benzodihydrofuryl, benzothiopyranyl, benzothiopyranyl, benzoxazinyl, benzoxazolyl, benzodioxolyl, benzodioxanyl, benzothiadiaazolyl, benzotriazinyl, benzothiazolyl, benzoxazolyl, phenothioxinyl, phenothiazolyl, phenothienyl (benzothiophenyl), phenopyranyl, phenoxazolyl, pyridinyl, dihydropyridinyl, tetrahydropyridinyl, piperidinyl, morpholiny, thiomorpholiny, pyrazinyl, pyrimidinyl, pyridazinyl, triazinyl, tetrazinyl, triazolyl, benzotriazolyl, tetrazolyl, imidazolyl, pyrazolyl, thiazolyl, thiadiazolyl, isothiazolyl, oxazolyl, oxadiazolyl, pyrrolyl, furyl, dihydrofuryl, furoyl, hydantoinyl, dioxolanyl, dioxolyl, dithianyl, dithienyl, dithiinyl, thienyl, indolyl, indazolyl, benzofuryl, quinolyl, quinazolinyl, quinoxaliny, carbazolyl, phenoxazinyl, phenothiazinyl, xanthenyl, purinyl, benzothienyl, naphthothienyl, thianthrenyl, pyranyl,

pyronyl, benzopyronyl, isobenzofuranyl, chromenyl, phenoxathiinyl, indoliziny, quinoliziny, isoquinolyl, phthalaziny, naphthiridiny, cinnoliny, pteridiny, carboliny, acridiny, perimidiny, phenanthroliny, phenaziny, phenothiaziny, imidazoliny, imidazolidiny, benzimi-dazolyl, pyrazoliny, pyrazolidiny, pyrroliny, pyrrolidiny,

5 piperaziny, uridiny, thymidiny, cytidiny, aziriny, aziridiny, diaziriny, diaziridiny, oxirany, oxaziridiny, dioxirany, thiirany, azetyl, dihydroazetyl, azetidiny, oxetyl, oxetany, oxetanony, homopiperaziny, homopiperidiny, thietyl, thietany, diazabicyclooctyl, diazetyl, diaziridinony, diaziridinethionyl, chromany, chromanony, thiochromany, thiochromanony, thiochromenyl, benzofurany, benzisothiazolyl,

10 benzocarbazolyl, benzochromony, benzisoalloxaziny, benzocoumariny, thiocoumariny, pheno-metoxaziny, phenoparoxaziny, phentriaziny, thiodiaziny, thiodiazolyl, indoxyl, thioindoxyl, benzodiaziny (e.g. phtalaziny), phtalidyl, phtalimidiny, phtalazonyl, alloxaziny, dibenzopyronyl (i.e. xanthony), xanthionyl, isatyl, isopyrazolyl, isopyrazolonyl, urazolyl, uraziny, uretiny, uretidiny, succiny, succinimido,

15 benzylsultimyl, benzylsultamyl and the like, including all possible isomeric forms thereof, wherein each carbon atom of said heterocyclic ring may furthermore be independently substituted with a substituent selected from the group consisting of halogen, nitro, C<sub>1-7</sub> alkyl (optionally containing one or more functions or radicals selected from the group consisting of carbonyl (oxo), alcohol (hydroxyl), ether (alkoxy),

20 acetal, amino, imino, oximino, alkylloximino, amino-acid, cyano, carboxylic acid ester or amide, nitro, thio C<sub>1-6</sub> alkyl, thio C<sub>3-6</sub> cycloalkyl, C<sub>1-6</sub> alkylamino, cycloalkylamino, alkenylamino, cycloalkenylamino, alkynylamino, arylamino, arylalkyl-amino, hydroxylalkylamino, mercaptoalkylamino, heterocyclic-substituted alkylamino, heterocyclic amino, heterocyclic-substituted arylamino, hydrazino, alkylhydrazino,

25 phenylhydrazino, sulfonyl, sulfonamido and halogen), C<sub>2-6</sub> alkenyl, C<sub>2-6</sub> alkynyl, halo C<sub>1-6</sub> alkyl, C<sub>3-6</sub> cycloalkyl, aryl, arylalkyl, alkylaryl, alkylacyl, arylacyl, hydroxyl, amino, C<sub>1-6</sub> alkylamino, cycloalkylamino, alkenylamino, cycloalkenylamino, alkynylamino, arylamino, arylalkylamino, hydroxyalkylamino, mercaptoalkylamino, heterocyclic-substituted alkylamino, heterocyclic amino, heterocyclic-substituted arylamino,

30 hydrazino, alkylhydrazino, phenylhydrazino, sulfhydryl, C<sub>1-6</sub> alkoxy, C<sub>3-6</sub> cycloalkoxy, aryloxy, arylalkyloxy, oxyheterocyclic, heterocyclic-substituted alkyloxy, thio C<sub>1-6</sub> alkyl, thio C<sub>3-6</sub> cycloalkyl, thioaryl, thioheterocyclic, arylalkylthio, heterocyclic-substituted alkylthio, formyl, hydroxylamino, cyano, carboxylic acid or esters or thioesters or amides thereof, thiocarboxylic acid or esters or thioesters or amides thereof; depending

35 upon the number of unsaturations in the 3 to 10 atoms ring, heterocyclic substituents may be sub-divided into heteroaromatic (or " heteroaryl ") and non-aromatic heterocyclic substituents; when a heteroatom of said non-aromatic heterocyclic radical



is nitrogen, the latter may further be substituted with a substituent selected from the group consisting of C<sub>1-6</sub> alkyl, C<sub>3-6</sub> cycloalkyl, aryl, arylalkyl and alkylaryl.

As used herein with respect to a substituting atom, and unless otherwise stated, the term halogen means any atom selected from the group consisting of fluorine,  
5 chlorine, bromine and iodine.

As used herein with respect to a substituent, and unless otherwise stated, the term " halo C<sub>1-6</sub> alkyl " means a C<sub>1-6</sub> alkyl radical (such as above defined) in which one or more hydrogen atoms are independently replaced by one or more halogen atoms (preferably fluorine, chlorine or bromine) such as, but not limited to, difluoromethyl,  
10 trifluoromethyl, trifluoroethyl, octafluoropentyl, dichloromethyl and the like.

As used herein, and unless otherwise stated, the term " heterocyclylsulfonyl " embraces heterocyclyl radicals as described above, attached to a divalent sulfonyl radical.

As used herein and unless otherwise stated, the term " stereoisomer " refers to all  
15 possible different isomeric as well as conformational forms which the compounds of structural formula (A) may possess, in particular all possible stereochemically and conformationally isomeric forms, all diastereomers, enantiomers and/or conformers of the basic molecular structure. Some compounds of the present invention may exist in different tautomeric forms, all of the latter being included within the scope of the  
20 present invention.

As used herein and unless otherwise stated, the term " enantiomer " means each individual optically active form of a compound of the invention, having an optical purity or enantiomeric excess (as determined by methods standard in the art) of at least 80% (i.e. at least 90% of one enantiomer and at most 10% of the other enantiomer),  
25 preferably at least 90% and more preferably at least 98%.

As used herein and unless otherwise stated, the term " solvate " includes any combination which may be formed by a derivative of this invention with a suitable inorganic solvent (e.g. hydrates) or organic solvent, such as but not limited to alcohols, ketones, esters, ethers, nitriles and the like.

30 The term "  $\alpha$ -synucleopathy " as used herein, unless otherwise stated, refers to a disease characterised by the presence of pathological deposition of insoluble  $\alpha$ -synuclein polymers or aggregates intracellularly and/or extracellularly. Such diseases include, but are not limited to, Parkinson's disease, diffuse Lewy body disease, traumatic brain injury, amyotrophic lateral sclerosis, Niemann-Pick disease,  
35 Hallervorden-Spatz syndrome, Down syndrome, neuroaxonal dystrophy, multiple system atrophy and Alzheimer's disease.

As used herein, the term " Parkinson's disease " refers to a chronic progressive nervous disease characterised by neurodegeneration, especially degeneration of dopaminergic neurons. Symptoms include stooped posture, resting tremor, weakness of resting muscles, a shuffling gait, speech impediments, movement difficulties and an eventual slowing of mental processes and dementia.

The term " neuroprotective " agent, as used herein, refers to drugs or chemical agents intended to prevent neurodegeneration, including drugs that slow down or stop the progression of neuronal degeneration.

## 10 DETAILED DESCRIPTION OF THE INVENTION

The present invention relates, in a first aspect, to a group of novel 1,2,4-thiadiazole derivatives which have desirable biological properties such as an inhibitory effect on  $\alpha$ -synuclein mediated toxicity. Based on this inhibitory activity, and the fact that these compounds are not toxic to neural cells, these compounds are useful in the prevention and/or treatment of  $\alpha$ -synucleopathies, e.g. in humans. In the broadest expression of the invention, the six classes of novel 1,2,4-thiadiazole derivatives of this invention may be represented by the structural formulae (A), (B), (C), (D), (E) and (F), including stereoisomers, solvates and salts thereof. These broad classes may be subdivided into several sub-classes, not only depending upon the specific structural formula (A) to (F) involved, but also wherein:

- each substituent  $R_1$  to  $R_5$  and  $R_7$  to  $R_{13}$ , and the linking moiety X in each of the structural formulae (A), (B), (C), (D), (E) and (F), and
- when referring to the structural formulae (A) and (D), n and the optionally substituted divalent group (A'), and
- when referring to the structural formulae (A), (B), (D) and (E), each substituent  $R_6$ , and
- when referring to the structural formulae (C) and (F), n and each substituent  $R_{14}$ ,  $R_{15}$ , R and R'

may be defined in a more restricted manner, at will and independently from each other.

In a particular embodiment of the first, second, third and fourth classes of derivatives represented by the structural formulae (A), (B), (C), (D), (E) and (F), the linking moiety X is a divalent saturated non-cyclic group comprising two nitrogen atoms and 1 to 6 carbon atoms (preferably 1 to 4 carbon atoms) in the main chain, wherein one carbon atom in the main chain is optionally substituted with oxo or thioxo, e.g. said linking moiety X is or comprises a urea or thiourea group. In one embodiment of the second and fourth classes of derivatives represented by the structural formulae (C) and (F), each  $R_{14}$  and each  $R_{15}$  is hydrogen. In a particular embodiment of the third and fourth

classes of derivatives represented by the structural formulae (D), (E) and (F), the Het<sup>1</sup> group is selected from the group consisting of pyridinyl, ethylpyridinyl, quinolinyl (all isomers thereof), ethylquinolinyl, indolyl (all isomers thereof), pyrazolyl (all isomers thereof), imidazolyl, cyanoimidazolyl, dicyanoimidazolyl, and pyrimidinyl (all isomers thereof). Exemplary but non-limiting embodiments of such sub-classes are illustrated in the following examples and defined in the set of claims. As will be readily understood by the skilled person, the possibility to independently combine one or more sub-sets of definitions for each of the substituents optionally present, and the linking moiety X, results from the independent consecutive steps involved in the synthetic route described herein for making these compounds. For reasons linked to the availability of non-cyclic branched diamines, it is for instance preferred that n is 1 or 2 when one of R<sub>14</sub> and R<sub>15</sub> is not hydrogen in the definitions of structural formulae (C) and (F).

The ability of the compounds of the invention to inhibit  $\alpha$ -synuclein mediated toxicity is based on their activity in the  $\alpha$ -synuclein cytotoxicity test described in the examples section herein. Treatment of mice with mitochondrial complex I inhibitors such as paraquat or MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) is a well-accepted and commonly used experimental set-up to study neuronal degeneration. Paraquat triggers synuclein-aggregation, which allegedly triggers a specific loss of dopaminergic neurons and ultimately a decline in the locomotion function. Briefly, one or more compounds are administered to paraquat-receiving mice and the onset of motoric dysfunction is assessed using a rotary rod device. A delay or absence in the occurrence of motoric problems in compound treated mice (compared to control mice treated with only vehicle) indicates that the compound(s) inhibit(s) synuclein-dependent degeneration of dopaminergic cells.

In the assays used herein, compounds were considered to be active when inhibiting  $\alpha$ -synuclein cytotoxicity by more than 25% relative to controls at a concentration of 20  $\mu$ g/mL or lower. Dose responses were carried out on all compounds found to be active (10 point curves in duplicate). Although the pharmacological properties of the compounds disclosed in this invention vary with structural change as expected, active compounds particularly possess EC<sub>50</sub>'s in a cell-based assay of synuclein cytotoxicity in the range 0.0001 to 10  $\mu$ M.

Based on these findings, methods for treating and preventing disorders or diseases provoked by cytotoxic intracellular  $\alpha$ -synuclein in mammals, e.g. in humans are provided herein. These methods comprise administering to a subject, e.g. a human being, suffering from or susceptible to such a disease or disorder, an effective amount

of one or more inhibitors of  $\alpha$ -synuclein cytotoxicity as defined by one of the broad structural formulae (A), (B), (C), (D), (E) and (F), or any sub-classes thereof.

As used herein, the term "effective amount" designates an amount sufficient to effect beneficial or desired clinical or biochemical results. An effective amount can be administered one or more times. For purposes of this invention, an effective amount of an inhibitor of  $\alpha$ -synuclein cytotoxicity is an amount that is sufficient to palliate, ameliorate, stabilize, reverse, slow down or delay the progression of a disease state or condition. In a particular embodiment of the invention, the "effective amount" is defined as an amount of compound capable of preventing deposition of insoluble  $\alpha$ -synuclein polymers or aggregates and/or capable of preventing the cytotoxic effects triggered by aggregation or polymerization of  $\alpha$ -synuclein, and is an amount that substantially reduces the symptoms of an  $\alpha$ -synucleopathy, such as Parkinson's disease. Other forms of effective amount may be for the treatment or prevention of the learning or memory impairment related to Alzheimer's disease.

As used herein, the terms "mammal", "subject" or "patient" for the purposes of a therapeutic or prophylactic treatment refers to any animal classified as a mammal, including humans, domestic and farm animals, such as but not limited to dogs, cats, pigs, horses, sheep, and the like. Most particularly, the mammal is a human being.

The various 1,2,4-thiadiazole compounds of the present invention can be synthesised in an effective manner according to the methods schematically described in the attached figures and more specifically illustrated in the following specific examples. These methods of producing the 1,2,4-thiadiazole compounds of the invention comprise a limited number of steps and start from commercially available, or readily accessible, materials. Generally, 1,2,4-thiadiazole compounds represented by the structural formulae (A), (B), (D) and (E) can be synthesised by a procedure including a sequence of steps according as shown in figure 1 and, more specifically with regard to compounds represented by formulae (A) and (B), as shown in figure 2.

In step (a) of figure 1, the benzonitrile derivative represented by the structural formula (I), optionally substituted on the aromatic ring and/or in alpha position to the cyano group, is reacted with ammonia, either as a gas or in aqueous solution, thus yielding the corresponding amidine represented by the structural formula (II).

The direct synthesis of amidines from nitriles and ammonia may be greatly facilitated by the presence of electron-withdrawing groups on the benzonitrile derivative represented by the structural formula (I). Optionally, this reaction may be carried out in the presence of an effective amount of one or more Lewis acids such as but not limited to  $\text{AlCl}_3$  or  $\text{ZnCl}_2$  at temperatures ranging from 20°C up to a maximum of 150-200°C.

Alternative methods for producing an amidine represented by the structural formula (II) from a benzonitrile derivative represented by the structural formula (I) have been described for instance in *Albany Molecular Research Technical Reports* (2000) volume 4, number 3.


- 5           Nitriles or cyanides that may be used in step (a) include, but are not limited to, 4-aminobenzylcyanide, 4-bromo-2,2-diphenylbutyronitrile, 3-chlorobenzylcyanide, 4-chlorobenzylcyanide, cyclohexylphenylacetoneitrile, 4-hydroxybenzylcyanide,  $\alpha$ -methylbenzylcyanide, 2-methylbenzylcyanide, 3-methylbenzylcyanide, 4-methylbenzylcyanide, 4-cyano-4-phenylcyclohexanone, 1-(2,4-dichlorophenyl)-1-cyclopropyl-
- 10 cyanide, 4-fluorophenylacetoneitrile, diphenylacetoneitrile, 3,4,5-trimethoxy-phenylacetoneitrile, 2,2-diphenylpropionitrile, 4-bromophenylacetoneitrile, 1-phenylcyclobutanecarbonitrile, 2,6-dichlorophenylacetoneitrile, (3,4-dimethoxy-phenyl)acetoneitrile, 4-nitrophenylacetoneitrile, 1-phenyl-1-cyclopropanecarbonitrile, 1-(4-chlorophenyl)-1-cyclopropanecarbonitrile, 1-(4-methylphenyl)-1-cyclopropane-carbonitrile, 1-phenyl-1-cyclo-
- 15 hexanecarbonitrile, 1-(4-chlorophenyl)-1-cyclohexane-carbonitrile, 1-(4-methylphenyl)-1-cyclohexanecarbonitrile, 1-(4-methoxyphenyl)-1-cyclohexanecarbonitrile, 2-nitrophenylacetoneitrile, (4-methoxyphenyl)acetoneitrile, 2,4-dichlorophenyl-acetoneitrile, (2-methoxyphenyl)acetoneitrile, benzyl cyanide, 2-chlorobenzyl cyanide, 3-phenoxybenzaldehyde-cyanohydrin, 3-(trifluoromethyl)-phenylacetoneitrile, (3-methoxyphenyl)-
- 20 acetoneitrile, 2-chloro-6-fluorophenylacetoneitrile, 3,4-dichlorophenylacetoneitrile, 4-amino-2-chlorodiphenylacetoneitrile, 2-fluorophenyl-acetoneitrile, 3-fluorophenylacetoneitrile, 2,3,4,5,6-pentafluorophenylacetoneitrile, 3,4-difluorophenylacetoneitrile, 3-bromophenylacetoneitrile, 2-chloro-4-fluorobenzyl cyanide, 1-(2-fluorophenyl)-cyclopentanecarbonitrile, 1-(2-fluorophenyl)-cyclohexane-carbonitrile, 1-(3-fluorophenyl)-cyclopentanecarbo-
- 25 nitrile, 1-(3-fluorophenyl)-cyclo-hexanecarbonitrile, 1-(4-fluorophenyl)-cyclopentane-carbonitrile, 1-(4-fluorophenyl)-cyclohexanecarbonitrile, 1-(2-chloro-4-fluorophenyl)-cyclopentane-carbonitrile, 1-(2-chloro-4-fluorophenyl)-cyclohexanecarbonitrile, 1-(2-chloro-6-fluorophenyl)-cyclo-pentanecarbonitrile, 1-(2-chloro-6-fluorophenyl)-cyclohexanecarbonitrile, 2,4-difluorophenylacetoneitrile, 2,5-difluorophenylacetoneitrile, 2,6-
- 30 difluorophenyl-acetoneitrile, 4-(trifluoromethyl)phenylacetoneitrile, 2-(trifluoromethyl)-phenylacetoneitrile, 3,5-bis-(trifluoromethyl)phenylacetoneitrile, 2,5-dimethylphenylacetoneitrile, 2-bromo-phenylacetoneitrile, 2,4,6-trimethylbenzylcyanide, 2,3-dichlorophenylacetoneitrile, 3,4-(methylenedioxy)phenylacetoneitrile, 1-(4-methoxyphenyl)-1-cyclopentanecarbonitrile, 1-(4-chlorophenyl)-1-cyclobutanecarbonitrile, 2-(4-chloro-2-
- 35 fluorophenyl)-acetoneitrile, 2-(3,5-difluorophenyl)-acetoneitrile, 2-(4-isobutylphenyl)-propanenitrile, 2-[-4[(4-methylbenzyl)-oxy]phenyl]acetoneitrile, 1-(3-chlorophenyl)-1-cyclohexanecarbonitrile, 3-chloro-5-fluorophenylcetoneitrile, 4-(trifluoromethoxy)-

phenylacetonitrile, 2-phenyl-2-piperidinoacetonitrile, 4-bromo-2-fluorobenzyl-cyanide, 2-(4-chlorophenyl)-2-morpholinoacetonitrile, 1-(4-methoxyphenyl)-1-cyclopropane-carbonitrile, 2-(4-aminophenyl)-3-[4-(dimethylamino)phenyl]propanenitrile, and 2-(4-hydroxyphenyl)-2-morpholinoacetonitrile.

5 According to a particular embodiment of the invention, the starting materials are selected from the group comprising 4-fluorobenzyl cyanide, 4-chlorobenzyl cyanide, 4-methylbenzyl cyanide, 3-methoxybenzyl cyanide and benzyl cyanide.

Alternatively an amidine represented by the structural formula (II) may be commercially available, either in the form of a base or preferably for stability reasons in the form of a salt, for example 2-(2,6-dichlorophenyl)ethanimidamide in its  
10 hydrochloride salt form, and may then be used as the starting point of figure 1.

Subsequently, the thiadiazole core of the compounds of this invention is synthesised in step (b) of figure 1 in a manner similar to that described in WO 99/51584. For instance, the amidine compound represented by the structural formula (II) may be reacted with  $\text{CCl}_3\text{SCl}$  to form the corresponding 3-substituted-5-chloro-thiadiazole compound represented by the structural formula (III) (step (b) of figure 1). The latter may then be reacted (step (c) of figure 1) under suitable conditions with a saturated or partly unsaturated heterocyclic derivative having the formula  $\text{R}''\text{-A}'\text{H}$  wherein  $\text{A}'$  is an optionally  $\text{R}_6$ -substituted heterocyclic ring with at least two nitrogen  
15 atoms (e.g. piperazine or similar) as defined hereinabove and wherein  $\text{R}''$  is attached to one nitrogen atom of said heterocyclic ring through a linking moiety to obtain either final compounds of the invention or intermediates therefor having the structural formula (IV), depending upon the exact nature of  $\text{R}''$ . More specifically, attachment of  $\text{R}''$  may be according to the formula:



or the formula  $\text{X-Het}^1$  (wherein each of X,  $\text{Het}^1$ ,  $\text{R}_7$ ,  $\text{R}_8$ ,  $\text{R}_9$ ,  $\text{R}_{10}$ , and  $\text{R}_{11}$  is independently as hereinabove defined), or attachment of  $\text{R}''$  may be suitable for producing intermediates having the structural formula (IV-A) (i.e. wherein  $\text{R}''$  is H) and intermediates having e.g. the structural formula (IV-B) (i.e. wherein  $\text{R}''$  is aminoethyl)  
30 shown in figure 2. The present invention thus also includes (although not specifically shown in figures 1 and 2), for producing derivatives represented by the structural formulae (D) and (E), a reaction with a heterocyclic derivative wherein the linking

moiety X (which may be a single bond) is located between a first (preferably saturated) optionally substituted heterocyclic ring A' with at least two nitrogen atoms (e.g. piperazine or similar, as detailed below) and a second (preferably unsaturated nitrogen-containing) heterocyclic ring Het<sup>1</sup> (instead of the optionally substituted phenyl ring shown above), wherein said second (preferably unsaturated nitrogen-containing) heterocyclic ring Het<sup>1</sup> may further be substituted with one or more substituents independently selected from the group consisting of halogen, trifluoromethyl, nitro, cyano and C<sub>1-10</sub> alkyl. A few illustrative heterocyclic derivatives corresponding to the latter embodiment of the invention are also listed below.

10 Piperazine derivatives useful for the displacement reaction in step (c) of figure 1 and thus directly yielding final compounds of the present invention - as defined by the structural formulae (A), (B), (D) and (E) - include, but are not limited to, 1-(4-nitrophenyl)piperazine, 1-(2-methoxyphenyl)piperazine, 1-(3-methoxyphenyl)piperazine dihydrochloride, 1-phenylpiperazine, 1-(3-chlorophenyl)piperazine, 1-(4-chlorophenyl)piperazine, 1-(3,4-dichlorophenyl)piperazine, 1-(2,3-dimethylphenyl)piperazine, 1-(2,4-dimethylphenyl)piperazine, 1-(2,5-dimethylphenyl)piperazine, 1-(3,4-dimethylphenyl)piperazine, 1-(5-chloro,2-methylphenyl)piperazine, 2-methyl-1-(3-methylphenyl)piperazine, 4-piperazinoacetophenone, 1-(4-fluorophenyl)piperazine, 1-(2-methoxyphenyl)piperazine hydrochloride, 1-(4-methoxyphenyl)piperazine, 1-(2-fluorophenyl)piperazine, 1-(3-methylphenyl)piperazine, 1-(4-methoxyphenyl)-2-methylpiperazine, 1-(2,4-di-fluorophenyl)piperazine, N-( $\alpha,\alpha,\alpha$ -trifluoro-*p*-tolyl)piperazine, 1-(4-hydroxyphenyl)piperazine, 1-(4-methylphenyl)piperazine, 1-[2-nitro-4-(trifluoromethyl)phenyl]piperazine, 1-(2-hydroxyphenyl)piperazine, benzyl 3-oxo-piperazine-1-carboxylate, 1-(2-chlorophenyl)piperazine, 1-(2-methylphenyl)piperazine, 1-cinnamylpiperazine, trans-1-cinnamylpiperazine, 1-(4-fluorobenzyl) piperazine and 2-methyl-4-piperazinoquinoline.

Alternatively, using the same synthetic pathway, another (i.e. non piperazinyl) preferably saturated or partly unsaturated heterocyclic ring having the structural formula (A') with at least two nitrogen atoms in the said heterocyclic ring and with a total of 5 to 7 atoms in the said heterocyclic ring may be introduced onto the thiadiazole core during step (c) of figure 1. Suitable alternative heterocyclic rings having the structural formula (A') include, but are not limited to, homopiperazinyl, pyrazolinyl, thiadiazinyl, oxadiazinyl, imidazolinyl, imidazolidinyl and pyrazolidinyl.

Commercially available reagents for such synthesis step (c) of figure 1, yielding final compounds of the present invention defined by the structural formulae (A) and (D) with a homopiperazinyl ring A' connected to the thiadiazole core include, but are not limited to, 1-(4-bromo-2-fluorobenzyl)-1,4-diazepane, 1-(4-bromo-2-fluoro-benzyl)-1,4-

diazepane, 1-(mesitylmethyl)-1,4-diazepane, 1-(4-bromo-benzyl)-1,4-diazepane, 6-chloro-2-(1,4-diazepan-1-yl)-1,3-benzothiazole, 1-(2-chloro-6-fluorobenzyl)-1,4-diazepane, 1-(4-fluorobenzyl)-1,4-diazepane, 5-(1,4-diazepan-1-yl)-3-phenyl-1,2,4-thiadiazole, 1-[3-chloro-5-(trifluoromethyl)-2-pyridyl]-1,4-diazepane, 1-[4-(trifluoromethyl)pyrimidin-2-yl]-1,4-diazepane, 1-(5-nitro-2-pyridyl)-1,4-diazepane, 2-(1,4-diazepan-1-yl)-nicotinonitrile, 6-chloro-2-(1,4-diazepan-1-yl)-1,3-benzothiazole, 6-(1,4-diazepan-1-yl)-nicotinonitrile, and 1-(6-methylpyrazin-2-yl)-1,4-diazepane.

Commercially available reagents for such synthesis step (c) of figure 1, yielding final compounds of the present invention defined by the structural formulae (A) and (D) with an imidazolidinyl ring A' connected to the thiadiazole core include, but are not limited to, 1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one. In the latter specific embodiment, the resulting imidazolidinyl ring A' is illustrative of a saturated heterocyclic ring wherein two substituents (denoted as R<sub>6</sub> in the structural formulae A and D) on the same carbon atom of said heterocyclic ring together form a heterocyclic ring system (*in casu* a 6-membered nitrogen-containing heterocyclic ring).

Commercially available reagents for such synthesis step (c) of figure 1, yielding final compounds of the present invention defined by the structural formulae (A) and (D) with a pyrazolidinyl ring A' connected to the thiadiazole core include, but are not limited to, 1-phenyl-3-pyrazolidinone, 1-phenyl-4-methyl-3-pyrazolidinone, 4,4-dimethyl-1-phenyl-3-pyrazolidinone and 4-hydroxymethyl-4-methyl-1-phenyl-3-pyrazolidinone.

When not commercially available for synthesis step (c) of figure 1, reagents yielding final compounds of the present invention defined by the structural formulae (A) and (D) with a pyrazolidinyl, imidazolidinyl, oxadiazinyl, thiadiazinyl, piperazinyl or homopiperazinyl ring A' connected to the thiadiazole core can be tailor-made according to specific prerequisites while using synthetic routes well known to the skilled person.

Figure 2 schematically illustrates alternative methods to prepare compounds according to structural formula (A) wherein step (c) of figure 1 comprises two subsequent reaction sub-steps. Although not specifically shown in figure 2, such alternative methods are also applicable to the preparation of compounds according to structural formula (D), provided that in the second sub-step a suitable heteroaryl carbonyl chloride, heteroaryl sulfonyl chloride, heteroarylamine, heteroaryl isocyanate or heteroaryl isothiocyanate, wherein the heteroaryl group may be anyone of the Het<sup>1</sup> species described above, is used in place of the corresponding arylcarbonyl chloride, aryl sulfonyl chloride, arylamine, aryl isocyanate or aryl isothiocyanate (wherein, as shown in figure 2, the aryl group is optionally substituted with one up to five substituents R<sub>7</sub>, R<sub>8</sub>, R<sub>9</sub>, R<sub>10</sub> and R<sub>11</sub>).



In a first sub-step, a thiadiazole intermediate compound represented by the structural formula (III) in figure 1 is first reacted under suitable conditions with a saturated or partly unsaturated heterocyclic derivative including an optionally R<sub>6</sub>-substituted heterocyclic ring A' with at least two nitrogen atoms and with a total of 5 to 7 atoms in said heterocyclic ring, said heterocyclic derivative having at least one amino group available for reaction with the chloro atom of the 3-substituted-5-chloro-thiadiazole compound represented by the structural formula (III) and another amino group available for reaction with an aryl derivative represented by a structural formula (V-A), (V-B), (V-C), (V-D) or (V-E) shown in figure 2, or a corresponding heteroaryl derivative including a heteroaryl group Het<sup>1</sup> as defined above. Examples of such heterocyclic compounds for use in the first sub-step of step (c) for the synthesis of appropriate intermediates having the structural formulae (IV-A) and (IV-B) shown in scheme 2 comprise, but are not limited to, the following:

- piperazinyl derivatives including piperazine, 2-methylpiperazine (either (R)-(-)-2-methylpiperazine or (S)-(+)-2-methylpiperazine), trans-2,5-dimethylpiperazine, and amino alkyl-substituted piperazines such as 1-(2-aminoethyl)piperazine, 1-(aminomethyl)piperazine, 1-(3-aminopropyl)piperazine, 1-(4-aminobutyl)piperazine, 1-(6-aminoethyl)piperazine, and the like;
- homopiperazinyl derivatives including homopiperazine;
- imidazolidinyl derivatives including 2-imidazolidone, 2-imidazolidinethione, 4-methylimidazolidine-2-thione, aminomethylimidazolidine, aminoethylimidazolidine, aminopropylimidazolidine, aminobutylimidazolidine, and 1-3-diazaspiro[4.5]decane-2,4-dione (in this specific embodiment, the resulting imidazolidinyl ring A' is illustrative of a saturated heterocyclic ring wherein two substituents, denoted as R<sub>6</sub> in the structural formula A, on the same carbon atom of said heterocyclic ring together form a homocyclic ring system, *in casu* a cyclohexyl group), hydantoin and hydantoin derivatives such as, but not limited to, 5,5-dimethylhydantoin, 2-thiohydantoin, 5-(4-methylphenyl)-5-phenylhydantoin, 5,5-diphenylhydantoin and 5-methyl-5-phenylhydantoin;
- pyrazolidine and aminoalkyl-substituted pyrazolidines such as aminomethylpyrazolidine, aminoethylpyrazolidine, aminopropylpyrazolidine and aminobutylpyrazolidine.

Due to the balance between nucleophilicity and steric hindrance of each of the two amino groups present in the saturated or partly unsaturated heterocyclic derivative

used in the first sub-step, it may be desirable (in order to avoid the possibility of producing a mixture of intermediates that may later have to be separated before performing the next reaction steps) to perform the above-mentioned reaction by:

- first reacting a saturated or partly unsaturated heterocyclic derivative wherein the amino group available for reaction (e.g. subsequent reaction) with an aryl derivative (formulae (V-A) to (V-E) shown in figure 2), or a Het<sup>1</sup>-containing heteroaryl derivative has been protected with an amino-protecting group, and
- secondly, after the reaction of said first sub-step has been substantially completed, deprotecting the resulting intermediate compound to achieve an amino-containing intermediate, e.g. as represented by structural formulae (IV-A) and (IV-B) in figure 2, that is readily available for the next reaction step.

N-protecting groups and amino-deprotecting techniques suitable for this particular purpose are well known to the person skilled in the art. Commonly used N-protecting groups are disclosed e.g. in Greene, "Protective Groups in Organic Synthesis" (John Wiley & Sons, New York, 1981). Suitable exemplary N-protecting groups include acyl groups such as formyl, acetyl, propionyl, pivaloyl, t-butylacetyl, 2-chloroacetyl, 2-bromoacetyl, trifluoroacetyl, trichloroacetyl, phthalyl, o-nitrophenoxyacetyl, .alpha.-chlorobutyryl, benzoyl, 4-chloro-benzoyl, 4-bromobenzoyl, 4-nitrobenzoyl, and the like; sulfonyl groups such as benzenesulfonyl, p-toluenesulfonyl, and the like; carbamate forming groups such as benzyloxycarbonyl, p-chlorobenzyloxycarbonyl, p-methoxybenzyloxycarbonyl, p-nitro-benzyloxycarbonyl, 2-nitrobenzyloxycarbonyl, p-bromobenzyloxycarbonyl, 3,4-dimethoxybenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, 2-nitro-4,5-dimethoxy-benzyloxycarbonyl, 3,4,5-trimethoxybenzyloxycarbonyl, 1-(p-biphenyl)-1-methyl-ethoxycarbonyl,  $\alpha,\alpha$ -dimethyl-3,5-dimethoxybenzyloxycarbonyl, benzhydryloxycarbonyl, t-butoxycarbonyl, diisopropylmethoxycarbonyl, isopropylloxycarbonyl, ethoxycarbonyl, methoxycarbonyl, allyloxycarbonyl, 2,2,2-trichloroethoxycarbonyl, phenoxycarbonyl, 4-nitrophenoxycarbonyl, fluorenyl-9-methoxycarbonyl, cyclopentylloxycarbonyl, adamantylloxycarbonyl, cyclohexyloxycarbonyl, phenylthiocarbonyl, and the like; arylalkyl groups such as benzyl, triphenylmethyl, benzyloxymethyl and the like; and silyl groups such as trimethylsilyl and the like. The most appropriate N-protecting groups include formyl, acetyl, benzoyl, pivaloyl, t-butylacetyl, phenylsulfonyl, benzyl, t-butoxycarbonyl (BOC) and benzyloxycarbonyl.

Subsequently, the N-protecting group may be removed by deprotection methods conventional in the art, such as, but not limited to:

- when the amino-protecting group is a phenylmethoxycarbonyl group, cleavage of the benzylic ether function by hydrogenolysis, e.g. using  $H_2$ , Pd-C at about 25°C, or under strongly acidic conditions (e.g. making use of bromhydric acid), or
- when the amino-protecting group is a tert-butoxycarbonyl group, by treatment with an acid, e.g. using aqueous hydrochloric acid or trifluoroacetic acid (hereinafter referred as TFA), under conditions mild enough to avoid further cleavage of the molecule, or
- when the amino-protecting group is a 9-fluorenylmethoxycarbonyl group, by treatment with a base such as piperidine.

10 In a second reaction sub-step as shown in figure 2, intermediate compounds represented by the structural formulae (IV-A) or (IV-B) are reacted under suitable conditions with a reagent susceptible to nucleophilic attack by a non-tertiary amino group, e.g. the secondary NH group present in intermediate compounds according to structural formula (IVA), or the terminal primary amino group present in intermediate  
15 compounds according to structural formula (IVB). Suitable such reagents include, but are not limited to, acid chlorides such as carbonyl chlorides or sulfonyl chlorides, or activated acids such as carboxylic acid anhydrides. Particular carbonyl chlorides for use in this reaction sub-step include benzoyl chlorides (as shown in structural formula V-A in figure 2, resulting in final compounds with a linking moiety  $X = C(=O)$  when  
20 starting from intermediate compounds according to structural formula (IV-A), or a linking moiety  $X = (CH_2)_2NHC(=O)$  when starting from intermediate compounds according to structural formula (IV-B)) and phenyl acetyl chlorides (as shown in formula V-C in figure 2, resulting in final compounds with a linking moiety  $X = C(=O)CH_2$  when  
25 starting from intermediate compounds according to structural formula (IV-A), or a linking moiety  $X = (CH_2)_2NHC(=O)CH_2$  when starting from intermediate compounds according to structural formula (IV-B)). Particular sulfonyl chlorides for use in this reaction sub-step include phenylsulfonyl chlorides (as shown in formula V-B in figure 2, resulting in final compounds with a linking moiety  $X = S(=O)_2$  when starting from  
intermediate compounds according to structural formula IV-A), or a linking moiety  $X = (CH_2)_2NHS(=O)_2$  when starting from intermediate compounds according to structural  
30 formula IV-B).

Benzoyl chlorides (as shown in formula V-A) suitable for use in the synthesis of the compounds of the present invention include, but are not limited to, benzoyl chloride, p-anisoyl-chloride, 2-bromobenzoyl chloride, 4-bromobenzoyl chloride, 3-chlorobenzoyl  
35 chloride, pentafluorobenzoyl chloride, 2-chlorobenzoyl chloride, p-toluoyl chloride, 4-chlorobenzoyl chloride, 2,4-dichlorobenzoyl chloride, 3,4-dichlorobenzoyl chloride, 4-nitrobenzoyl chloride, 4-fluorobenzoyl chloride, 2-fluoro-benzoyl chloride, o-toluoyl

chloride, m-toluoyl chloride, 4-cyanobenzoyl chloride, 3-nitrobenzoyl chloride, 4-tert-butyl-benzoyl chloride, 4-biphenylcarbonyl chloride, 3,5-dimethoxybenzoyl chloride, 3-fluorobenzoyl chloride, 2,6-dichlorobenzoyl chloride, 4-butylbenzoyl chloride, 4-heptyloxybenzoyl chloride, 4-hexylbenzoyl chloride, 4-hexyloxybenzoyl chloride, 4-pentylbenzoyl chloride, m-anisoyl chloride, 2,6-difluoro-benzoyl chloride, 2-nitrobenzoyl chloride, 4-chloro-3-nitrobenzoylchloride, 3,4-difluoro-benzoyl chloride, 2-iodobenzoyl chloride, 1-naphthoyl chloride, o-anisoyl chloride, 2,4-difluorobenzoyl chloride, 4-(trifluoromethyl)benzoyl chloride, m-anisoyl chloride, 2,6-difluorobenzoyl chloride, 2-nitrobenzoyl chloride, 4-chloro-3-nitro-benzoylchloride, 3,4-difluorobenzoyl chloride, 2-iodobenzoyl chloride, 1-naphthoyl chloride, o-anisoyl chloride, 2,4-difluorobenzoyl chloride, 4-(trifluoromethyl)benzoyl chloride, 3-(chloro-methyl)-benzoyl chloride, 4-(chloromethyl)-benzoyl chloride, 3-(dichloromethyl)-benzoyl chloride, 2,3,4,5-tetrafluorobenzoyl chloride, 2,4,6-trichlorobenzoyl chloride, 2,3,4-trifluorobenzoyl chloride, 2,4,6-trifluorobenzoyl chloride, 4-bromo-2-fluoro-benzoyl chloride, 2,3,5,6-tetrafluorobenzoyl chloride, 3,5-dinitrobenzoyl chloride, 4-heptylbenzoyl chloride, 4-iodobenzoyl chloride, 4-octylbenzoyl chloride, 4-pentyl-oxybenzoyl chloride, 4-phenylazobenzoyl chloride, 4-propylbenzoyl chloride, methyl 4-chloro-carbonylbenzoate, 3,5-dichlorobenzoyl chloride, 3-fluoro-4-trifluoromethyl-benzoyl chloride, 2,6-dimethoxybenzoyl chloride, piperonyloyl chloride, 2,4-dimethoxybenzoyl chloride, 3,4-dihydro-2H-1,5-benzodioxepine-6-carbonyl chloride, 2,3-dihydro-1,4-benzodioxine-6-carbonyl chloride, 2,3-dihydro-1,4-benzodioxine-5-carbonyl chloride, 1-benzofuran-5-carbonyl chloride, 2,1,3-benzothiadiazole-4-carbonyl chloride, 2,1,3-benzothiadiazole-5-carbonyl chloride, 1,2,3-benzothia-diazole-5-carbonyl chloride, 2,1,3-benzoxadiazole-5-carbonyl chloride, 6-quinoxaline-carbonyl chloride, 4-(2-thienyl)-benzoyl chloride, 4-methyl-3,4-dihydro-2H-1,4-benzoxazine-7-carbonyl chloride, 4-(1,2,3-thiadiazol-4-yl)benzoyl chloride, 4-(1H-pyrazol-1-yl)benzoyl chloride, 1-methyl-1H-1,2,3-benzotriazole-5-carbonyl chloride, 1-benzothiophene-5-carbonyl chloride, 2,2-dimethyl-2,3-dihydro-1-benzofuran-7-carbonyl chloride, 4-[(dipropyl-amino)sulfonyl] benzene-1-carbonyl chloride, 4-[3-(trifluoromethyl)-1H-pyrazol-1-yl]-benzoyl chloride, 2-bromo-5-methoxybenzene-1-carbonyl chloride, 5-bromo-2,3,4-trimethylbenzoyl chloride, 2-chloro-6-fluorobenzene-1-carbonyl chloride, 2,3-dimethylbenzene-1-carbonyl chloride, 3,4-dimethylbenzene-1-carbonyl chloride, 2-chloro-4-fluorobenzoyl chloride, 5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthalene-carbonyl chloride, 2-(4-methoxyphenoxy)-5-nitrobenzene-1-carbonyl chloride, 2,3-difluorobenzoyl chloride, 2-fluoro-5-(trifluoromethyl)benzoyl chloride, 2,3,6-trifluorobenzoyl chloride, 1-isopropyl-1H-1,2,3-benzotriazole-5-carbonyl chloride, 1-isopropyl-1H-1,2,3-benzotriazole-5-carbonyl chloride, 3-fluoro-4-methylbenzoyl chloride, 3-(cyclo-

pentyloxy)-4-methoxybenzoyl chloride, 4-fluoro-3-(trifluoromethyl)benzoyl chloride, 2,3-dihydro-1-benzofuran-7-carbonyl chloride, 3-(2-methyl-thiazol-4-yl)-benzoyl chloride, 1-isopropyl-2-(trifluoromethyl)-1H-benzimida-zole-5-carbonyl chloride, 5-bromo-2,3-dihydrobenzo[b]furan-7-carbonyl chloride, 2,4,6-trimethylbenzoyl chloride, 2-(2-thienyl)-  
 5 benzoyl chloride, 3-cyanobenzoyl chloride, acetylsalicyloyl chloride, 3-(5-methyl-1,2,4-oxadiazol-3-yl)-benzoyl chloride, and 4-(5-methyl-1,2,4-oxadiazol-3-yl)-benzoyl chloride.

According to a particular embodiment the benzoyl chloride reagent may be selected from the group consisting of 2-fluorobenzoyl chloride, 4-ethylbenzoyl chloride,  
 10 4-butylbenzoyl chloride, 4-methoxybenzoyl chloride, piperonyloyl chloride, 4-hexylbenzoyl chloride, 3-chlorobenzoyl chloride, 4-fluorobenzoyl chloride, p-toluoyl chloride, 3-fluorobenzoyl chloride, 4-chlorobenzoyl chloride, benzoyl chloride, 4-tert-butylbenzoyl chloride, 4-biphenylcarbonyl chloride, o-anisoyl chloride, 1-naphthoyl chloride, 2-naphthoyl chloride, 4-pentylbenzoyl chloride, 4-bromobenzoyl chloride, 2,4-  
 15 dimethoxybenzoyl chloride, 3,5-dichlorobenzoyl chloride, 3-bromobenzoyl chloride, 2-bromobenzoyl chloride 3-trifluoromethylbenzoyl chloride, 4-trifluoro-methylbenzoyl chloride and 2-ethylbenzoyl chloride.

Numerous other carbonyl chlorides are known to the person skilled in the art and commercially available for use as acylating reagent for use in the reaction step  
 20 illustrated in figure 2. Particular carbonyl chlorides for use in the method of the invention include, but are not limited to, cinnamoyl chloride, hydrocinnamoyl chloride, 2-phenylbutyryl chloride, phenylacetyl chloride and 4-fluorophenylacetyl chloride.

Phenylsulfonyl chlorides (represented by the structural formula V-B) suitable for use in the synthesis of the compounds of the present invention include, but are not  
 25 limited to, 4-fluorobenzenesulfonyl chloride, 2-mesitylenesulfonyl chloride, 4-methoxybenzene-sulfonyl chloride, p-toluenesulfonyl chloride, pentafluorobenzene-sulfonyl chloride, benzenesulfonyl chloride, 4-bromobenzenesulfonyl chloride, N-acetylsulfanilyl chloride, 2,4,6-triisopropyl-benzenesulfonyl chloride 2-naphthalenesulfonylchloride, 4-chloro-benzenesulfonyl chloride 3,5-dichloro-2-hydroxy-  
 30 benzenesulfonylchloride, 2,5-dichloro-benzenesulfonyl chloride, pipsyl chloride, 1-naphthalenesulfonylchloride, methyl 2-(chlorosulfonyl)-benzoate, 4-tert-butylbenzene-sulfonyl chloride, 3-(trifluoromethyl) benzenesulfonyl chloride, 2-bromobenzenesulfonyl chloride, 4-acetylbenzene-sulfonylchloride, 2-(trifluoromethyl)-benzenesulfonyl chloride, 3,4-dichlorobenzene-sulfonyl chloride, 3,4-dimethoxybenzenesulfonyl chloride, 3-  
 35 chlorobenzenesulfonyl chloride, 2-chloro-4-fluorobenzenesulfonyl chloride, 3,5-dichlorobenzenesulfonyl chloride, 3-chloro-4-fluorobenzenesulfonyl chloride, 2,4-dichlorobenzenesulfonyl chloride, 2,5-dimethoxybenzenesulfonyl chloride, 3-bromo-

benzenesulfonyl chloride, 2,3-dichlorobenzenesulfonyl chloride, 5-fluoro-2-methylbenzenesulfonyl chloride, 3-fluorobenzenesulfonyl chloride, 2,3,5,6-tetramethylbenzenesulfonyl chloride, 3-chloro-2-methylbenzenesulfonyl chloride, 2,5-dibromo-3,6-difluoro-benzenesulfonyl chloride, 2,6-difluorobenzenesulfonyl chloride, 2-chlorobenzenesulfonyl chloride, 5-bromo-2-methoxybenzenesulfonyl chloride, 5-chloro-2-methoxybenzenesulfonyl chloride, 2,4-difluorobenzenesulfonyl chloride, 2-cyanobenzenesulfonyl chloride, 2-chloro-5-(trifluoromethyl)-benzenesulfonyl chloride, 4-bromomethylbenzenesulfonyl chloride, 2,4-dimethoxybenzenesulfonyl chloride, 4-chloro-3-nitrobenzenesulfonyl chloride, 4-(chlorosulfonyl)-benzoic acid, 3-nitrobenzenesulfonyl chloride, 4-nitrobenzenesulfonyl chloride, 2-(methylsulfonyl)-benzenesulfonyl chloride, 4-(methylsulfonyl)-benzene-sulfonyl chloride, 3-(chlorosulfonyl)-benzoic acid, 2,4-dichloro-5-methylbenzene-sulfonyl chloride, 4-(trifluoromethoxy)-benzenesulfonyl chloride, 2-methoxy-4-nitrobenzenesulfonyl chloride, 4-bromo-2-chlorobenzenesulfonyl chloride, 2,3-dihydro-1-benzofuran-5-sulfonyl chloride, 2,3-dihydro-1,4-benzodioxine-6-sulfonyl chloride, 1,3-benzothiazole-6-sulfonyl chloride, 2,1,3-benzothiadiazole-4-sulfonyl chloride, 2,1,3-benzothiadiazole-5-sulfonyl chloride, 2,1,3-benzoxadiazole-4-sulfonyl chloride, 3,4-dihydro-2H-1,5-benzodioxepine-7-sulfonyl chloride, 4-methyl-3,4-dihydro-2H-1,4-benzoxazine-7-sulfonyl chloride, 4-(1,3-oxazol-5-yl)benzenesulfonyl chloride, 4-(1,2,3-thiadiazol-4-yl)benzenesulfonyl chloride, 4-(1H-pyrazol-1-yl)benzenesulfonyl chloride, 4-(3-chloro-2-cyanophenoxy)benzene-1-sulfonyl chloride, 5-chlorosulfonyl-2-hydroxy-benzoic acid, 4-bromo-2,5-difluorobenzene-1-sulfonyl chloride, 4-(acetyl-amino)-3-chloro-benzene-1-sulfonyl chloride, 3,5-di-(trifluoromethyl)-benzene-1-sulfonyl chloride, 2-fluorobenzenesulfonyl chloride, 4-methyl-3-nitrobenzene-1-sulfonyl chloride, 5-chloro-2,1,3-benzoxadiazole-4-sulfonyl chloride, 3-(5-methyl-1,3,4-oxadiazol-2-yl) benzenesulfonyl chloride, methyl 3-(chlorosulfonyl)-4-methoxybenzoate, 4-bromo-2-(trifluoromethyl)-benzenesulfonyl chloride, 2,2-dimethyl-6-chromanesulfonyl chloride, 4-(morpholine-4-sulfonyl) benzenesulfonyl chloride, 4-(pyrrolidine-1-sulfonyl)-benzene-sulfonyl chloride, 3-(2-methyl-4-pyrimidinyl)benzenesulfonyl chloride, 2-cyano-5-methylbenzenesulfonyl chloride, 2,5-dimethylbenzenesulfonyl chloride, 4-chloro-3-(trifluoromethyl)-benzene-sulfonyl chloride, 4-bromo-2-methylbenzene-1-sulfonyl chloride, 2-chloro-4-(trifluoromethyl)-benzene-1-sulfonyl chloride, 2-chloro-4-cyano-benzene-1-sulfonyl chloride, 2,6-dichloro-4-(trifluoromethyl)-benzene-1-sulfonyl chloride, 3,4-difluorobenzene-1-sulfonyl chloride, 2-iodobenzene-1-sulfonyl chloride, 4-methyl-1-naphthalenesulfonyl chloride, 4-(trifluoromethyl)benzene-1-sulfonyl chloride, 2,6-dichlorobenzene-1-sulfonyl chloride, 2-(trifluoromethoxy)benzene-1-sulfonyl chloride, 4-cyanobenzene-1-sulfonyl chloride, 4-butoxybenzene-1-sulfonyl chloride, 2,3,4-trifluorobenzene-1-sulfonyl

chloride, 4-bromo-2-(trifluoromethoxy) benzene-1-sulfonyl chloride, 3-cyanobenzene-1-sulfonyl chloride, 3-chloro-4-methylbenzene-1-sulfonyl chloride, 4-bromo-2-ethylbenzene-1-sulfonyl chloride, 5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthalene-sulfonyl chloride, 4-(2-chloro-6-nitrophenoxy)benzene-1-sulfonyl chloride, 3,5-dichloro-  
 5 4-(2-chloro-4-nitrophenoxy) benzene-1-sulfonyl chloride, 4-pentylbenzene-1-sulfonyl chloride, 4-ethylbenzene-1-sulfonyl chloride, 4-propylbenzene-1-sulfonyl chloride, 4-butylbenzene-1-sulfonyl chloride, 3-toluenesulfonyl chloride, 4-isopropylbenzenesulfonyl chloride, 4-(2-oxo-1-pyrrolidinyl)benzene sulfonyl chloride, 4-(2-methoxyphenoxy)benzenesulfonyl chloride, 4-(2-chloro-phenoxy)benzenesulfonyl  
 10 chloride, 4-(2-methylphenoxy) benzenesulfonyl chloride, 4'-chloro(1,1'-biphenyl)-4-sulfonyl chloride, 4'-fluoro(1,1'-biphenyl)-4-sulfonyl chloride, 4'-methoxy-(1,1'-biphenyl)-4-sulfonyl chloride, 3',4'-dichloro-(1,1'-biphenyl)-4-sulfonyl chloride, 4-phenoxybenzenesulfonyl chloride, 4'-methyl-(1,1'-biphenyl)-4-sulfonyl chloride, 5-bromo-2,3-dihydrobenzo[b]furan-7-sulphonyl chloride, 3,4,5-trifluoro-benzenesulfonyl  
 15 chloride, 3-(5-methyl-1,2,4-oxadiazol-3-yl)benzenesulfonyl chloride, 4-(2-methyl-1,3-thiazol-4-yl)benzenesulfonyl chloride, 1-acetyl-5-indolinesulfonyl chloride, 3-(2-methyl-1,3-thiazol-4-yl)benzene-sulfonyl chloride and 1,3-benzodioxole-5-sulfonyl chloride.

Phenylacetyl chlorides (structural formula V-C) suitable for use in the synthesis of the compounds of the present invention include, but are not limited to, phenylacetyl  
 20 chloride, 4-methoxyphenylacetyl chloride, 2-(2-naphthyl)acetyl chloride, 2-(3,5-difluorophenyl)ethanoyl chloride, 2-(1-naphthyl)ethanoyl chloride, 4-chlorophenylacetyl chloride, 3-methoxyphenylacetyl chloride, and 4-fluorophenylacetyl chloride.

The intermediate compounds represented by the structural formulae (IV-A) and (IV-B) may also be reacted with an aryl isocyanate (structural formula V-E shown in  
 25 figure 2) or a heteroaryl isocyanate in order to yield final compounds with structural formulae (A), (B), (D) or (E) wherein X is a urea linking moiety (when starting from intermediate compounds according to structural formula IV-A) or comprises a urea linkage (e.g.  $X = (CH_2)_2NHC(=O)NH$  when starting from intermediate compounds according to structural formula IV-B), i.e. X corresponds to the definition of a divalent  
 30 saturated non-cyclic hydrocarbon group comprising one or more carbon atoms and two nitrogen atoms in the main chain, one of said carbon atoms being substituted with oxo.

Aryl isocyanates (represented by the structural formula V-E) suitable for use in the synthesis of compounds of the present invention with structural formula (A) include, but are not limited to, 4-fluorophenyl isocyanate, phenyl isocyanate, *m*-tolyl isocyanate,  
 35 *p*-tolyl isocyanate, 4-chlorophenyl isocyanate, ethyl 4-isocyanatobenzoate, 2-fluorophenyl isocyanate, 3-fluorophenyl isocyanate,  $\alpha,\alpha,\alpha$ -trifluoro-*o*-tolyl isocyanate, tolylene-2,4-diisocyanate, tolylene 2,6-diisocyanate, 4-methoxyphenyl isocyanate, 4-

bromophenyl isocyanate, 2-methoxy-phenyl isocyanate, 3-Methoxyphenyl isocyanate, 2,4-dichlorophenyl isocyanate, o-tolyl isocyanate, 3,4-dichlorophenyl isocyanate, 2-nitrophenyl isocyanate, 4-nitrophenyl isocyanate, 2,4-difluorophenyl isocyanate, 2-bromophenyl isocyanate, 2,6-difluoro-phenyl isocyanate, 2-(trifluoromethoxy)phenyl isocyanate, 2-chloro-5-(trifluoro-methyl)phenyl isocyanate, 4-chloro-2-(trifluoro-methyl)phenyl isocyanate, 4-chloro-3-(trifluoromethyl)phenyl isocyanate, 2,5-difluoro-phenyl isocyanate, 4-(trifluoro-methoxy)phenyl isocyanate, 2-ethoxyphenyl isocyanate, 4-ethoxyphenyl isocyanate, 4-isopropylphenyl isocyanate, 3-acetylphenyl isocyanate, 2,6-diisopropylphenyl isocyanate, 3-bromophenyl isocyanate, 3,5-dichlorophenyl isocyanate, 4-fluoro-3-nitrophenyl isocyanate, 3,5-dimethylphenyl isocyanate, 3,5-bis(trifluoromethyl)phenyl isocyanate, 3-cyanophenyl isocyanate, 4-(methylthio)phenyl isocyanate, 2-ethylphenyl isocyanate, 2,6-dimethyl-phenyl isocyanate,  $\alpha,\alpha,\alpha$ -trifluoro-p-tolyl isocyanate, 2,3-dichlorophenyl isocyanate, 4-methyl-3-nitrophenyl isocyanate, 2,4-dimethoxyphenyl isocyanate, 4-(chloro-methyl)phenyl isocyanate, 4-bromo-2-chlorophenyl isocyanate, 2-bromo-4,6-difluoro-phenyl isocyanate, 4-bromo-2-fluoro-phenyl isocyanate, 4-(dimethylamino)phenyl isocyanate, 2-fluoro-5-methylphenyl isocyanate, 4-fluoro-2-nitrophenyl isocyanate, 2-fluoro-3-(trifluoromethyl)phenyl isocyanate, 2-fluoro-5-(trifluoromethyl)phenyl isocyanate, 2-fluoro-6-(trifluoromethyl)-phenyl isocyanate, 4-fluoro-2-(trifluoromethyl) phenyl isocyanate, 4-fluoro-3-(trifluoromethyl)phenyl isocyanate, 4-(heptyloxy)phenyl isocyanate, 2-iodophenyl isocyanate, 2-naphthyl isocyanate, 2-n-propylphenyl isocyanate, 4-(trifluoromethylthio)phenyl isocyanate, 2,3,4-trifluorophenyl isocyanate, 2,6-dichlorophenyl isocyanate, 3-nitrophenyl isocyanate, 3-chlorophenyl isocyanate, 2-chlorophenyl isocyanate, 1-naphthyl isocyanate, 2,3-dimethylphenyl isocyanate, 3-chloro-4-fluorophenyl isocyanate, 2,5-dimethylphenyl isocyanate, 3,4-difluorophenyl isocyanate, 2,3-dihydro-1-benzofuran-5-yl isocyanate, 2,3-dihydro-1,4-benzodioxin-6-yl isocyanate, 6-fluoro-4H-1,3-benzodioxin-8-yl isocyanate, 2,1,3-benzothiadiazol-4-yl isocyanate, 3,4-dihydro-2H-1,5-benzodioxepin-7-yl isocyanate, 3-(cyclopentyloxy)-4-methoxyphenyl isocyanate, 2-(methylthio)phenyl isocyanate, 2-(*tert*-butyl)phenyl isocyanate, 4-(*tert*-butyl)phenyl isocyanate, 3-chloro-2-methylphenyl isocyanate, 4-butyl-2-methylphenyl isocyanate, 2-ethyl-6-methylphenyl isocyanate, 4-chloro-3-nitrophenyl isocyanate, 4-bromo-2-methylphenyl isocyanate, 3-(methylthio)phenyl isocyanate, 5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthalenyl isocyanate, 5-fluoro-2-methylphenyl isocyanate, 4-phenoxyphenyl isocyanate, 4-methoxy-2-methyl-phenyl isocyanate,  $\alpha,\alpha,\alpha$ -trifluoro-*m*-tolyl isocyanate, 2,6-dibromo-4-isopropylphenyl isocyanate, 2,6-dimethoxyphenyl isocyanate, 2-(4-isocyanatophenyl)thiophene, 4-(3-isocyanatophenyl)-2-methyl-1,3-thiazole, 3-(3-isocyanatophenyl)-5-methyl-1,2,4-oxa-



diazole, 1-benzothiophen-5-yl isocyanate, 1-(3-isocyanatophenyl)-1H-pyrrole, 1-(4-isocyanatophenyl)-1H-pyrrole, 3,5-dimethoxyphenyl isocyanate and 2,4,6-trichlorophenyl isocyanate.

The intermediate compounds represented by the structural formulae (IV-A) and (IV-B) may also be reacted with an aryl or heteroaryl isothiocyanate in order to yield final compounds with structural formulae (A), (B), (D) or (E) wherein X is a thiourea linking moiety (when starting from intermediate compounds according to structural formula IV-A) or comprises a thiourea linkage (e.g.  $X = (CH_2)_2NHC(=S)NH$  when starting from intermediate compounds according to structural formula IV-B), i.e. X corresponds to the definition of a divalent saturated non-cyclic hydrocarbon group comprising one or more carbon atoms and two nitrogen atoms in the main chain, one of said carbon atoms being substituted with thioxo. Aryl isothiocyanates suitable for use in the synthesis of the compounds of the present invention include, but are not limited to, phenyl isothiocyanate, 4-fluorophenyl isothiocyanate, methyl 2-isocyanatobenzoate, 2-chlorophenyl isothiocyanate, 3-chlorophenyl isothiocyanate, *o*-tolyl isothiocyanate, *m*-tolyl isothiocyanate, *p*-tolyl isothiocyanate, 2-methoxyphenyl isothiocyanate, 2-bromophenyl isothiocyanate, 3-bromophenyl isothiocyanate, 2,4-dichlorophenyl isothiocyanate, 2-fluorophenyl isothiocyanate, 4-methoxyphenyl isothiocyanate,  $\alpha,\alpha,\alpha$ -trifluoro-*m*-tolyl isothiocyanate, 3-fluorophenyl isothiocyanate, 3,5-bis(trifluoromethyl)phenyl isothiocyanate, 1-naphthyl isothiocyanate, 4-dimethylamino-1-naphthyl isothiocyanate, 4-(methylthio)phenyl isothiocyanate, 2-methoxy-5-methylphenyl isothiocyanate, 4-cyanophenyl isothiocyanate, 3-chloro-4-fluorophenyl isothiocyanate, 4-nitrophenyl isothiocyanate, 4-bromophenyl isothiocyanate, 2,3-dihydro-1,4-benzodioxin-6-yl isothiocyanate, 1,3-benzodioxol-5-yl isothiocyanate, 4-(1H-pyrazol-1-yl)phenyl isothiocyanate, 2-(trifluoromethyl)phenyl isothiocyanate, 2,3-dimethylphenyl isothiocyanate, 2-isopropylphenyl isothiocyanate, 4-iso-propylphenyl isothiocyanate, 5-chloro-2-methoxyphenyl isothiocyanate, 2,4-dimethoxyphenyl isothiocyanate, 2,4-dichloro-6-methylphenyl isothiocyanate, 2-bromo-4-isopropylphenyl isothiocyanate, 5-chloro-2-fluorophenyl isothiocyanate, 4-(trifluoromethoxy)phenyl isothiocyanate, 3,5-dimethylphenyl isothiocyanate, 3,5-dimethoxyphenyl isothiocyanate, 4-chlorophenyl isothiocyanate, 3,4-dimethoxyphenyl isothiocyanate, 2,6-dimethylphenyl isothiocyanate, 3-methoxyphenyl isothiocyanate, mesityl isothiocyanate, 4-(benzyloxy)phenyl isothiocyanate, 2,4-dimethylphenyl isothiocyanate, 2-bromo-5-fluorophenyl isothiocyanate, 5-fluoro-2-methylphenyl isothiocyanate, 4-chloro-2,5-dimethoxyphenyl isothiocyanate, 2,5-dichlorophenyl isothiocyanate, 2-(tert-butyl)-4,5,6-trimethyl-3-nitrophenyl isothiocyanate, 2-isopropyl-6-methylphenyl

isothiocyanate, 4-ethoxyphenyl isothiocyanate, 5-chloro-2-methylphenyl isothiocyanate, 2-ethyl-6-methylphenyl isothiocyanate and 4-(trifluoromethyl) phenyl isothiocyanate.

Alternatively, intermediates represented by the structural formula (IV-A) or (IV-B) may be derivatised with a carbonylation (acylation) agent (e.g. carbonyl diimidazole abbreviated as CDI in figure 2) and then reacted with an aromatic amine (e.g. represented by the structural formula (V-D) in figure 2) or a Het<sup>1</sup>-containing heteroaromatic amine. Suitable acylating agents include diphosgene and triphosgene, or may be represented by the structural formula Y-C(=O)-R''' wherein:

- R''' denotes an aliphatic group having 1 to 4 carbon atoms which may be substituted by alkoxy having 1 to 3 carbon atoms; a cycloaliphatic group having 5 to 7 carbon atoms; a bicycloaliphatic group having 7 to 14 carbon atoms; a tricycloaliphatic group having 7 to 16 carbon atoms; an alkoxy group having 1 to 6 C atoms; an aryloxy group having 6 to 10 carbon atoms; an alkoxycarbonyl group having a total of 2 to 7 carbon atoms; an aryl group having 6 to 10 carbon atoms and optionally mono-, di- or trisubstituted by 1 to 3 halogen atoms and/or 1 to 3 alkyl groups having 1 to 3 carbon atoms and/or 1 to 3 alkoxy groups having 1 to 3 carbon atoms and/or 1 or 2 nitro groups; and
- Y is an atom or group of atoms which can be removed by a nucleophile. In this formula Y denotes, for example, in particular halogen, preferably chloro or bromo; hydroxyl; an alkoxy group in particular having 1 to 5 carbon atoms; an aryloxy group, in particular wherein aryl is a phenyl which may be monosubstituted or polysubstituted by alkyl and/or nitro (e.g. tolyl, dinitrophenyl or nitrophenyl); O(C=O)R'''; -O(C=O)O-alkyl, in particular having 1 to 5 carbon atoms in the alkyl radical; or the radical of an azole or benzazole bonded via a nitrogen atom and having at least two nitrogen atoms in the quasi-aromatic five-membered ring. Suitable acylating agents thus represent, for example, haloformic acid esters, of which chloroformic acid esters are preferred (Y = halogen); carboxylic acids (Y = OH); alkyl and aryl esters, of which the tolyl, 2,4-dinitro or 4-nitrophenyl esters are preferred; anhydrides; mixed carboxylic acid carbonic acid anhydrides; or heterocyclic amides or azolides, in particular of N,N'-carbonyldiazoles such as, for example, N,N'-carbonyldiimidazole, 2,2'-carbonyl-1,2,3-ditriazole, 1,1'-carbonyl-1,2,4-ditriazole, N,N'-carbonyl-dipyrazole, and 2,2'-carbonyl-ditriazole.

The resulting acylated derivative (e.g. an imidazo-carbonyl derivative when starting from CDI) may then be further reacted with an amino-containing compound, particularly an aniline derivative represented by the structural formula (V-D) as shown in figure 2, wherein R<sub>7</sub>, R<sub>8</sub>, R<sub>9</sub>, R<sub>10</sub> and R<sub>11</sub> are as defined above, or a Het<sub>1</sub>-containing heteroaryl amine, thereby providing further compounds of the invention with structural formulae

(A), (B), (D) or (E). The carbonylation and further urea formation by reaction with an amino-containing compound may be most particularly carried out in a one-pot procedure. Amino-containing compounds suitable for the latter reaction include arylamines as shown in figure 2, but also arylalkylamines, arylalkenylamines, arylalkynylamines wherein one or more of the carbon atoms in the said alkyl, alkenyl or alkynyl moiety is optionally replaced by a heteroatom selected from the group consisting of O, N and S, and wherein the aryl group is optionally mono- or poly-substituted.

Suitable aniline derivatives represented by the structural formula (V-D) for use in the above reaction step include, but are not limited, to 2,6-dimethylaniline, 2-methylaniline, 3-fluoroaniline, 4-ethylaniline, 2, 4-dimethoxyaniline, 2,6-dichloroaniline, 3-cyanoaniline, and 2,4-fluoroaniline. Also suitable are C<sub>1-4</sub> alkoxy-anilines and C<sub>1-4</sub> alkylthio-anilines (or salts thereof) being optionally further substituted at another position of the phenyl ring. Representative examples of such optionally substituted C<sub>1-4</sub> alkoxy-anilines or C<sub>1-4</sub> alkylthio-anilines include, but are not limited to, 2-methoxyaniline, 3-methoxyaniline, 4-methoxyaniline, 2-ethoxyaniline, 3-ethoxyaniline, 4-ethoxyaniline, 4-bromo-3-ethoxyaniline hydrochloride, 2-propoxyaniline, 3-propoxyaniline, 4-propoxyaniline, 3-isopropoxyaniline, 4-isopropoxyaniline, 2,5-diethoxyaniline, 3,4-diethoxyaniline, 4-*n*-butoxyaniline, 3-*n*-butoxyaniline, 2-*n*-butoxyaniline, 4-isobutoxyaniline, 3-isobutoxyaniline, 2-isobutoxyaniline, 2-methyl-4-methoxyaniline, 2-(methylthio)aniline, 3-(methylthio)aniline, 4-(methylthio)aniline, 2-trifluoromethoxyaniline, 3-trifluoromethoxyaniline, 4-trifluoromethoxyaniline, 5-chloro-2-(methylthio)aniline, 2-bromo-4-methoxyaniline, 2-bromo-5-methoxyaniline, 3-bromo-4-methoxyaniline, 4-bromo-3-methoxyaniline, 5-bromo-2-methoxyaniline, 2-iodo-5-methoxyaniline, 3-iodo-4-methoxyaniline, 5-iodo-2-methoxyaniline, 2-chloro-5-methoxyaniline, 3-chloro-2-methoxyaniline, 3-chloro-4-methoxyaniline, 4-chloro-3-methoxyaniline, 5-chloro-2-methoxyaniline, 2-fluoro-4-methoxyaniline, 2-fluoro-6-methoxyaniline, 3-fluoro-2-methoxyaniline, 3-fluoro-4-methoxyaniline, 3-fluoro-5-methoxyaniline, 4-fluoro-3-methoxyaniline, 5-fluoro-2-methoxyaniline, 2-(difluoromethoxy)aniline, 3-(difluoromethoxy)aniline, 4-(difluoromethoxy)aniline and 2,4-dichloro-5-methoxyaniline.

Suitable arylalkylamines for use in the above reaction step include, but are not limited to, 2-chlorobenzylamine, 4-chlorobenzylamine, 2,4-dichlorobenzylamine, 3,4-dichlorobenzylamine, 4-methoxybenzylamine, 4-methylbenzylamine, piperonyl-amine, 3,4-dimethoxybenzylamine, 3-methylbenzylamine, 3-fluorobenzylamine, 2-methylbenzylamine, 2-methoxybenzylamine, 3-methoxybenzylamine, 2-fluorobenzylamine, 4-fluorobenzylamine, 3,4-dihydroxybenzylamine, 3-chlorobenzylamine, 4-(trifluoromethoxy)benzylamine, 2,6-difluorobenzylamine, 3,5-bis(trifluoromethyl)-

benzylamine, 2,4-difluorobenzylamine, 2,5-difluorobenzylamine, 3,4-difluorobenzylamine, 2-(trifluoromethyl)benzylamine, 3-(trifluoromethyl)benzylamine, 2-bromobenzylamine, 4-bromobenzylamine, 2-chloro-6-fluorobenzylamine, 2,5-dimethylbenzylamine, 3,4,5-Trimethoxybenzylamine, 2,4,6-trimethylbenzylamine, 2,4-dimethylbenzylamine,

5 2,3-dichlorobenzylamine, 1-naphthalenemethylamine, 3-iodobenzylamine, 2-hydroxybenzylamine, 3-bromobenzylamine, 2,6-dichlorobenzylamine, 3,4-dihydro-2H-1,5-benzodioxepin-6-ylmethylamine, 2,3-dihydro-1,4-benzodioxin-6-ylmethylamine, 2,3-dihydro-1,4-benzodioxin-5-ylmethylamine, 1-benzofuran-5-ylmethylamine, 4-(thien-2-yl)benzylamine, 3,4-dihydro-2H-1,5-benzodioxepin-7-ylmethylamine, 4-morpholino-

10 benzylamine, 4-(1H-pyrazol-1-yl)benzylamine, 4-(4-methylpiperazino)benzylamine, 2-piperidinobenzylamine, 3-(1H-pyrrol-1-yl)benzylamine, 2-morpholinobenzylamine, 4-(1H-pyrrol-1-yl)benzylamine, 2-chloro-6-phenoxybenzylamine, 2-(methylthio)benzylamine, 2-(trifluoromethoxy)benzylamine, 2,3-dimethylbenzylamine, 4-(trifluoromethyl)benzylamine, 3,5-dichlorobenzylamine, 2-(aminomethyl)-3-fluoroaniline, 3-chloro-4-

15 fluorobenzylamine, 2,5-dimethoxybenzylamine, 2,5-dichlorobenzylamine, 2,6-dimethoxybenzylamine, 2,4-dichloro-6-methylbenzylamine, 3-chloro-4-methylbenzylamine, 4-fluoro-3-(trifluoromethyl)benzylamine, 4-fluoro-2-(trifluoromethyl)benzylamine, 3-(piperidin-1-ylmethyl)benzylamine, 1-benzothiophen-5-ylmethylamine, 4-(morpholinomethyl)benzylamine, (3-((4-methylpiperidino)methyl)phenyl)methanamine, (4-

20 piperidinophenyl)methylamine, (3-piperidinophenyl)methylamine, 1-[2-(4-methylpiperazin-1-yl)phenyl]methanamine, (1,4-dimethyl-1,2,3,4-tetrahydroquinoxalin-6-yl)methylamine, 3-(trifluoromethoxy)benzylamine, 4-bromo-2-fluorobenzylamine, 2-(1H-pyrazol-1-yl)benzylamine, tert-butyl-4-(2-(aminomethyl)phenyl)piperazine-1-carboxylate, (3-morpholinophenyl)methylamine, tert-butyl-N-[4-(aminomethyl)

25 phenyl]carbamate, [2-(1H-pyrrol-1-yl)phenyl]methylamine, 1-[3-(4-methylpiperazin-1-yl)phenyl]methanamine, [4-(1-pyrrolidinyl)phenyl]methanamine, (3-pyrrolidin-1-ylphenyl)methylamine, [4-(2-morpholinoethoxy)phenyl]methylamine, [2-(2-morpholinoethoxy)phenyl]methylamine, [3-(2-morpholinoethoxy)phenyl]methylamine, [3-(morpholinomethyl)phenyl]methylamine, [4-(piperidinomethyl)phenyl]methylamine, {4-[(4-methylpiperazin-1-yl)methyl]phenyl}methylamine, [4-(2-furyl)phenyl]methylamine, tert-butyl-4-[4-(aminomethyl)phenyl]tetrahydro-1(2H)-pyrazinecarboxylate, (2,2-

30 dimethyl-2,3-dihydro-1-benzofuran-7-yl)methylamine, [3-(1H-1,2,4-triazol-1-yl)phenyl]methylamine, (4-thien-3-ylphenyl)methylamine, 1-[2-(morpholin-4-ylmethyl)phenyl]methanamine, {2-[(4-methylpiperazin-1-yl)methyl]phenyl}methylamine, [3-(2-furyl)phenyl]methylamine, (3-(thien-2-yl)phenyl)methylamine, [2-(2-furyl)phenyl]methylamine, 4-(pyrrolidin-1-ylmethyl)benzylamine, 4-[(4-methylperhydro-1,4-diazepin-1-yl)methyl]benzylamine, 4-[2-(dimethylamino)ethoxy]benzylamine, (2-

pyrrolidin-1-ylphenyl)methylamine, [3-(1-pyrrolidinylmethyl)phenyl]methanamine, (3-thien-3-ylphenyl)methylamine, 2-[2-(dimethylamino)ethoxy]benzylamine, 2-(phenoxymethyl)benzylamine, (1-methyl-1H-indol-4-yl)methylamine, 4-(4-methylperhydro-1,4-diazepin-1-yl)benzylamine, (1-methyl-1H-indol-6-yl)methylamine, 5 [3-(1,3-thiazol-2-yl)phenyl]methylamine, 3-(1H-pyrazol-1-ylmethyl)benzylamine, (1-Methyl-1H-indol-5-yl)methylamine, 3-(phenoxymethyl)benzylamine, 2-morpholino-5-(trifluoromethyl)benzylamine, [4-(1,3-thiazol-2-yl)phenyl]methylamine, 3-(1-methyl-1H-pyrazol-3-yl)benzylamine, 2-(4-methylperhydro-1,4-diazepin-1-yl)benzylamine, 4-[3-(dimethylamino)propoxy]benzylamine, 3-(2-methyl-1H-imidazol-1-yl)benzylamine, 4-(2-10 methyl-1H-imidazol-1-yl)benzylamine, 2-(2-methyl-1H-imidazol-1-yl)benzylamine, [4-(tetrahydropyran-4-yloxy)phenyl]methylamine, 3-[3-(dimethylamino)propoxy]benzylamine, 2-[3-(dimethylamino) propoxy]benzylamine, 3-pyrimidin-2-ylbenzylamine, 4-(1-methyl-1H-pyrazol-3-yl)benzylamine and 3-(1-methyl-1H-pyrazol-5-yl)benzylamine and 1-(1-benzothien-7-yl)methanamine.

15 Suitable Het<sub>1</sub>-containing heteroaryl amines for use in the above reaction step include, but are not limited to, 6-ethylpyridin-2-amine, 2-(2-aminoethyl)pyridine, 3-(2-aminoethyl)pyridine, 4-(2-aminoethyl)pyridine, 2-amino-4-ethylpyridine, 2-amino-3-ethylquinoline, tryptamine, aminoindole (all isomers thereof), aminopyrazole (all isomers thereof), aminopyrimidine (all isomers thereof), aminoimidazole (all isomers thereof), amino-(cyanoimidazole), and amino-(dicyanoimidazole). 20

When step (c) comprises two sub-steps as described herein-above, the order of performing the different reactions is not critical for the present invention and therefore can be changed at will. For example, the amino-containing compound comprising an optionally substituted heterocyclic ring (A') with at least two nitrogen atoms in the said 25 heterocyclic ring and with a total of 5 to 7 atoms may first be reacted with either one of the aryl-containing reagents represented by the structural formulae (V-A), (V-B), (V-E) or (V-C) or their Het<sub>1</sub>-containing analogues, or CDI followed by reaction with an aryl-containing compound represented by the structural formula (V-D) or one of its Het<sub>1</sub>-containing analogues. The resulting intermediate compound may then be used for 30 reaction with the 3-substituted-5-chloro-thiadiazole represented by the structural formula (III) to yield a final compound according to the invention.

When one or more of R<sub>7</sub>, R<sub>8</sub>, R<sub>9</sub>, R<sub>10</sub> and R<sub>11</sub> is a C<sub>1-6</sub> alkylcarbonyloxy group, and X is sulfonyl, it may be necessary to prepare the required phenyl-sulfonyl chloride having structural formula (V-B) by first reacting an optionally substituted phenol with a 35 carboxylic acid chloride, such as described in U.S. Patent No. 6,486,183 with respect to 3-fluoro-1-propionyloxybenzene, and then sulfonating the resulting product. An alternative method is also provided in the following examples.

Generally, 1,2,4-thiadiazole compounds having the structural formula (C) can be synthesised according to the principles of figures 3 and 4. Steps (a) and (b) of figure 3 proceed in the same way as described for figure 1 hereinbefore. In step (c) of figure 3, a non-cyclic diamine represented by the structural formula  $R'NH-(CHR_{15})_n-CHR_{14}-NHR$ , wherein  $n$ ,  $R$ ,  $R'$ ,  $R_{14}$  and  $R_{15}$  are as defined herein-above in the structural formula (C), is used as a reactant to convert the intermediate represented by the structural formula (III) into an intermediate represented by the structural formula (VI). The aliphatic chain comprised between the two nitrogen atoms of said non-cyclic diamine may be linear (i.e.  $R_{14}$  and  $R_{15}$  are both hydrogen) or may be branched (i.e. at least one of  $R_{14}$  and  $R_{15}$  is not hydrogen). Suitable examples of non-cyclic linear diamines include, but are not limited to, ethylenediamine, propylenediamine, *N*-methylethylenediamine, *N,N'*-dimethylethylenediamine, *N,N'*-diisopropylethylene-diamine, *N,N'*-diethylethylenediamine, 1,4-diaminobutane, 1,5-diaminopentane, 1,6-diaminohexane, 1,7-diaminoheptane, 1,8-diaminooctane, 1,9-diamino-nonane, 1,10-diaminodecane and 1,12-diaminododecane, most of them being commercially available. Suitable examples of non-cyclic branched diamines include, but are not limited to, the commercially available 1,2-diaminopropane as well as the following:

- 2,3-diaminobutane, the preparation and characterisation of which are known from Scaros et al. in *Tetrahedron: Assymetry* (1997) 8(9):1501-1506 and from Sarneski et al. in *Anal. Chem.* (1976) 48(9):1303-1308;
- 1,3-diaminobutane (CAS No. 590-88-5, ICSC No. 1078);
- 1,2-diaminobutane, the purification and characterisation of which are known from Douslin et al. in a report of the Bureau of Mines Bartlesville Okla Petroleum Research Center (1967);
- 1,2-diaminopentane, the preparation of which is known from WO2006/034440; and
- 1,3-diaminopentane, the production of which is known from U.S. Patent No. 5,898,085.

Suitable reaction conditions for the reaction of a non-cyclic linear or branched diamine having the structural formula  $R'NH-(CHR_{15})_n-CHR_{14}-NHR$  with a 3-substituted-5-chloro-thiadiazole compound represented by the structural formula (III) are well known in the art. In certain situations where competing amino reactive sites may be present such as, but not limited to, when in the structural formula (C)  $R$  is hydrogen and  $R'$  is  $C_{1-4}$  alkyl (illustrated below), or one of  $R_{14}$  and  $R_{15}$  is not hydrogen, it may be desirable (in order to reduce or avoid the possibility of producing a mixture of intermediates represented by the structural formula (VI) that may later have to be separated before performing the next reaction steps) to perform the above-mentioned reaction by first reacting a *N*-protected non-cyclic linear or branched diamine having

the structural formula  $R'-N(PG)-(CHR_{15})_n-CHR_{14}-NH_2$ , wherein PG is an amino-protecting group, and after said reaction step (c) has been completed, secondly deprotecting the resulting intermediate compound to achieve an intermediate represented by the structural formula (VI). N-protecting groups and amino-deprotecting techniques suitable for this particular purpose are well known to the person skilled in the art. Commonly used N-protecting groups are disclosed e.g. in Greene, "Protective Groups in Organic Synthesis" (John Wiley & Sons, New York, 1981). Suitable exemplary N-protecting groups include acyl groups such as formyl, acetyl, propionyl, pivaloyl, t-butylacetyl, 2-chloroacetyl, 2-bromoacetyl, trifluoroacetyl, trichloroacetyl, phthalyl, o-nitrophenoxycarbonyl, .alpha.-chlorobutyryl, benzoyl, 4-chloro-benzoyl, 4-bromobenzoyl, 4-nitrobenzoyl, and the like; sulfonyl groups such as benzenesulfonyl, p-toluenesulfonyl, and the like; carbamate forming groups such as benzyloxycarbonyl, p-chlorobenzyloxycarbonyl, p-methoxybenzyloxycarbonyl, p-nitro-benzyloxycarbonyl, 2-nitrobenzyloxycarbonyl, p-bromobenzyloxycarbonyl, 3,4-dimethoxybenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, 2-nitro-4,5-dimethoxybenzyloxycarbonyl, 3,4,5-trimethoxybenzyloxycarbonyl, 1-(p-biphenyl)-1-methylethoxycarbonyl,  $\alpha,\alpha$ -dimethyl-3,5-dimethoxybenzyloxycarbonyl, benzhydryloxycarbonyl, t-butoxycarbonyl, diisopropylmethoxycarbonyl, isopropylloxycarbonyl, ethoxycarbonyl, methoxycarbonyl, allyloxycarbonyl, 2,2,2-trichloroethoxycarbonyl, phenoxycarbonyl, 4-nitrophenoxycarbonyl, fluorenyl-9-methoxycarbonyl, cyclopentylloxycarbonyl, adamantylloxycarbonyl, cyclohexylloxycarbonyl, phenylthiocarbonyl, and the like; arylalkyl groups such as benzyl, triphenylmethyl, benzyloxymethyl and the like; and silyl groups such as trimethylsilyl and the like. The most appropriate N-protecting groups include formyl, acetyl, benzoyl, pivaloyl, t-butylacetyl, phenylsulfonyl, benzyl, t-butoxycarbonyl (BOC) and benzyloxycarbonyl.

Finally, the N-protecting group may be removed by deprotection methods conventional in the art, such as, but not limited to:

- when the amino-protecting group is a phenylmethoxycarbonyl group, cleavage of the benzylic ether function by hydrogenolysis, e.g. using  $H_2$ , Pd-C at about 25°C, or under strongly acidic conditions (e.g. making use of bromhydric acid), or
- when the amino-protecting group is a tert-butoxycarbonyl group, by treatment with an acid, e.g. using aqueous hydrochloric acid or trifluoroacetic acid (hereinafter referred as TFA), under conditions mild enough to avoid further cleavage of the molecule, or
- when the amino-protecting group is a 9-fluorenylmethoxycarbonyl group, by treatment with a base such as piperidine.

When step (c) is sub-divided into two sub-steps, the second sub-step may proceed according to figure 4, i.e. by reacting an intermediate compound represented by the structural formula (VI) with an aryl derivative represented by a structural formula (V-A), (V-B), (V-C), (V-D) or (V-E) shown in figure 4, or a corresponding heteroaryl derivative including a heteroaryl group Het<sup>1</sup>, said reaction proceeding in a manner similar to the corresponding reaction described for figure 2.

The above description provides general schemes for making all 1,2,4-thiadiazole compounds of the present invention. A list of exemplary, but non-limiting, compounds which have been effectively synthesised according to the described methods is provided in Table 1 herein.

The 1,2,4-thiadiazole derivatives having the above structural formulae (A), (B) and (C) may be in the form of a pharmaceutically acceptable salt. The latter include any therapeutically active non-toxic addition salt which 1,2,4-thiadiazole compounds having the general formulae (A), (B) and (C) are able to form with a salt-forming agent. Such addition salts may conveniently be obtained by treating the said derivative of the invention with an appropriate salt-forming acid or base. For instance, derivatives having basic properties may be converted into the corresponding therapeutically active, non-toxic acid addition salt form by treating the free base form with a suitable amount of an appropriate acid following conventional procedures. Examples of such appropriate salt-forming acids include, for instance, inorganic acids resulting in forming salts such as but not limited to hydrohalides (e.g. hydrochloride and hydrobromide), sulfate, nitrate, phosphate, diphosphate, carbonate, bicarbonate, and the like; and organic monocarboxylic or dicarboxylic acids resulting in forming salts such as, for example, acetate, propanoate, hydroxyacetate, 2-hydroxypropanoate, 2-oxopropanoate, lactate, pyruvate, oxalate, malonate, succinate, maleate, fumarate, malate, tartrate, citrate, methanesulfonate, ethanesulfonate, benzoate, 2-hydroxybenzoate, 4-amino-2-hydroxybenzoate, benzene-sulfonate, p-toluenesulfonate, salicylate, p-aminosalicylate, pamoate, bitartrate, camphorsulfonate, edetate, 1,2-ethanedisulfonate, fumarate, glucoheptonate, gluconate, glutamate, hexylresorcinate, hydroxynaphthoate, hydroxyethanesulfonate, mandelate, methylsulfate, pantothenate, stearate, as well as salts derived from ethanedioic, propanedioic, butanedioic, (Z)-2-butenedioic, (E)-2-butenedioic, 2-hydroxybutanedioic, 2,3-dihydroxybutane-dioic, 2-hydroxy-1,2,3-propanetricarboxylic and cyclohexanesulfamic acids and the like.

The 1,2,4-thiadiazole derivatives of the general formulae (A), (B) and (C) having acidic properties may be converted in a similar manner into the corresponding therapeutically active, non-toxic base addition salt form. Examples of appropriate salt-forming bases include, for instance, inorganic bases like metallic hydroxides such as



but not limited to those of alkali and alkaline-earth metals like calcium, lithium, magnesium, potassium and sodium, or zinc, resulting in the corresponding metal salt; organic bases such as but not limited to ammonia, alkylamines, benzathine, hydrabamine, arginine, lysine, N,N'-dibenzylethylenediamine, chlorprocaine, choline, diethanolamine, ethylene-diamine, N-methylglucamine, procaine and the like.

Reaction conditions for treating the 1,2,4-thiadiazole derivatives having the structural formulae (A), (B) and (C) of this invention with an appropriate salt-forming acid or base are similar to standard conditions involving the same acid or base but different organic compounds with basic or acidic properties, respectively. Preferably, in view of its use in a pharmaceutical composition or in the manufacture of a medicament for treating specific diseases, the pharmaceutically acceptable salt will be designed, i.e. the salt-forming acid or base will be selected so as to impart greater water-solubility, lower toxicity, greater stability and/or slower dissolution rate to the derivative of this invention.

In order to suitably use a 1,2,4-thiadiazole compound disclosed in this invention or a pharmaceutically acceptable salt, pro-drug or solvate thereof, for the therapeutic treatment (including prophylactic treatment) of mammals including humans, it is usually formulated in accordance with standard pharmaceutical practice as a pharmaceutical composition including one or more appropriate pharmaceutically acceptable excipients.

In another embodiment, this invention provides combinations, preferably synergistic combinations, of one or more derivatives represented by the general formulae (A), (B) and (C) with one or more biologically-active drugs being preferably selected from the group consisting of neuro-protective agents and  $\alpha$ -synuclein deposition inhibitors. As is conventional in the art, the evaluation of a synergistic effect in a drug combination may be made by analysing the quantification of the interactions between individual drugs, using the median effect principle described by Chou et al. in *Adv. Enzyme Reg.* (1984) 22:27. Briefly, this principle states that interactions (synergism, additivity, antagonism) between two drugs can be quantified using the combination index (hereinafter referred as CI) defined by the following equation:

$$CI_x = \frac{ED_x^{1c}}{ED_x^{1a}} + \frac{ED_x^{2c}}{ED_x^{2a}}$$

wherein  $ED_x$  is the dose of the first or respectively second drug used alone (1a, 2a), or in combination with the second or respectively first drug (1c, 2c), which is needed to produce a given effect. The said first and second drug have synergistic or additive or antagonistic effects depending upon  $CI < 1$ ,  $CI = 1$ , or  $CI > 1$ , respectively. As will be explained in more detail herein below, this principle may be applied to a number of

desirable effects such as, but not limited to, an activity against neurodegenerative disorders.

The term "pharmaceutically acceptable carrier or excipient" as used herein in relation to pharmaceutical compositions and combined preparations means any material or substance with which the active principle, i.e. the 1,2,4-thiadiazole derivative of the general formulae (A), (B) and (C), and optionally the neuro-protective agent or  $\alpha$ -synuclein deposition inhibitor, may be formulated in order to facilitate its application or dissemination to the locus to be treated, for instance by dissolving, dispersing or diffusing the said composition, and / or to facilitate its storage, transport or handling without impairing its effectiveness. The pharmaceutically acceptable carrier may be a solid or a liquid or a gas which has been compressed to form a liquid, i.e. the compositions of this invention can suitably be used as concentrates, emulsions, solutions, granulates, dusts, sprays, aerosols, pellets or powders.

Suitable pharmaceutical carriers for use in the said pharmaceutical compositions and their formulation are well known to those skilled in the art. There is no particular restriction to their selection within the present invention although, due to the usually low or very low water-solubility of the derivatives of this invention, special attention will be paid to the selection of suitable carrier combinations that can assist in properly formulating them in view of the expected time release profile. Suitable pharmaceutical carriers include additives such as wetting agents, dispersing agents, stickers, adhesives, emulsifying or surface-active agents, thickening agents, complexing agents, gelling agents, solvents, coatings, antibacterial and antifungal agents (for example phenol, sorbic acid, chlorobutanol), isotonic agents (such as sugars or sodium chloride) and the like, provided the same are consistent with pharmaceutical practice, i.e. carriers and additives which do not create permanent damage to mammals.

The pharmaceutical compositions of the present invention may be prepared in any known manner, for instance by homogeneously mixing, dissolving, spray-drying, coating and/or grinding the active ingredients, in a one-step or a multi-steps procedure, with the selected carrier material and, where appropriate, the other additives such as surface-active agents. may also be prepared by micronisation, for instance in view to obtain them in the form of microspheres usually having a diameter of about 1 to 10  $\mu\text{m}$ , namely for the manufacture of microcapsules for controlled or sustained release of the biologically active ingredient(s).

Suitable surface-active agents to be used in the pharmaceutical compositions of the present invention are non-ionic, cationic and/or anionic surfactants having good emulsifying, dispersing and/or wetting properties. Suitable anionic surfactants include

both water-soluble soaps and water-soluble synthetic surface-active agents. Suitable soaps are alkaline or alkaline-earth metal salts, unsubstituted or substituted ammonium salts of higher fatty acids ( $C_{10}$ - $C_{22}$ ), e.g. the sodium or potassium salts of oleic or stearic acid, or of natural fatty acid mixtures obtainable from coconut oil or tallow oil.

5 Synthetic surfactants include sodium or calcium salts of polyacrylic acids; fatty sulphonates and sulphates; sulphonated benzimidazole derivatives and alkylarylsulphonates. Fatty sulphonates or sulphates are usually in the form of alkaline or alkaline-earth metal salts, unsubstituted ammonium salts or ammonium salts substituted with an alkyl or acyl radical having from 8 to 22 carbon atoms, e.g. the  
10 sodium or calcium salt of lignosulphonic acid or dodecylsulphonic acid or a mixture of fatty alcohol sulphates obtained from natural fatty acids, alkaline or alkaline-earth metal salts of sulphuric or sulphonic acid esters (such as sodium lauryl sulphate) and sulphonic acids of fatty alcohol/ethylene oxide adducts. Suitable sulphonated benzimidazole derivatives preferably contain 8 to 22 carbon atoms. Examples of  
15 alkylarylsulphonates are the sodium, calcium or alkanolamine salts of dodecylbenzene sulphonic acid or dibutyl-naphtalenesulphonic acid or a naphtalene-sulphonic acid/formaldehyde condensation product. Also suitable are the corresponding phosphates, e.g. salts of phosphoric acid ester and an adduct of p-nonylphenol with ethylene and / or propylene oxide, or phospholipids. Suitable phospholipids for this  
20 purpose are the natural (originating from animal or plant cells) or synthetic phospholipids of the cephalin or lecithin type such as e.g. phosphatidylethanolamine, phosphatidylserine, phosphatidylglycerine, lysolecithin, cardiolipin, dioctanylephosphatidylcholine, dipalmitoylphosphatidylcholine and their mixtures.

Suitable non-ionic surfactants include polyethoxylated and polypropoxylated  
25 derivatives of alkylphenols, fatty alcohols, fatty acids, aliphatic amines or amides containing at least 12 carbon atoms in the molecule, alkylarenesulphonates and dialkylsulphosuccinates, such as polyglycol ether derivatives of aliphatic and cycloaliphatic alcohols, saturated and unsaturated fatty acids and alkylphenols, said derivatives preferably containing 3 to 10 glycol ether groups and 8 to 20 carbon atoms  
30 in the (aliphatic) hydrocarbon moiety and 6 to 18 carbon atoms in the alkyl moiety of the alkylphenol. Further suitable non-ionic surfactants are water-soluble adducts of polyethylene oxide with polypropylene glycol, ethylenediamino-polypropylene glycol containing 1 to 10 carbon atoms in the alkyl chain, which adducts contain 20 to 250 ethyleneglycol ether groups and / or 10 to 100 propyleneglycol ether groups. Such  
35 compounds usually contain from 1 to 5 ethyleneglycol units per propyleneglycol unit. Representative examples of non-ionic surfactants are nonylphenol-polyethoxyethanol, castor oil polyglycolic ethers, polypropylene/ polyethylene oxide adducts,

tributylphenoxypolyethoxyethanol, polyethyleneglycol and octylphenoxypolyethoxyethanol. Fatty acid esters of polyethylene sorbitan (such as polyoxyethylene sorbitan trioleate), glycerol, sorbitan, sucrose and pentaerythritol are also suitable non-ionic surfactants.

5            Suitable cationic surfactants include quaternary ammonium salts, preferably halides, having four hydrocarbon radicals optionally substituted with halo, phenyl, substituted phenyl or hydroxy; for instance quaternary ammonium salts containing as N-substituent at least one C<sub>8</sub>-C<sub>22</sub> alkyl radical (e.g. cetyl, lauryl, palmityl, myristyl, oleyl and the like) and, as further substituents, unsubstituted or halogenated lower alkyl, 10 benzyl and / or hydroxy-C<sub>1-4</sub> alkyl radicals.

          A more detailed description of surface-active agents suitable for this purpose may be found for instance in " McCutcheon's Detergents and Emulsifiers Annual " (MC Publishing Corp., Ridgewood, New Jersey, 1981), " Tensid-Taschenbuch ", 2<sup>nd</sup> ed. (Hanser Verlag, Vienna, 1981) and " Encyclopaedia of Surfactants (Chemical 15 Publishing Co., New York, 1981).

          Structure-forming, thickening or gel-forming agents may be included into the pharmaceutical compositions and combined preparations of the invention. Suitable such agents are in particular highly dispersed silicic acid, such as the product commercially available under the trade name Aerosil; bentonites; tetraalkyl ammonium 20 salts of montmorillonites (e.g., products commercially available under the trade name Bentone), wherein each of the alkyl groups may contain from 1 to 20 carbon atoms; cetostearyl alcohol and modified castor oil products (e.g. the product commercially available under the trade name Antisettle).

          Gelling agents which may be included into the pharmaceutical compositions 25 and combined preparations of the present invention include, but are not limited to, cellulose derivatives such as carboxymethylcellulose, cellulose acetate and the like; natural gums such as arabic gum, xanthum gum, tragacanth gum, guar gum and the like; gelatin; silicon dioxide; synthetic polymers such as carbomers, and mixtures thereof. Gelatin and modified celluloses represent a preferred class of gelling agents.

30            Other optional excipients which may be included in the pharmaceutical compositions and combined preparations of the present invention include additives such as magnesium oxide; azo dyes; organic and inorganic pigments such as titanium dioxide; UV-absorbers; stabilisers; odor masking agents; viscosity enhancers; antioxidants such as, for example, ascorbyl palmitate, sodium bisulfite, sodium 35 metabisulfite and the like, and mixtures thereof; preservatives such as, for example, potassium sorbate, sodium benzoate, sorbic acid, propyl gallate, benzylalcohol, methyl paraben, propyl paraben and the like; sequestering agents such as ethylene-diamine

tetraacetic acid; flavoring agents such as natural vanillin; buffers such as citric acid and acetic acid; extenders or bulking agents such as silicates, diatomaceous earth, magnesium oxide or aluminum oxide; densification agents such as magnesium salts; and mixtures thereof.

5 Additional ingredients may be included in order to control the duration of action of the biologically-active ingredient in the compositions and combined preparations of the invention. Control release compositions may thus be achieved by selecting appropriate polymer carriers such as for example polyesters, polyamino-acids, polyvinyl-pyrrolidone, ethylene-vinyl acetate copolymers, methylcellulose, carboxy-  
10 methylcellulose, protamine sulfate and the like. The rate of drug release and duration of action may also be controlled by incorporating the active ingredient into particles, e.g. microcapsules, of a polymeric substance such as hydrogels, polylactic acid, hydroxymethyl-cellulose, polymethyl methacrylate and the other above-described polymers. Such methods include colloid drug delivery systems like liposomes,  
15 microspheres, microemulsions, nanoparticles, nanocapsules and so on. Depending on the route of administration, the pharmaceutical composition or combined preparation of the invention may also require protective coatings.

Pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation  
20 thereof. Typical carriers for this purpose therefore include biocompatible aqueous buffers, ethanol, glycerol, propylene glycol, polyethylene glycol, complexing agents such as cyclodextrins and the like, and mixtures thereof.

In order to suitably use compounds disclosed in this invention – represented by structural formulae (A), (B) and (C) - for therapeutic or prophylactic purpose, such  
25 compounds are preferably administered so that a daily dose in the range of, for example, 0.1 mg to 75 mg per kg body weight is received, said daily dose being given if required in divided sub-doses. In general, lower doses will be administered when a parenteral route is employed. Thus, for example, for intravenous administration, a dose in the range of, for example, 0.5 mg to 30 mg per kg body weight will preferably be  
30 used. Similarly, for administration by inhalation, a dose in the range of, for example, 0.5 mg to 25 mg per kg body weight will preferably be used. According to a particular embodiment, the envisaged administration route for the compounds of the invention is oral administration, particularly in tablet form. Typically, unit dosage forms will contain about 1 mg to 500 mg of a compound of this invention.

35 Another embodiment of this invention includes the various precursor or " pro-drug " forms of the compounds of the present invention. It may be desirable to

formulate the compounds of the present invention in the form of a chemical species which itself is not significantly biologically-active, but which when delivered to the body of a human being or higher mammal will undergo a chemical reaction catalysed by the normal function of the body, *inter alia*, enzymes present in the stomach or in blood serum, said chemical reaction having the effect of releasing a compound as defined herein. The term "pro-drug" thus relates to these species which are converted *in vivo* into the active pharmaceutical ingredient.


The pro-drugs of the present invention can have any form suitable to the formulator, for example, esters are non-limiting common pro-drug forms. In the present case, however, the pro-drug may necessarily exist in a form wherein a covalent bond is cleaved by the action of an enzyme present at the target *locus*. For example, a C-C covalent bond may be selectively cleaved by one or more enzymes at said target *locus* and, therefore, a pro-drug in a form other than an easily hydrolysable precursor, *inter alia* an ester, an amide, and the like, may be used.

For the purposes of the present invention the term "therapeutically suitable pro-drug" is defined herein as "a compound modified in such a way as to be transformed *in vivo* to the therapeutically active form, whether by way of a single or by multiple biological transformations, when in contact with the tissues of humans or mammals to which the pro-drug has been administered, and without undue toxicity, irritation, or allergic response, and achieving the intended therapeutic outcome".

The following examples are provided for illustrative purpose only, and do not constitute an exhaustive list of compounds that can be made and used according to the above-mentioned general principles of the present invention.

#### Example 1 - amidine formation

A few illustrative amidines corresponding to the structural formula (II) herein-above have been prepared according to step (a) of scheme 1, more schematically shown below:



The above starting nitrile compound RCN, wherein R corresponds to (R<sub>1</sub>,R<sub>2</sub>,R<sub>3</sub>,R<sub>4</sub>,R<sub>5</sub>-substituted phenyl)-CR<sub>12</sub>R<sub>13</sub>- in the structural formula (I) of scheme 1, is first treated with gaseous HCl in a mixture of anhydrous chloroform and methanol to yield


the imino ether hydrochloride shown above. Subsequently, the mixture is treated with dry ammonia to yield the desired amidine compound.

Examples 2 to 13 - synthesis of 3-(substituted)benzyl-5-chloro-1,2,4-thiadiazole derivatives

3-(substituted)benzyl-5-chloro-1,2,4-thiadiazole intermediate derivatives represented by the structural formula (III) in step (b) of scheme 1 have been obtained according to the following detailed procedure:


In a three-necked 500 mL flask equipped with a mechanical stirrer, a dropping funnel and a thermometer, dichloromethane (DCM) (130 ml) was charged and the appropriate amidine hydrochloride from example 1 (0.1 mole) was suspended therein upon efficient stirring. Then perchloromethyl mercaptane (16.73 g, 0.09 mole) was added to the suspension. The stirred solution was cooled to  $-14^{\circ}\text{C}$  by using a ammonium chloride-ice cooling bath. Then an aqueous NaOH solution (20 g, 0.5 mole dissolved in 30 ml distilled water) was added dropwise to the solution upon efficient stirring while keeping the temperature below  $-8^{\circ}\text{C}$ . When addition was completed, the reaction mixture was stirred for another hour while letting temperature rise up to room temperature. The precipitated NaCl was filtered off and washed with DCM. The organic phase of the filtrate was separated and saved. The aqueous phase was washed three times with 20 ml DCM. The collected organic phases including the previously saved solution were washed four times with water (20 ml). The organic phase was dried over anhydrous sodium sulphate and evaporated to dryness. The residue was distilled in high motor vacuum using a vacuum-jacketed Vigreux-column. In this way, the following species were obtained and characterized by their boiling point (b.p.) and molecular weight:

- 5-chloro-3-(4-methylbenzyl)-[1,2,4]thiadiazole (example 2): starting from 31.8 g (172 mmole) 4-methylbenzyl amidine hydrochloride, 16.7 g was obtained (yield 48%); molecular weight 224.7, b.p.  $130-135^{\circ}\text{C}/1\text{ Hg mm}$ .




- 5-chloro-3-(4-fluorobenzyl)-[1,2,4]thiadiazole (example 3): starting from 18.4 g (97.5 mmole) 4-fluorobenzyl amidine hydrochloride, 13.45 g was obtained (yield : 67%); molecular weight 228.7, bp:  $120-125^{\circ}\text{C}/1\text{ Hg mm}$ .

43




- 5-chloro-3-(3-methoxybenzyl)-[1,2,4]thiadiazole (example 4): starting from 84.8 g (423 mmole) 3-methoxybenzyl amidine hydrochloride, 68.7 g was obtained (yield : 75%); molecular weight 240.7, bp: 132-135 °C/1 Hg mm.



5

- 5-chloro-3-(3-fluoro-benzyl)-[1,2,4]thiadiazole (example 5): starting from 2-(3-fluoro-phenyl)-acetamidine hydrochloride (8.87 g, 47 mmole) 4.08 g (yield 38%) was obtained; b.p.: 98-100°C/0.1 Hg mm.




MW = 188.63

MW = 228.68

10

- 5-chloro-3-(2-fluoro-benzyl)-[1,2,4]thiadiazole (example 6): starting from 2-(2-fluoro-phenyl)-acetamidine hydrochloride (18.1 g, 96 mmole) 10.6 g (yield 48%) was obtained; b.p.: 105-107°C/0.1 Hg mm.




MW = 188.63

MW = 228.68

15

- 3-benzyl-5-chloro-[1,2,4]thiadiazole (example 7) starting from phenylacetamidine hydrochloride (10.5 g; 61.4 mmole) 3.3 g (yield 25%) was obtained; b.p.: 102-104°C/0.1 Hg mm.




MW = 170.64


MW = 210.69




- 5-chloro-3-(3-methyl-benzyl)-[1,2,4]thiadiazole (example 8) starting from 2-*m*-tolyl-acetamidine hydrochloride (16.62 g; 90 mmole) 9.8 g (yield 48%) was obtained; b.p.: 114-118°C/0.2 Hg mm.




- 5 - 5-chloro-3-(2-methyl-benzyl)-[1,2,4]thiadiazole (example 9) starting from 2-*o*-tolyl-acetamidine hydrochloride (17.55 g; 95 mmole) 10.2 g (yield 48 %) was obtained; b.p.: 112-114°C/0.2 Hg mm.




- 10 - 5-chloro-3-(2-methoxy-benzyl)-[1,2,4]thiadiazole (example 10) starting from 2-(2-methoxy-phenyl)-acetamidine hydrochloride (19.07 g; 95 mmole) 12.1 g (yield 53 %) was obtained; b.p.: 132-134°C/1 Hg mm.



- 15 - 5-chloro-3-(4-methoxy-benzyl)-[1,2,4]thiadiazole (example 11) starting from 2-(4-methoxy-phenyl)-acetamidine hydrochloride (16.05 g; 80 mmole) 6.2 g (yield 32 %) was obtained; b.p.: 138-140°C/1 Hg mm.




- 5-chloro-3-(3-methyl-4-fluoro-benzyl)-[1,2,4]thiadiazole (example 12) starting from 2-(3-methyl-4-fluoro-phenyl)-acetamidine hydrochloride (15.70 g; 77.46 mmole) 7.3 g (yield 39 %) was obtained; b.p.: 113-115°C/0.5 Hg mm.



5

- 5-chloro-3-(4-chloro-benzyl)-[1,2,4]thiadiazole (example 13) starting from 2-(4-chloro-phenyl)-acetamidine hydrochloride (189 g; 918 mmole) 39.7 g (yield 20 %) was obtained; b.p.: 132-135°C/1 Hg mm.




- 10 Examples 14 to - nucleophilic replacement with piperazines onto 5-chloro-3-(substituted benzyl)-1,2,4-thiadiazole derivatives

1,2,4-thiadiazole intermediate derivatives represented by the structural formula (IV) have been obtained according to step (c) of scheme 1, more schematically shown in scheme 3 below (i.e. wherein Ar<sup>1</sup> corresponds to (R<sub>1</sub>,R<sub>2</sub>,R<sub>3</sub>,R<sub>4</sub>,R<sub>5</sub>-substituted phenyl), R<sup>2</sup> corresponds to R<sub>6</sub>, and each of R<sub>12</sub> and R<sub>13</sub> in scheme 1 is hydrogen), using the following detailed procedure:

15


Scheme 3




- 20 The piperazine derivative (used in a 5-fold molar excess) was dissolved in ethanol and a 3-(substituted benzyl)-5-chloro-1,2,4-thiadiazole derivative from examples 2-13 was added in portions. The reaction mixture was refluxed until the reaction was complete. The course of the reaction was monitored by thin layered chromatography (TLC) in an eluent mixture of DCM-EtOH 5:1. The reaction time
- 25 ranged from 3 to 6 hours for the various intermediate compounds synthesised in this

set of examples. When reaction was complete, the reaction mixture was evaporated to dryness. The residue was dissolved in water and the product was extracted with DCM. The organic phase was washed with water in order to remove remaining traces of the piperazine derivative, then it was dried over  $\text{MgSO}_4$  and evaporated to dryness. Purity of the product obtained was checked by TLC using as an eluent mixture DCM:EtOH in a volume ratio 5:1 containing a few drops of a 25% aqueous ammonium hydroxide solution. When TLC showed apolar impurities, the product was dissolved in a 5% aqueous HCl solution and impurities were washed away with ethyl-acetate, the aqueous phase was made alkaline (pH: 10-11) with a 10% aqueous NaOH solution and the product was extracted with DCM. In this way, the following species were obtained and characterized by their molecular weight and nuclear magnetic resonance spectra:


- 3-methyl-1-[3-(4-methyl-benzyl)-[1,2,4]thiadiazol-5-yl]-piperazine (example 14): starting from 3.37 g of 5-chloro-3-(4-methylbenzyl)-[1,2,4]thiadiazole (example 2; 15 mmole) and 2-methyl-piperazine (7.51 g, 75 mmole), 4.05 g of the title compound (molecular weight 288.4) was obtained after a 3 hour reaction time (94% yield).




- 1-[3-(4-fluoro-benzyl)-[1,2,4]thiadiazol-5-yl]-piperazine (example 15): starting with 3.43 g of 5-chloro-3-(4-fluorobenzyl)-[1,2,4]thiadiazole (example 3; 15 mmole) and piperazine (6.46 g; 75 mmole), 3.73 g of the title compound (molecular weight 278.4) was obtained after 6 hours reaction (89% yield).




- 1-[3-(3-methoxy-benzyl)-[1,2,4]thiadiazol-5-yl]-piperazine (example 16): starting from 2.41 g of 5-chloro-3-(4-fluorobenzyl)-[1,2,4]thiadiazole (example 3; 10 mmole) and piperazine (4.31 g; 10 mmole), 2.65 g of the title compound (molecular weight 290.4) was obtained after 5 hours reaction time (91% yield).




- 5 - 1.58 g (yield 89%) 1-[3-(3-fluoro-benzyl)-[1,2,4]thiadiazol-5-yl]-piperazine (example 17) was obtained starting from the 5-chloro-3-(3-fluoro-benzyl)-[1,2,4]thiadiazole of example 5 (1.6 g; 7.0 mmole) and piperazine (3.0 g; 35 mmole) after a reaction time of 5 hours.



- 10 - 1.53 g (yield 78%) of 1-[3-(2-fluoro-benzyl)-[1,2,4]thiadiazol-5-yl]-piperazine (example 18) was obtained starting from the 5-chloro-3-(2-fluoro-benzyl)-[1,2,4]thiadiazole of example 6 (1.6 g; 7.0 mmole) and piperazine (3.0 g; 35 mmole) after a reaction time of 5 hours.




- 15 - 1.41 g (yield 77%) of 1-(3-benzyl-[1,2,4]thiadiazol-5-yl)-piperazine (example 19) was obtained starting from the 3-benzyl-5-chloro-[1,2,4]thiadiazole of example 7 (1.47 g; 7.0 mmole) and piperazine (3.0 g; 35 mmole) after a reaction time of 5 hours.




- 1.54 g (yield 80%) of 1-[3-(3-methyl-benzyl)-[1,2,4]thiadiazol-5-yl]-piperazine (example 20) was obtained starting from the 5-chloro-3-(3-methyl-benzyl)-[1,2,4]thiadiazole of example 8 (1.57 g; 7.0 mmole) and piperazine (3.0 g; 35 mmole) after a reaction time of 5 hours.

5




- 1.52 g (yield 79%) of 1-[3-(2-methyl-benzyl)-[1,2,4]thiadiazol-5-yl]-piperazine (example 21) was obtained starting from the 5-chloro-3-(2-methyl-benzyl)-[1,2,4]thiadiazole of example 9 (1.57 g; 7.0 mmole) and piperazine (3.0 g; 35 mmole) after a reaction time of 5 hours.

10




- 1.68 g (yield 83%) of 1-[3-(2-methoxy-benzyl)-[1,2,4]thiadiazol-5-yl]-piperazine (example 22) was obtained starting from the 5-chloro-3-(2-methoxy-benzyl)-[1,2,4]thiadiazole of example 10 (1.69 g; 7.0 mmole) and piperazine (3.0 g; 35 mmole) after a reaction time of 5 hours.

15



- 1.71 g (yield 84%) of 1-[3-(4-methoxy-benzyl)-[1,2,4]thiadiazol-5-yl]-piperazine (example 23) was obtained starting from the 5-chloro-3-(4-methoxy-benzyl)-[1,2,4]thiadiazole of example 11 (1.69 g; 7.0 mmole) and piperazine (3.0 g; 35 mmol) after a reaction time of 5 hours.

20




MW = 240.72

MW = 290.39

- 2.07 g (yield 86%) of 1-[3-(3-methyl-4-fluoro-benzyl)-[1,2,4]thiadiazol-5-yl]-piperazine (example 24) was obtained starting from the 5-chloro-3-(3-methyl-4-fluoro-benzyl)-[1,2,4]thiadiazole of example 12 (2.0 g; 8.24 mmole) and piperazine (3.55 g; 41.2 mmole) after a reaction time of 6 hours.

5




MW = 242.71

MW = 292.38

- 1.24 g (yield 88%) of 1-[3-(3-methoxy-benzyl)-[1,2,4]thiadiazol-5-yl]-3-methylpiperazine (example 26) was obtained starting from the 5-chloro-3-(3-methoxy-benzyl)-[1,2,4]thiadiazole of example 4 (500 mg; 2.08 mmole) and 2-methylpiperazine (1.04 g; 10.4 mmole) after a reaction time of 6 hours.

10




MW = 245.13

MW = 294.81

- 562 mg (yield 89%) of 1-[3-(3-methoxy-benzyl)-[1,2,4]thiadiazol-5-yl]-3-methylpiperazine (example 26) was obtained starting from the 5-chloro-3-(3-methoxy-benzyl)-[1,2,4]thiadiazole of example 4 (500 mg; 2.08 mmole) and 2-methylpiperazine (1.04 g; 10.4 mmole) after a reaction time of 6 hours.

15


50



The following intermediate compounds are also synthesised, while using the above mentioned experimental conditions, from 2-methylpiperazine and the relevant 3-(substituted benzyl)-5-chloro-1,2,4-thiadiazole derivative from examples 2 to 13:

- 5        - 3-methyl-1-[3-(4-fluoro-benzyl)-[1,2,4]thiadiazol-5-yl]-piperazine (example 27),
- 3-methyl-1-[3-(3-methoxy-benzyl)-[1,2,4]thiadiazol-5-yl]-piperazine (example 28),
- 3-methyl-1-[3-(3-fluoro-benzyl)-[1,2,4]thiadiazol-5-yl]-piperazine (example
- 10       29),
- 3-methyl-1-[3-(2-fluoro-benzyl)-[1,2,4]thiadiazol-5-yl]-piperazine (example 30),
- 3-methyl-1-(3-benzyl-[1,2,4]thiadiazol-5-yl)-piperazine (example 31),
- 3-methyl-1-[3-(3-methyl-benzyl)-[1,2,4]thiadiazol-5-yl]-piperazine (example
- 15       32),
- 3-methyl-1-[3-(2-methyl-benzyl)-[1,2,4]thiadiazol-5-yl]-piperazine (example 33),
- 3-methyl-1-[3-(2-methoxy-benzyl)-[1,2,4]thiadiazol-5-yl]-piperazine (example 34),
- 20       - 3-methyl-1-[3-(4-methoxy-benzyl)-[1,2,4]thiadiazol-5-yl]-piperazine (example 35),
- 3-methyl-1-[3-(3-methyl-4-fluoro-benzyl)-[1,2,4]thiadiazol-5-yl]-piperazine (example 36),
- 3-methyl-1-[3-(4-chloro-benzyl)-[1,2,4]thiadiazol-5-yl]-piperazine (example
- 25       37), and
- 3-methyl-1-[3-(3-methoxy-benzyl)-[1,2,4]thiadiazol-5-yl]-piperazine (example 38).

2.75 mg (yield 75%) of 1-[3-(3-methoxy-benzyl)-[1,2,4]thiadiazol-5-yl]-[1,4]diazepane (example 39) was obtained starting from the 5-chloro-3-(3-methoxy-benzyl)-[1,2,4]thiadiazole of example 4 (2.89 g; 12 mmoles) and homopiperazine (6.0 g; 60 mmoles) after a reaction time of 6 hours.



The following intermediate compounds are also synthesised from homopiperazine and the relevant 3-(substituted benzyl)-5-chloro-1,2,4-thiadiazole derivative from examples 2 to 13, while using the above mentioned experimental conditions:

- 1-[3-(4-methyl-benzyl)-[1,2,4]thiadiazol-5-yl]-1,4-diazepane (example 40),
- 1-[3-(4-fluoro-benzyl)-[1,2,4]thiadiazol-5-yl]-1,4-diazepane (example 41),
- 1-[3-(3-fluoro-benzyl)-[1,2,4]thiadiazol-5-yl]-1,4-diazepane (example 42),
- 1-[3-(2-fluoro-benzyl)-[1,2,4]thiadiazol-5-yl]-1,4-diazepane (example 43),
- 1-[3-(3-benzyl)-[1,2,4]thiadiazol-5-yl]-1,4-diazepane (example 44),
- 1-[3-(3-methyl-benzyl)-[1,2,4]thiadiazol-5-yl]-1,4-diazepane (example 45),
- 1-[3-(2-methyl-benzyl)-[1,2,4]thiadiazol-5-yl]-1,4-diazepane (example 46),
- 1-[3-(2-methoxy-benzyl)-[1,2,4]thiadiazol-5-yl]-1,4-diazepane (example 47),
- 1-[3-(4-methoxy-benzyl)-[1,2,4]thiadiazol-5-yl]-1,4-diazepane (example 48),
- 1-[3-(3-methyl-4-fluoro-benzyl)-[1,2,4]thiadiazol-5-yl]-1,4-diazepane (example 49), and
- 1-[3-(4-chloro-benzyl)-[1,2,4]thiadiazol-5-yl]-1,4-diazepane (example 50).

The following intermediate compounds are also synthesised from 2,5-dimethylpiperazine and the relevant 3-(substituted benzyl)-5-chloro-1,2,4-thiadiazole derivative from examples 2 to 13, while using the above mentioned experimental conditions:

- 2,5-dimethyl-1-[3-(4-fluoro-benzyl)-[1,2,4]thiadiazol-5-yl]-piperazine (example 51),
- 2,5-dimethyl-1-[3-(3-methoxy-benzyl)-[1,2,4]thiadiazol-5-yl]-piperazine (example 52),
- 2,5-dimethyl-1-[3-(3-fluoro-benzyl)-[1,2,4]thiadiazol-5-yl]-piperazine (example 53),
- 2,5-dimethyl-1-[3-(2-fluoro-benzyl)-[1,2,4]thiadiazol-5-yl]-piperazine (example 54),
- 2,5-dimethyl-1-[3-(3-benzyl)-[1,2,4]thiadiazol-5-yl]-piperazine (example 55),
- 2,5-dimethyl-1-[3-(3-methyl-benzyl)-[1,2,4]thiadiazol-5-yl]-piperazine (example 56),



- 2,5-dimethyl-1-[3-(2-methyl-benzyl)-[1,2,4]thiadiazol-5-yl]-piperazine (example 57),
- 2,5-dimethyl-1-[3-(2-methoxy-benzyl)-[1,2,4]thiadiazol-5-yl]-piperazine (example 58),
- 5    - 2,5-dimethyl-1-[3-(4-methoxy-benzyl)-[1,2,4]thiadiazol-5-yl]-piperazine (example 59),
- 2,5-dimethyl-1-[3-(3-methyl-4-fluoro-benzyl)-[1,2,4]thiadiazol-5-yl]-piperazine (example 60),
- 2,5-dimethyl-1-[3-(4-chloro-benzyl)-[1,2,4]thiadiazol-5-yl]-piperazine (example 61), and
- 10    - 2,5-dimethyl-1-[3-(3-methoxy-benzyl)-[1,2,4]thiadiazol-5-yl]-piperazine (example 62).

The following intermediate compounds are also synthesised from 1-(2-aminoethyl)piperazine and the relevant 3-(substituted benzyl)-5-chloro-1,2,4-thiadiazole derivative from examples 2 to 13, while using the above mentioned experimental conditions:


- 2-{4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]piperazin-1-yl}ethanamine (example 63),
- 2-{4-[3-benzyl-1,2,4-thiadiazol-5-yl]piperazin-1-yl}ethanamine (example 64),
- 20    - 2-{4-[3-(4-chlorobenzyl)-1,2,4-thiadiazol-5-yl]piperazin-1-yl}ethanamine (example 65),
- 2-{4-[3-(4-methylbenzyl)-1,2,4-thiadiazol-5-yl]piperazin-1-yl}ethanamine (example 66),
- 2-{4-[3-(3-methoxybenzyl)-1,2,4-thiadiazol-5-yl]piperazin-1-yl}ethanamine (example 67),
- 25    - 2-{4-[3-(3-fluorobenzyl)-1,2,4-thiadiazol-5-yl]piperazin-1-yl}ethanamine (example 68),
- 2-{4-[3-(2-fluorobenzyl)-1,2,4-thiadiazol-5-yl]piperazin-1-yl}ethanamine (example 69),
- 30    - 2-{4-[3-(3-methylbenzyl)-1,2,4-thiadiazol-5-yl]piperazin-1-yl}ethanamine (example 70),
- 2-{4-[3-(2-methylbenzyl)-1,2,4-thiadiazol-5-yl]piperazin-1-yl}ethanamine (example 71),
- 2-{4-[3-(2-methoxybenzyl)-1,2,4-thiadiazol-5-yl]piperazin-1-yl}ethanamine (example 72),
- 35    - 2-{4-[3-(4-methoxybenzyl)-1,2,4-thiadiazol-5-yl]piperazin-1-yl}ethanamine (example 73), and

- 2-{4-[3-(3-methyl-4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]piperazin-1-yl}ethanamine (example 74).

In addition, the final compounds 113, 114 and 185 to 188 named and shown in table 1 below have been synthesised according to the above mentioned experimental conditions while starting from suitable N-substituted piperazine reagents (N-benzylpiperazine, N-(1,3-benzodioxol-5-ylmethyl)-piperazine, N-(2-methylphenyl)-piperazine, N-(2-ethoxyphenyl)-piperazine, N-(2-fluorophenyl)-piperazine and N-(3-trifluoromethylphenyl)-piperazine, respectively). However, for the isolation of the final desired product, the organic phase (DCM) was first washed with a 5% aqueous citric acid solution, water, a 5% aqueous Na<sub>2</sub>CO<sub>3</sub> solution, and water, respectively. The organic phase was separated, dried over MgSO<sub>4</sub>, filtered and, evaporated to dryness. The residue was crystallised by diethyl ether to yield the desired compound.


Examples 75 to 182 - nucleophilic replacement with non-cyclic diamines onto 5-chloro-3-(substituted benzyl)-1,2,4-thiadiazole derivatives

1,2,4-thiadiazole intermediate derivatives represented by the structural formula (VI) have been obtained according to the following scheme 4, i.e. in a manner similar to step (c) of scheme 1, except that the diamine reagent is not a saturated or partly unsaturated heterocyclic diamine like a piperazine derivative, but a non-cyclic diamine.




- 639 mg (yield 58%) of *N*-[3-(3-methoxy-benzyl)-[1,2,4]thiadiazol-5-yl]-ethane-1,2-diamine (example 75) was obtained starting from the 5-chloro-3-(3-methoxy-benzyl)-[1,2,4]thiadiazole (1.0 g; 4.15 mmole) of example 4 and ethylenediamine (1.25 g; 20.77 mmole) after a reaction time of 5 hours.


54



- 533 mg (yield 58%) of *N*-[3-(3-methoxy-benzyl)-[1,2,4]thiadiazol-5-yl]-propane-1,3-diamine (example 76) was obtained starting from the 5-chloro-3-(3-methoxy-benzyl)-[1,2,4]thiadiazole of example (800 mg; 3.23 mmole) and propylene diamine (1.23 g; 16.62 mmole) after a reaction time of 5 hours.




- 578 mg (yield 62%) of *N*-[3-(3-methoxy-benzyl)-[1,2,4]thiadiazol-5-yl]-*N*-methyl-ethane-1,2-diamine (example 77) was obtained starting from the 5-chloro-3-(3-methoxy-benzyl)-[1,2,4]thiadiazole of example 4 (800 mg; 3.23 mmole) and *N*-methyl-ethylenediamine (1.23 g; 16.6 mmol; 1.46 ml) after a reaction time of 100 minutes.




- 85 mg (yield 15%) of *N*-[3-(3-methoxy-benzyl)-[1,2,4]thiadiazol-5-yl]-*N'*-methyl-ethane-1,2-diamine (example 78) was prepared in two steps as follows. First, 786 mg (yield 100%) *N*-Boc-*N*-methyl-*N'*-[3-(3-methoxy-benzyl)-[1,2,4]thiadiazol-5-yl]-ethane-1,2-diamine was obtained according to the above procedure after a reaction time of 3 hours, starting from the 5-chloro-3-(3-methoxy-benzyl)-[1,2,4]thiadiazole (500 mg; 2.08 mmole) of example 4 and *N*-Boc-*N*-methyl-ethylenediamine. The obtained Boc-


protected sample (786 mg; 2.08 mmole) was taken up into DCM (4 ml) and TFA (2 ml) was added dropwise to the mixture. The resulting solution was stirred for 3 hours at room temperature. The course of reaction was monitored by TLC using DCE-EtOH 10:1 as the eluent mixture. The pH of the reaction mixture was set to 11 by adding 10% aqueous sodium carbonate. The mixture was diluted with DCM (10 ml), the organic phase was separated, dried over  $\text{MgSO}_4$ , filtered and evaporated to dryness. The crude product was purified on a silica pad eluting with chloroform to yield the title product.



- 278 mg (yield 48%) of *N*-[3-(3-methoxy-benzyl)-[1,2,4]thiadiazol-5-yl]-propane-1,2-diamine (example 79) was obtained starting from the 5-chloro-3-(3-methoxy-benzyl)-[1,2,4]thiadiazole of example 4 (500 mg; 2.08 mmole) and 2-methyl-ethylenediamine (770 mg; 10.4 mmole) after a reaction time of 100 minutes.



- 283 mg (yield 47%) of *N*-[3-(3-methoxy-benzyl)-[1,2,4]thiadiazol-5-yl]-*N,N'*-dimethyl-ethane-1,2-diamine (example 80) was obtained starting from 5-chloro-3-(3-methoxy-benzyl)-[1,2,4]thiadiazole (500 mg; 2.08 mmole) and *N,N'*-dimethyl-ethylenediamine (915 mg; 10.4 mmole) after a reaction time of 100 minutes.



By analogy with example 75, the following intermediate compounds are also synthesised from ethylenediamine and the relevant 3-(substituted benzyl)-5-chloro-1,2,4-thiadiazole derivative from examples 2 to 13, while using the above mentioned experimental conditions:

- *N*-[3-(4-methyl-benzyl)-[1,2,4]thiadiazol-5-yl]-ethane-1,2-diamine (example 81),
- *N*-[3-(4-fluoro-benzyl)-[1,2,4]thiadiazol-5-yl]-ethane-1,2-diamine (example 82),
- *N*-[3-(3-fluoro-benzyl)-[1,2,4]thiadiazol-5-yl]-ethane-1,2-diamine (example 83),
- *N*-[3-(2-fluoro-benzyl)-[1,2,4]thiadiazol-5-yl]-ethane-1,2-diamine (example 84),
- *N*-[3-(3-benzyl)-[1,2,4]thiadiazol-5-yl]-ethane-1,2-diamine (example 85),
- *N*-[3-(3-methyl-benzyl)-[1,2,4]thiadiazol-5-yl]-ethane-1,2-diamine (example 86),
- *N*-[3-(2-methyl-benzyl)-[1,2,4]thiadiazol-5-yl]-ethane-1,2-diamine (example 87),
- *N*-[3-(2-methoxy-benzyl)-[1,2,4]thiadiazol-5-yl]-ethane-1,2-diamine (example 88),
- *N*-[3-(4-methoxy-benzyl)-[1,2,4]thiadiazol-5-yl]-ethane-1,2-diamine (example 89),
- *N*-[3-(3-methyl-4-fluoro-benzyl)-[1,2,4]thiadiazol-5-yl]-ethane-1,2-diamine (example 90), and

- *N*-[3-(4-chloro-benzyl)-[1,2,4]thiadiazol-5-yl]-ethane-1,2-diamine (example 91).

By analogy with example 76, the following intermediate compounds are also synthesised from propylenediamine and the relevant 3-(substituted benzyl)-5-chloro-1,2,4-thiadiazole derivative from examples 2 to 13, while using the above mentioned experimental conditions:

- *N*-[3-(4-methyl-benzyl)-[1,2,4]thiadiazol-5-yl]-propane-1,3-diamine (example 92),
- *N*-[3-(4-fluoro-benzyl)-[1,2,4]thiadiazol-5-yl]-propane-1,3-diamine (example 93),
- *N*-[3-(3-fluoro-benzyl)-[1,2,4]thiadiazol-5-yl]-propane-1,3-diamine (example 94),
- *N*-[3-(2-fluoro-benzyl)-[1,2,4]thiadiazol-5-yl]-propane-1,3-diamine (example 95),
- *N*-[3-(3-benzyl)-[1,2,4]thiadiazol-5-yl]-propane-1,3-diamine (example 96),
- *N*-[3-(3-methyl-benzyl)-[1,2,4]thiadiazol-5-yl]-propane-1,3-diamine (example 97),
- *N*-[3-(2-methyl-benzyl)-[1,2,4]thiadiazol-5-yl]-propane-1,3-diamine (example 98),
- *N*-[3-(2-methoxy-benzyl)-[1,2,4]thiadiazol-5-yl]-propane-1,3-diamine (example 99),
- *N*-[3-(4-methoxy-benzyl)-[1,2,4]thiadiazol-5-yl]-propane-1,3-diamine (example 100),
- *N*-[3-(3-methyl-4-fluoro-benzyl)-[1,2,4]thiadiazol-5-yl]-propane-1,3-diamine (example 101), and
- *N*-[3-(4-chloro-benzyl)-[1,2,4]thiadiazol-5-yl]-propane-1,3-diamine (example 102).

By analogy with example 77, the following intermediate compounds are also synthesised from ethylenediamine and the relevant 3-(substituted benzyl)-5-chloro-1,2,4-thiadiazole derivative from examples 2 to 13, while using the above mentioned experimental conditions:

- *N*-[3-(4-methyl-benzyl)-[1,2,4]thiadiazol-5-yl]-*N*-methyl-ethane-1,2-diamine (example 103),
- *N*-[3-(4-fluoro-benzyl)-[1,2,4]thiadiazol-5-yl]-*N*-methyl-ethane-1,2-diamine (example 104),
- *N*-[3-(3-fluoro-benzyl)-[1,2,4]thiadiazol-5-yl]-*N*-methyl-ethane-1,2-diamine (example 105),

- *N*-[3-(2-fluoro-benzyl)-[1,2,4]thiadiazol-5-yl]-*N*-methyl-ethane-1,2-diamine (example 106),
- *N*-[3-(3-benzyl)-[1,2,4]thiadiazol-5-yl]-*N*-methyl-ethane-1,2-diamine (example 107),
- 5 - *N*-[3-(3-methyl-benzyl)-[1,2,4]thiadiazol-5-yl]-*N*-methyl-ethane-1,2-diamine (example 108),
- *N*-[3-(2-methyl-benzyl)-[1,2,4]thiadiazol-5-yl]-*N*-methyl-ethane-1,2-diamine (example 109),
- *N*-[3-(2-methoxy-benzyl)-[1,2,4]thiadiazol-5-yl]-*N*-methyl-ethane-1,2-diamine (example 110),
- 10 - *N*-[3-(4-methoxy-benzyl)-[1,2,4]thiadiazol-5-yl]-*N*-methyl-ethane-1,2-diamine (example 111),
- *N*-[3-(3-methyl-4-fluoro-benzyl)-[1,2,4]thiadiazol-5-yl]-*N*-methyl-ethane-1,2-diamine (example 112), and
- 15 - *N*-[3-(4-chloro-benzyl)-[1,2,4]thiadiazol-5-yl]-*N*-methyl-ethane-1,2-diamine (example 113).

By analogy with example 78, the following intermediate compounds are also synthesised from ethylenediamine and the relevant 3-(substituted benzyl)-5-chloro-1,2,4-thiadiazole derivative from examples 2 to 13, while using the above mentioned experimental conditions:

- *N*-[3-(4-methyl-benzyl)-[1,2,4]thiadiazol-5-yl]-*N'*-methyl-ethane-1,2-diamine (example 114),
- *N*-[3-(4-fluoro-benzyl)-[1,2,4]thiadiazol-5-yl]-*N'*-methyl-ethane-1,2-diamine (example 115),
- 25 - *N*-[3-(3-fluoro-benzyl)-[1,2,4]thiadiazol-5-yl]-*N'*-methyl-ethane-1,2-diamine (example 116),
- *N*-[3-(2-fluoro-benzyl)-[1,2,4]thiadiazol-5-yl]-*N'*-methyl-ethane-1,2-diamine (example 117),
- *N*-[3-(3-benzyl)-[1,2,4]thiadiazol-5-yl]-*N'*-methyl-ethane-1,2-diamine (example 118),
- 30 - *N*-[3-(3-methyl-benzyl)-[1,2,4]thiadiazol-5-yl]-*N'*-methyl-ethane-1,2-diamine (example 119),
- *N*-[3-(2-methyl-benzyl)-[1,2,4]thiadiazol-5-yl]-*N'*-methyl-ethane-1,2-diamine (example 120),
- 35 - *N*-[3-(2-methoxy-benzyl)-[1,2,4]thiadiazol-5-yl]-*N'*-methyl-ethane-1,2-diamine (example 121),

- *N*-[3-(4-methoxy-benzyl)-[1,2,4]thiadiazol-5-yl]-*N'*-methyl-ethane-1,2-diamine (example 122),
- *N*-[3-(3-methyl-4-fluoro-benzyl)-[1,2,4]thiadiazol-5-yl]-*N'*-methyl-ethane-1,2-diamine (example 123), and
- 5       - *N*-[3-(4-chloro-benzyl)-[1,2,4]thiadiazol-5-yl]-*N'*-methyl-ethane-1,2-diamine (example 124).

By analogy with example 79, the following intermediate compounds are also synthesised from propylenediamine and the relevant 3-(substituted benzyl)-5-chloro-1,2,4-thiadiazole derivative from examples 2 to 13, while using the above mentioned  
10       experimental conditions:

- *N*-[3-(4-methyl-benzyl)-[1,2,4]thiadiazol-5-yl]-propane-1,2-diamine (example 125),
- *N*-[3-(4-fluoro-benzyl)-[1,2,4]thiadiazol-5-yl]-propane-1,2-diamine (example 126),
- 15       - *N*-[3-(3-fluoro-benzyl)-[1,2,4]thiadiazol-5-yl]-propane-1,2-diamine (example 127),
- *N*-[3-(2-fluoro-benzyl)-[1,2,4]thiadiazol-5-yl]-propane-1,2-diamine (example 128),
- *N*-[3-(3-benzyl)-[1,2,4]thiadiazol-5-yl]-propane-1,2-diamine (example 129),
- 20       - *N*-[3-(3-methyl-benzyl)-[1,2,4]thiadiazol-5-yl]-propane-1,2-diamine (example 130),
- *N*-[3-(2-methyl-benzyl)-[1,2,4]thiadiazol-5-yl]-propane-1,2-diamine (example 131),
- *N*-[3-(2-methoxy-benzyl)-[1,2,4]thiadiazol-5-yl]-propane-1,2-diamine (example 132),
- 25       - *N*-[3-(4-methoxy-benzyl)-[1,2,4]thiadiazol-5-yl]-propane-1,2-diamine (example 133),
- *N*-[3-(3-methyl-4-fluoro-benzyl)-[1,2,4]thiadiazol-5-yl]-propane-1,2-diamine (example 134), and
- 30       - *N*-[3-(4-chloro-benzyl)-[1,2,4]thiadiazol-5-yl]-propane-1,2-diamine (example 135).

By analogy with example 80, the following intermediate compounds are also synthesised from ethylenediamine and the relevant 3-(substituted benzyl)-5-chloro-1,2,4-thiadiazole derivative from examples 2 to 13, while using the above mentioned  
35       experimental conditions:

- *N*-[3-(4-methyl-benzyl)-[1,2,4]thiadiazol-5-yl]-*N,N'*-dimethyl-ethane-1,2-diamine (example 136),



- *N*-[3-(4-fluoro-benzyl)-[1,2,4]thiadiazol-5-yl]-*N,N'*-dimethyl-ethane-1,2-diamine (example 137),
- *N*-[3-(3-fluoro-benzyl)-[1,2,4]thiadiazol-5-yl]-*N,N'*-dimethyl-ethane-1,2-diamine (example 138),
- 5     - *N*-[3-(2-fluoro-benzyl)-[1,2,4]thiadiazol-5-yl]-*N,N'*-dimethyl-ethane-1,2-diamine (example 139),
- *N*-[3-(3-benzyl)-[1,2,4]thiadiazol-5-yl]-*N,N'*-dimethyl-ethane-1,2-diamine (example 140),
- *N*-[3-(3-methyl-benzyl)-[1,2,4]thiadiazol-5-yl]-*N,N'*-dimethyl-ethane-1,2-diamine (example 141),
- 10     - *N*-[3-(2-methyl-benzyl)-[1,2,4]thiadiazol-5-yl]-*N,N'*-dimethyl-ethane-1,2-diamine (example 142),
- *N*-[3-(2-methoxy-benzyl)-[1,2,4]thiadiazol-5-yl]-*N,N'*-dimethyl-ethane-1,2-diamine (example 143),
- 15     - *N*-[3-(4-methoxy-benzyl)-[1,2,4]thiadiazol-5-yl]-*N,N'*-dimethyl-ethane-1,2-diamine (example 144),
- *N*-[3-(3-methyl-4-fluoro-benzyl)-[1,2,4]thiadiazol-5-yl]-*N,N'*-dimethyl-ethane-1,2-diamine (example 145), and
- *N*-[3-(4-chloro-benzyl)-[1,2,4]thiadiazol-5-yl]-*N,N'*-dimethyl-ethane-1,2-diamine (example 146).
- 20

The following intermediate compounds are also synthesised from *N,N'*-diethylethylenediamine and the relevant 3-(substituted benzyl)-5-chloro-1,2,4-thiadiazole derivative from examples 2 to 13, while using the above mentioned experimental conditions:

- 25     - *N*-[3-(4-methyl-benzyl)-[1,2,4]thiadiazol-5-yl]-*N,N'*-diethyl-ethane-1,2-diamine (example 147),
- *N*-[3-(4-fluoro-benzyl)-[1,2,4]thiadiazol-5-yl]-*N,N'*-diethyl-ethane-1,2-diamine (example 148),
- *N*-[3-(3-methoxy-benzyl)-[1,2,4]thiadiazol-5-yl]-*N,N'*-diethyl-ethane-1,2-diamine (example 149),
- 30     - *N*-[3-(3-fluoro-benzyl)-[1,2,4]thiadiazol-5-yl]-*N,N'*-diethyl-ethane-1,2-diamine (example 150),
- *N*-[3-(2-fluoro-benzyl)-[1,2,4]thiadiazol-5-yl]-*N,N'*-diethyl-ethane-1,2-diamine (example 151),
- 35     - *N*-[3-(3-benzyl)-[1,2,4]thiadiazol-5-yl]-*N,N'*-diethyl-ethane-1,2-diamine (example 152),

- *N*-[3-(3-methyl-benzyl)-[1,2,4]thiadiazol-5-yl]-*N,N'*-diethyl-ethane-1,2-diamine (example 153),
- *N*-[3-(2-methyl-benzyl)-[1,2,4]thiadiazol-5-yl]-*N,N'*-diethyl-ethane-1,2-diamine (example 154),
- 5 - *N*-[3-(2-methoxy-benzyl)-[1,2,4]thiadiazol-5-yl]-*N,N'*-diethyl-ethane-1,2-diamine (example 155),
- *N*-[3-(4-methoxy-benzyl)-[1,2,4]thiadiazol-5-yl]-*N,N'*-diethyl-ethane-1,2-diamine (example 156),
- *N*-[3-(3-methyl-4-fluoro-benzyl)-[1,2,4]thiadiazol-5-yl]-*N,N'*-diethyl-ethane-1,2-diamine (example 157), and
- 10 - *N*-[3-(4-chloro-benzyl)-[1,2,4]thiadiazol-5-yl]-*N,N'*-diethyl-ethane-1,2-diamine (example 158).

The following intermediate compounds are also synthesised from *N,N'*-diisopropylethylenediamine and the relevant 3-(substituted benzyl)-5-chloro-1,2,4-thiadiazole derivative from examples 2 to 13, while using the above mentioned experimental conditions:

- *N*-[3-(4-methyl-benzyl)-[1,2,4]thiadiazol-5-yl]-*N,N'*-diisopropyl-ethane-1,2-diamine (example 159),
- *N*-[3-(4-fluoro-benzyl)-[1,2,4]thiadiazol-5-yl]-*N,N'*-diisopropyl-ethane-1,2-diamine (example 160),
- 20 - *N*-[3-(3-methoxy-benzyl)-[1,2,4]thiadiazol-5-yl]-*N,N'*-diisopropyl-ethane-1,2-diamine (example 161),
- *N*-[3-(3-fluoro-benzyl)-[1,2,4]thiadiazol-5-yl]-*N,N'*-diisopropyl-ethane-1,2-diamine (example 162),
- 25 - *N*-[3-(2-fluoro-benzyl)-[1,2,4]thiadiazol-5-yl]-*N,N'*-diisopropyl-ethane-1,2-diamine (example 163),
- *N*-[3-(3-benzyl)-[1,2,4]thiadiazol-5-yl]-*N,N'*-diisopropyl-ethane-1,2-diamine (example 164),
- *N*-[3-(3-methyl-benzyl)-[1,2,4]thiadiazol-5-yl]-*N,N'*-diisopropyl-ethane-1,2-diamine (example 165),
- 30 - *N*-[3-(2-methyl-benzyl)-[1,2,4]thiadiazol-5-yl]-*N,N'*-diisopropyl-ethane-1,2-diamine (example 166),
- *N*-[3-(2-methoxy-benzyl)-[1,2,4]thiadiazol-5-yl]-*N,N'*-diisopropyl-ethane-1,2-diamine (example 167),
- 35 - *N*-[3-(4-methoxy-benzyl)-[1,2,4]thiadiazol-5-yl]-*N,N'*-diisopropyl-ethane-1,2-diamine (example 168),

- *N*-[3-(3-methyl-4-fluoro-benzyl)-[1,2,4]thiadiazol-5-yl]-*N,N'*-diisopropyl-ethane-1,2-diamine (example 169), and
- *N*-[3-(4-chloro-benzyl)-[1,2,4]thiadiazol-5-yl]-*N,N'*-diisopropyl-ethane-1,2-diamine (example 170).

5       The following intermediate compounds are also synthesised from 1,4-diaminobutane and the relevant 3-(substituted benzyl)-5-chloro-1,2,4-thiadiazole derivative from examples 2 to 13, while using the above mentioned experimental conditions:

- 10       - *N*-[3-(4-methyl-benzyl)-[1,2,4]thiadiazol-5-yl]-butane-1,4-diamine (example 171),
- *N*-[3-(4-fluoro-benzyl)-[1,2,4]thiadiazol-5-yl]-butane-1,4-diamine (example 172),
- *N*-[3-(3-fluoro-benzyl)-[1,2,4]thiadiazol-5-yl]-butane-1,4-diamine (example 173),
- 15       - *N*-[3-(2-fluoro-benzyl)-[1,2,4]thiadiazol-5-yl]-butane-1,4-diamine (example 174),
- *N*-[3-(3-benzyl)-[1,2,4]thiadiazol-5-yl]-butane-1,4-diamine (example 175),
- *N*-[3-(3-methyl-benzyl)-[1,2,4]thiadiazol-5-yl]-butane-1,4-diamine (example 176),
- 20       - *N*-[3-(2-methyl-benzyl)-[1,2,4]thiadiazol-5-yl]-butane-1,4-diamine (example 177),
- *N*-[3-(2-methoxy-benzyl)-[1,2,4]thiadiazol-5-yl]-butane-1,4-diamine (example 178),
- *N*-[3-(4-methoxy-benzyl)-[1,2,4]thiadiazol-5-yl]-butane-1,4-diamine (example 179),
- 25       - *N*-[3-(3-methyl-4-fluoro-benzyl)-[1,2,4]thiadiazol-5-yl]-butane-1,4-diamine (example 180),
- *N*-[3-(3-methoxy-benzyl)-[1,2,4]thiadiazol-5-yl]-butane-1,4-diamine (example 181), and
- 30       - *N*-[3-(4-chloro-benzyl)-[1,2,4]thiadiazol-5-yl]-butane-1,4-diamine (example 182).

      The following intermediate compounds are also synthesised from 1,5-diaminopentane and the relevant 3-(substituted benzyl)-5-chloro-1,2,4-thiadiazole derivative from examples 2 to 13, while using the above mentioned experimental conditions:

- 35       - *N*-[3-(4-methyl-benzyl)-[1,2,4]thiadiazol-5-yl]-pentane-1,5-diamine (example 183),

- *N*-[3-(4-fluoro-benzyl)-[1,2,4]thiadiazol-5-yl]-pentane-1,5-diamine (example 184),
- *N*-[3-(3-fluoro-benzyl)-[1,2,4]thiadiazol-5-yl]-pentane-1,5-diamine (example 185),
- 5 - *N*-[3-(2-fluoro-benzyl)-[1,2,4]thiadiazol-5-yl]-pentane-1,5-diamine (example 186),
- *N*-[3-(3-benzyl)-[1,2,4]thiadiazol-5-yl]-pentane-1,5-diamine (example 187),
- *N*-[3-(3-methyl-benzyl)-[1,2,4]thiadiazol-5-yl]-pentane-1,5-diamine (example 188),
- 10 - *N*-[3-(2-methyl-benzyl)-[1,2,4]thiadiazol-5-yl]-pentane-1,5-diamine (example 189),
- *N*-[3-(2-methoxy-benzyl)-[1,2,4]thiadiazol-5-yl]-pentane-1,5-diamine (example 190),
- *N*-[3-(4-methoxy-benzyl)-[1,2,4]thiadiazol-5-yl]-pentane-1,5-diamine (example 191),
- 15 - *N*-[3-(3-methyl-4-fluoro-benzyl)-[1,2,4]thiadiazol-5-yl]-pentane-1,5-diamine (example 192),
- *N*-[3-(3-methoxy-benzyl)-[1,2,4]thiadiazol-5-yl]-pentane-1,5-diamine (example 193), and
- 20 - *N*-[3-(4-chloro-benzyl)-[1,2,4]thiadiazol-5-yl]-pentane-1,5-diamine (example 194).

The following intermediate compounds are also synthesised from 1,6-diaminohexane and the relevant 3-(substituted benzyl)-5-chloro-1,2,4-thiadiazole derivative from examples 2 to 13, while using the above mentioned experimental conditions:

- *N*-[3-(4-methyl-benzyl)-[1,2,4]thiadiazol-5-yl]-hexane-1,6-diamine (example 195),
- *N*-[3-(4-fluoro-benzyl)-[1,2,4]thiadiazol-5-yl]-hexane-1,6-diamine (example 196),
- 30 - *N*-[3-(3-fluoro-benzyl)-[1,2,4]thiadiazol-5-yl]-hexane-1,6-diamine (example 197),
- *N*-[3-(2-fluoro-benzyl)-[1,2,4]thiadiazol-5-yl]-hexane-1,6-diamine (example 198),
- *N*-[3-(3-benzyl)-[1,2,4]thiadiazol-5-yl]-hexane-1,6-diamine (example 199),
- 35 - *N*-[3-(3-methyl-benzyl)-[1,2,4]thiadiazol-5-yl]-hexane-1,6-diamine (example 200),


- *N*-[3-(2-methyl-benzyl)-[1,2,4]thiadiazol-5-yl]-hexane-1,6-diamine (example 201),
- *N*-[3-(2-methoxy-benzyl)-[1,2,4]thiadiazol-5-yl]-hexane-1,6-diamine (example 202),
- 5 - *N*-[3-(4-methoxy-benzyl)-[1,2,4]thiadiazol-5-yl]-hexane-1,6-diamine (example 203),
- *N*-[3-(3-methyl-4-fluoro-benzyl)-[1,2,4]thiadiazol-5-yl]-hexane-1,6-diamine (example 204),
- *N*-[3-(3-methoxy-benzyl)-[1,2,4]thiadiazol-5-yl]-hexane-1,6-diamine (example 205), and
- 10 - *N*-[3-(4-chloro-benzyl)-[1,2,4]thiadiazol-5-yl]-hexane-1,6-diamine (example 206).

15 Example 207 - N-sulfonylation of 1,2,4-thiadiazole intermediate derivatives represented by the structural formulae (IV) and (VI)

1,2,4-thiadiazole compounds represented by the structural formulae (A) to (F) have been obtained according to scheme 2 through reaction of a 1,2,4-thiadiazole intermediate derivative represented by the structural formula (IVA), (IVB) or (VI) with an aryl or heteroaryl sulfonyl halide such as, but not limited to, an arylsulfonyl chloride having the structural formula (VB). The reaction is more schematically shown in scheme 5 below for making 1,2,4-thiadiazole compounds represented by the structural formula (B), i.e. wherein Ar<sup>1</sup> is R<sub>1</sub>,R<sub>2</sub>,R<sub>3</sub>,R<sub>4</sub>,R<sub>5</sub>-substituted phenyl, R<sup>2</sup> corresponds to R<sub>6</sub>, X is SO<sub>2</sub>, and R<sup>3</sup> is R<sub>7</sub>,R<sub>8</sub>,R<sub>9</sub>,R<sub>10</sub>,R<sub>11</sub>-substituted phenyl, using the following detailed procedure. 1,2,4-thiadiazole compounds represented by the structural formulae (C) and (F) have also been obtained by analogy to scheme 5 through the reaction of a 1,2,4-thiadiazole intermediate derivative represented by the structural formula (VI) with an aryl or heteroaryl sulfonyl halide such as an arylsulfonyl chloride having the structural formula (VB).

Scheme 5

30




To the substituted 1,2,4-thiadiazole intermediate derivative represented by the structural formula (IVA) or (IVB) or (VI) (250 μmole) dissolved in DCM (2-3 ml) TEA


(500  $\mu$ mole) was added. The reaction mixture was stirred at room temperature and then the appropriate aryl or heteroaryl sulfonyl chloride derivative (250  $\mu$ mole) was added. The reaction mixture was further stirred at room temperature until total consumption of the starting products. The course of the reaction was monitored by TLC  
5 using dichloroethane (DCE)-EtOH 10:1 as an eluent mixture. The reaction time varied between 2 hours and 5 hours. When the reaction was complete DCM (2-3 ml) was added and the resulting solution was washed with a 5% aqueous citric acid solution (5 ml), water (5 ml), a 5% aqueous  $\text{Na}_2\text{CO}_3$  solution, and water (5 ml), respectively. The organic phase was separated, dried over  $\text{MgSO}_4$ , filtered and, evaporated to dryness.  
10 The residue was crystallised by diethyl ether to yield the desired compound.

More specifically, the following compounds (wherein compound numbers refer to table 1 below) have been obtained while using the above-mentioned detailed procedure:


- compound **60**: 1-[4-methoxyphenylsulfonyl]-4-[3-(4-methylbenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine: starting from 3-methyl-1-[3-(4-methylbenzyl)-[1,2,4]thiadiazol-5-yl]-piperazine (1.25 mmol) and 1 equivalent of 4-methoxy-phenylsulphonyl chloride, after 4 hours reaction time the title compound was obtained in 99% yield.




- compound **74**: 1-[4-methoxyphenylsulfonyl]-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]piperazine: starting from 400 mg 1-[3-(4-fluoro-benzyl)-[1,2,4]thiadiazol-5-yl]-piperazine (1.237 mmole) and 1 equivalent of 4-methoxy-phenylsulphonyl chloride, 453 mg of the title compound was obtained after 3 hours of reaction (70% yield).




- compound **44**: 1-[3-methoxyphenylsulfonyl]-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]piperazine: starting from 80 mg 1-[3-(4-fluoro-benzyl)-[1,2,4]thiadiazol-5-yl]-piperazine (0.287 mmole) and 1 equivalent of 3-methoxyphenylsulfonyl chloride, 102 mg of the title compound was obtained after 4 hours of reaction in 79% yield.




- compound **53**: 1-[4-methoxyphenylsulfonyl]-4-[3-(3-methoxybenzyl)-1,2,4-thiadiazol-5-yl]piperazine: starting from 150 mg 1-[3-(3-methoxybenzyl)-[1,2,4]thiadiazol-5-yl]-piperazine (0.517 mmol) and 1 equivalent of 4-methoxyphenylsulfonyl chloride, 156 mg of the title compound was obtained after 5 hours of reaction in 66% yield.




- compound **192**: 1-[4-methoxyphenylsulfonyl]-4-[3-(4-chloro-benzyl)-1,2,4-thiadiazol-5-yl]piperazine: starting from 1-[3-(4-chlorobenzyl)-[1,2,4]thiadiazol-5-yl]-piperazine and 4-methoxyphenylsulfonyl chloride, 75 mg of the title compound was obtained after 2 hours of reaction in 48% yield.




- compound **193**: 1-[4-methoxyphenylsulfonyl]-4-[3-(3-fluoro-benzyl)-1,2,4-thiadiazol-5-yl]piperazine: starting from 1-[3-(3-fluoro-benzyl)-[1,2,4]thiadiazol-5-yl]-piperazine and 4-methoxyphenylsulfonyl chloride, 118 mg of the title compound was obtained after 2 hours of reaction in 49% yield.



- 5 - compound **194**: 1-[4-methoxyphenylsulfonyl]-4-[3-(2-fluoro-benzyl)-1,2,4-thiadiazol-5-yl]piperazine: starting from 1-[3-(2-fluorobenzyl)-[1,2,4]thiadiazol-5-yl]-piperazine and 4-methoxyphenylsulfonyl chloride, 142 mg of the title compound was obtained after 2 hours of reaction in 59% yield.




- 10 - compound **195**: 1-[2-methoxyphenylsulfonyl]-4-[3-(4-fluoro-benzyl)-1,2,4-thiadiazol-5-yl]piperazine: starting from 1-[3-(4-fluorobenzyl)-[1,2,4]thiadiazol-5-yl]-piperazine and 2-methoxyphenylsulfonyl chloride, 251 mg of the title compound was obtained (78% yield).




- 20 - compound **196**: 1-[4-ethoxyphenylsulfonyl]-4-[3-(4-fluoro-benzyl)-1,2,4-thiadiazol-5-yl]piperazine: starting from 1-[3-(4-fluorobenzyl)-[1,2,4]thiadiazol-5-yl]-piperazine and 4-ethoxyphenylsulfonyl chloride, 125 mg of the title compound was obtained (50% yield) after 4 hours reaction time.




68




- 5      - compound **197**: 1-[4-ethylphenylsulfonyl]-4-[3-(4-fluoro-benzyl)-1,2,4-thiadiazol-5-yl]piperazine: starting from 1-[3-(4-fluoro-benzyl)-[1,2,4]thiadiazol-5-yl]-piperazine and 4-ethylphenylsulfonyl chloride, 158 mg of the title compound was obtained (66% yield) after 7 hours reaction time.



- 10      - compound **198**: 1-phenylsulfonyl-4-[3-(4-fluoro-benzyl)-1,2,4-thiadiazol-5-yl]piperazine: starting from 1-[3-(4-fluoro-benzyl)-[1,2,4]thiadiazol-5-yl]-piperazine and phenylsulfonyl chloride, 85 mg of the title compound was obtained (71% yield) after 5 hours reaction time.




- 15      - compound **199**: 1-[4-methoxyphenylsulfonyl]-4-[3-benzyl-1,2,4-thiadiazol-5-yl]piperazine: starting from 1-[3-benzyl-1,2,4]thiadiazol-5-yl]-piperazine and 4-methoxyphenylsulfonyl chloride, 170 mg of the title compound was obtained (69% yield) after 2 hours reaction time.




- 20      - compound **200**: 1-(4-propionyloxy)benzenesulfonyl-4-[3-(4-fluoro-benzyl)-1,2,4-thiadiazol-5-yl]piperazine: starting from 1-[3-(4-fluoro-benzyl)-


[1,2,4]thiadiazol-5-yl]-piperazine and 4-propionyloxybenzene-sulfonyl chloride, 90 mg of the title compound was obtained (20% yield) after 6 hours reaction time. The crude product was purified by column chromatography using chloroform as eluent.



For this purpose, 4-propionyloxybenzenesulfonyl chloride itself was made in two steps being schematically shown as follows:




10 To a solution of sodium 4-hydroxybenzenesulfonate dihydrate (1.0 g; 4.31 mmole) in pyridine (5 ml) propionic anhydride (1.68 g; 12.92 mmole) was added. The mixture was stirred at room temperature for 6 hours. The course of reaction was monitored by TLC using DCE-EtOH 5:1 as an eluent mixture. The precipitated acylated product (928 mg; 3.68 mmole) was collected by filtration and dried in a vacuum desiccator.



The sulfonic acid sodium salt (928 mg) and phosphorus pentachloride (766 mg; 3.68 mmole) were heated at 120°C for 4 hours. The mixture was poured onto ice-water and the precipitated desired product (521 mg) was collected by filtration.


20 - compound **201**: 1-[4-methoxyphenylsulfonyl]-4-[3-(3-methyl-benzyl)-1,2,4-thiadiazol-5-yl]piperazine: starting from 1-[3-(3-methyl-benzyl)-[1,2,4]thiadiazol-5-yl]-piperazine and 4-methoxyphenylsulfonyl chloride, 982

mg of the title compound was obtained (76% yield) after 5 hours reaction time.




- 5                      - compound **202**: 1-[4-methoxyphenylsulfonyl]-4-[3-(2-methyl-benzyl)-1,2,4-thiadiazol-5-yl]piperazine: starting from 1-[3-(2-methyl-benzyl)-[1,2,4]thiadiazol-5-yl]-piperazine and 4-methoxyphenylsulfonyl chloride, 159 mg of the title compound was obtained (65% yield) after 4 hours reaction time.

10



15


- compound **203**: 1-[4-methoxyphenylsulfonyl]-4-[3-(2-methoxy-benzyl)-1,2,4-thiadiazol-5-yl]piperazine: starting from 1-[3-(2-methoxy-benzyl)-[1,2,4]thiadiazol-5-yl]-piperazine and 4-methoxyphenylsulfonyl chloride, 61 mg of the title compound was obtained (26% yield) after 2 hours reaction time.




20

- compound **204**: 1-[4-methoxyphenylsulfonyl]-4-[3-(3-methyl-4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]piperazine: starting from 1-[3-(3-methyl-4-fluorobenzyl)-[1,2,4]thiadiazol-5-yl]-piperazine and 4-methoxyphenyl-sulfonyl chloride, 229 mg of the title compound was obtained (96% yield) after 6 hours reaction time.


25




- 5 - compound **205**: 1-[4-methoxyphenylsulfonyl]-4-[3-(4-methoxy-benzyl)-1,2,4-thiadiazol-5-yl]piperazine: starting from 1-[3-(4-methoxy-benzyl)-[1,2,4]thiadiazol-5-yl]-piperazine and 4-methoxyphenylsulfonyl chloride, 117 mg of the title compound was obtained (49% yield) after 4 hours reaction time.




- 10 - compound **206**: 1-[2-thienylsulfonyl]-4-[3-(2-methyl-benzyl)-1,2,4-thiadiazol-5-yl]piperazine: starting from 1-[3-(2-methyl-benzyl)-[1,2,4]thiadiazol-5-yl]-piperazine and 2-thienylsulfonyl chloride, 143 mg of the title compound was obtained (63% yield) after 4 hours reaction time.




- 15 - compound **207**: 1-[4-bromophenylsulfonyl]-4-[3-(3-methoxy-benzyl)-1,2,4-thiadiazol-5-yl]piperazine: starting from 1-[3-(3-methoxy-benzyl)-[1,2,4]thiadiazol-5-yl]-piperazine and 4-bromophenylsulfonyl chloride, 146 mg of the title compound was obtained (83% yield) after 4 hours reaction time.
- 20




- 5        - compound **208**: 1-[4-methoxyphenylsulfonyl]-4-[3-(3-methoxybenzyl)-1,2,4-thiadiazol-5-yl]-2-methyl-piperazine: starting from 1-[3-(3-methoxybenzyl)-[1,2,4]thiadiazol-5-yl]-2-methyl-piperazine and 4-methoxyphenylsulfonyl chloride, 141 mg of the title compound was obtained after 2 hours of reaction in 90% yield.




- 10        - compound **209**: *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(3-methoxybenzyl)-1,2,4-thiadiazol-5-yl]-ethane-1,2-diamine: starting from the *N*-[3-(3-methoxybenzyl)-[1,2,4]thiadiazol-5-yl]-ethane-1,2-diamine of example 75 and 4-methoxyphenylsulfonyl chloride, 135 mg of the title compound was obtained after 5 hours of reaction in 82% yield.




- 20        - compound **210**: *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(3-methoxybenzyl)-1,2,4-thiadiazol-5-yl]-propane-1,2-diamine: starting from the *N*-[3-(3-methoxybenzyl)-[1,2,4]thiadiazol-5-yl]-propane-1,2-diamine of example 79 and 4-methoxyphenylsulfonyl chloride, 149 mg of the title compound was obtained after 2 hours of reaction in 92% yield.




- 5        - compound **211**: *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(3-methoxybenzyl)-1,2,4-thiadiazol-5-yl]-propane-1,3-diamine: starting from the *N*-[3-(3-methoxybenzyl)-[1,2,4]thiadiazol-5-yl]-propane-1,3-diamine of example 76 and 4-methoxyphenylsulfonyl chloride, 124 mg of the title compound was obtained after 5 hours of reaction in 77% yield.




- 10       - compound **212**: 1-[4-methoxyphenylsulfonyl]-4-[3-(3-methoxybenzyl)-1,2,4-thiadiazol-5-yl]diazepane: starting from the 1-[3-(3-methoxybenzyl)-[1,2,4]thiadiazol-5-yl]-diazepane of example 39 and 4-methoxyphenylsulfonyl chloride, 133 mg of the title compound was obtained after 2 hours of reaction in 85% yield.




- 15       - compound **213**: *N'*-[4-methoxyphenylsulfonyl]-*N*-[3-(3-methoxybenzyl)-1,2,4-thiadiazol-5-yl]-*N*-methylethane-1,2-diamine: starting from the *N*-[3-(3-methoxybenzyl)-[1,2,4]thiadiazol-5-yl]-*N*-methylethane-1,2-diamine of example 77 and 4-methoxyphenylsulfonyl chloride, 133 mg of the title compound was obtained after 2 hours of reaction in 83% yield.
- 20



- 5        - compound **214**: *N'*-[4-methoxyphenylsulfonyl]-*N*-[3-(3-methoxybenzyl)-1,2,4-thiadiazol-5-yl]-*N'*-methylethane-1,2-diamine: starting from the *N*-[3-(3-methoxybenzyl)-[1,2,4]thiadiazol-5-yl]-*N'*-methylethane-1,2-diamine of example 78 and 4-methoxyphenylsulfonyl chloride, 56 mg of the title compound was obtained after 2 hours of reaction in 41% yield.



- 10       - compound **215**: *N'*-[4-methoxyphenylsulfonyl]-*N*-[3-(3-methoxybenzyl)-1,2,4-thiadiazol-5-yl]-*N,N'*-dimethylethane-1,2-diamine: starting from the *N*-[3-(3-methoxybenzyl)-[1,2,4]thiadiazol-5-yl]-*N,N'*-dimethylethane-1,2-diamine of example 80 and 4-methoxyphenylsulfonyl chloride, 133 mg of the title compound was obtained after 2 hours of reaction in 84% yield.



The final compounds **30** to **85** named and structurally shown in table 1 were also synthesised using these experimental conditions.

20


Example 208 - N-acylation of 1,2,4-thiadiazole intermediate derivatives represented by the structural formulae (IV) and (VI)

1,2,4-thiadiazole compounds represented by the structural formulae (A) to (F) have been obtained according to scheme 2 through reaction of a 1,2,4-thiadiazole intermediate derivative represented by a structural formula (IVA), (IVB) or (VI) with a suitable aryl or heteroaryl carbonyl chloride. A more detailed synthetic procedure is as follows.

25


To a 1,2,4-thiadiazole intermediate derivative produced according to a previous example (approximately 250  $\mu$ mole) dissolved in DCM (2-3 ml) triethylamine (500  $\mu$ mole) was added. The reaction mixture was stirred at room temperature and then the appropriate acyl chloride derivative (1.0 molar equivalent) was added. The reaction mixture was further stirred at room temperature until total consumption of the starting product. The course of the reaction was monitored by TLC using dichloroethane(DCE)-EtOH 10:1 as an eluent mixture. The reaction time varied between 2 hours and 5 hours. When the reaction was complete, DCM (2-3 ml) was added to it and the resulting solution was washed with a 5% aqueous citric acid solution (5 ml), water (5 ml), a 5% aqueous  $\text{Na}_2\text{CO}_3$  solution, and water (5 ml), respectively. The organic phase was separated, dried over  $\text{MgSO}_4$ , filtered and, evaporated to dryness. The residue was crystallised by diethyl ether to yield the desired compound.

- compound 1: 4-phenylacetyl-1-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]piperazine: starting from 1-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]piperazine and 1 equivalent of phenylacetyl chloride, the title compound was obtained.



The title compound was characterised by mass spectrometry as follows: MS (m/z) : 397.18 ( $[\text{M}+\text{H}]^+$ , 100).

- compound 216: 4-(4-methoxybenzoyl)-1-[3-(3-methoxybenzyl)-1,2,4-thiadiazol-5-yl]piperazine: starting from 1-[3-(3-methoxybenzyl)-1,2,4-thiadiazol-5-yl]piperazine and 4-methoxybenzoyl chloride (59 mg; 344  $\mu$ mole), 118 mg of the title compound (yield: 81%) was obtained after 2 hours reaction time.





The final compounds 1-8, 86-90, 94-112, 115-184 and 189-191 named and structurally shown in table 1 were also synthesised using these experimental conditions.

5 Example 209 - N-alkylation of 1,2,4-thiadiazole intermediate derivatives represented by the structural formulae (IV) and (VI)

1,2,4-thiadiazole compounds represented by the structural formulae (A) to (F) have been obtained according to scheme 2 through reaction of a 1,2,4-thiadiazole intermediate derivative represented by the structural formula (IVA), (IVB) or (VI) with a  
10 suitable heteroaryl carboxylic acid halide, phenylalkyl carboxylic acid halide (such as the phenylacetyl chloride represented by the structural formula VC) or phenylalkenyl carboxylic acid halide or phenylalkynyl carboxylic acid halide. A suitable synthetic procedure is detailed as follows. The reaction can be performed starting from acid  
15 chlorides such as, but not limited to, phenylacetyl chloride, 2-phenylbutyric acid chloride, 3-phenylbutyric acid chloride, 4-phenylbutyric acid chloride, 2-phenylpropionic acid chloride, hydrocinnamoyl chloride, 5-phenylvaleric acid chloride, cinnamoyl chloride, phenylpropionic acid chloride, styrylacetic acid chloride and the like.

To the substituted a 1,2,4-thiadiazole intermediate derivative (approximately 250  $\mu$ mole) dissolved in DCM (2-3 ml), triethylamine (2.0 molar equivalent) was added.  
20 The reaction mixture was stirred at room temperature and then the appropriate phenylalkyl or phenylalkenyl or phenylalkynyl carboxylic acid chloride derivative (1.0 molar equivalent) was added. The reaction mixture was further stirred at room temperature until total consumption of the starting intermediate. The course of reaction was monitored by TLC using dichloroethane(DCE)-EtOH 10:1 as an eluent mixture.  
25 The reaction time varied between 3 and 5 hours. When the reaction was complete, DCM (2-3 ml) was added to it and the resulting solution was washed with 5% aqueous citric acid solution (5 ml), water (5 ml), 5% aqueous Na<sub>2</sub>CO<sub>3</sub> solution, and water (5 ml), respectively. The organic phase was separated, dried over MgSO<sub>4</sub>, filtered and, evaporated to dryness. The residue was crystallized by diethyl ether to yield the  
30 desired compound.


The final compounds **91-93** (starting from cinnamoyl chloride) and **113-114** named and structurally shown in table 1 were synthesised using these experimental conditions.

35 Example 210 - urea-linkage and thiourea-linkage formation onto 1,2,4-thiadiazole intermediate derivatives represented by the structural formulae (IV) and (VI)

To a solution of an aryl isocyanate (represented by the structural formula V-E), heteroaryl isocyanate, aryl isothiocyanate or heteroaryl isothiocyanate (approximately 250  $\mu$ mole) in tetrahydrofuran with a trace of DMF (2-3 ml) diisopropylethyl amine (2.2 molar equivalent) was added. Subsequently, 1 molar equivalent of the substituted  
5 1,2,4-thiadiazole intermediate derivative represented by a structural formulae (IVA), (IVB) or (VI) was added. The reaction mixture was stirred at room temperature until total consumption of the starting intermediate. The course of reaction was monitored by TLC using dichloroethane (DCE)-EtOH 10:1 as an eluent mixture. Suitable reaction times were between 3 and 5 hours. When reaction was completed, the reaction mixture  
10 was evaporated until almost dry. DCM (2-3 ml) was added to it and the resulting mixture was washed with a 5% aqueous citric acid solution (5 ml), water (5 ml), a 5% aqueous  $\text{Na}_2\text{CO}_3$  solution, and water (5 ml), respectively. The organic phase was separated, dried over  $\text{MgSO}_4$ , filtered and, evaporated to dryness. The residue was crystallised by diethyl ether to yield the desired compound. The following final  
15 compounds **9 to 29** of the invention were synthesised using these experimental conditions.

Example 211 – synthesis of 1-(4-hydroxybenzenesulfonyl)-4-[3-(4-fluoro-benzyl)-1,2,4-thiadiazol-5-yl]piperazine

20 1-(4-propionyloxy)benzenesulfonyl-4-[3-(4-fluoro-benzyl)-1,2,4-thiadiazol-5-yl]piperazine from a previous example (compound **200**) was further chemically modified according to the following scheme:



More specifically, to a solution of the starting 1,2,4-thiadiazolyl derivative (80 mg; 163  $\mu$ mole) in EtOH (1 ml) KOH (18 mg; 326  $\mu$ mole) and a few drops of water were added. The mixture was stirred at room temperature for 80 minutes and the course of reaction was monitored by TLC using DCE-EtOH 10:1 as an eluent mixture.

5 After the reaction was completed, the reaction mixture was evaporated to dryness. The residue was dissolved in a minimal amount of water and pH was set at 5 by the dropwise addition of 5% aqueous HCl. The precipitate was collected by filtration and dried in a vacuum dessiccator until weight remained constant, thus resulting in 16 mg (yield: 23%) of the pure desired 1-(4-hydroxybenzenesulfonyl)-4-[3-(4-fluoro-benzyl)-

10 1,2,4-thiadiazol-5-yl]piperazine (compound **217**).

#### Example 212 - construction of an $\alpha$ -synuclein over-expressing cell line

An  $\alpha$ -synuclein expression plasmid was constructed by sub-cloning the *NcoI/XhoI* fragment from 212T-SYN(WT) (Griffioen et al., *Biochem Biophys Acta* (2006)

15 1762(3):312-318) containing the cDNA of human wild type  $\alpha$ -synuclein correspondingly into a standard mammalian expression vector pcDNA3.1 (Invitrogen) resulting into the plasmid pcDNA3.1-SYNwt. Plasmids pcDNA3.1 and pcDNA3.1-SYNwt were transfected to human neuroblastoma cells (ATCC No. CRL-2267) and independent clonal lines with the plasmids stably integrated into the genome were selected. These

20 resulted in cell lines named M17 (transfected with pcDNA3.1) and M17-SYNwt (transfected with pcDNA3.1-SYNwt). Over-expression of  $\alpha$ -synuclein in M17-SYNwt cell lines was confirmed by Western analysis.

#### Example 213 - use of $\alpha$ -synuclein expressing cells as a model for neuronal

25 degradation

Due to the high levels of  $\alpha$ -synuclein M17-SYNwt cells are exquisitely sensitivity to paraquat, a well-known risk factor of synuclein-dependent neuronal degeneration. In degenerated or dead cells lactate dehydrogenase (LDH) is leaked out of the cells into the extracellular environment due to a loss of plasma-membrane integrity. This

30 principle was used to determine cytotoxicity by quantifying the level of leaked LDH into the growth medium.

The detailed method for determining  $\alpha$ -synuclein cytotoxicity was as follows: From appropriate precultures of M17 and M17-SYN cells were seeded at 50,000 cells/cm<sup>2</sup> in Optimem Reduced Serum without phenol red (available from InVitrogen, Cat. 31985-047) supplemented with 5% fetal calf serum, 1 mM sodium pyruvate, 1 x

35 non-essential amino acids, 500  $\mu$ g/ml G418 0,5 x antibiotic/antimycotic. After 3 hours of incubation at 37°C/5% CO<sub>2</sub> paraquat was added to the cells (final concentration of 32

mM), together with the test compound and the cells were further incubated for 40 hours. Subsequently, LDH activity was determined using Promega Cytotox 96 Non-Radioactive cytotoxicity assay, (Cat. G1780) according the instructions of the supplier.

Figure 1 shows that treatment of M17-SYNwt cells, but not of M17 cells with paraquat led to a relatively high level of LDH leaked into the medium demonstrating that  $\alpha$ -synuclein mediates cellular degeneration or cell death in response to paraquat.

Example 214 - use of  $\alpha$ -synuclein expressing cells in screening exemplary compounds for synuclein-mediated toxicity

$\alpha$ -synuclein expressing neuroblastoma cells made it possible to assess the ability of compounds of the invention to counteract  $\alpha$ -synuclein cytotoxicity. Active inhibitors of  $\alpha$ -synuclein cytotoxicity were found to provoke a decrease of LDH leakage in paraquat-treated M17-SYNwt cells. Since this method monitors leaked LDH from degenerated or dead cells only non-toxic compounds will be identified as active inhibitors of  $\alpha$ -synuclein-mediated cytotoxicity. Lack of toxicity is an important characteristic for compounds to be administered as a medicament to patients in need thereof.

A compound was considered to be active in this test when inhibiting  $\alpha$ -synuclein cytotoxicity by more than 25% relative to untreated M17-SYNwt cells at a concentration of 20  $\mu$ g/mL or lower. In these experiments, the control group consisted of M17-SYNwt cells treated with DMSO, the untreated paraquat group consisted of M17-SYNwt cells treated with paraquat and DMSO, and the treated paraquat group consisted of M17-SYNwt cells treated with paraquat and the test compound dissolved in DMSO.

In order to determine EC50, exemplary compounds of the present invention were tested at different concentrations ranging from a poorly or non-effective (i.e. a relatively low) concentration to an effective (i.e. relatively higher) concentration. These data were also used for calculation of percent inhibition (referred as " % Inhib. " in table 2). Percent inhibition was calculated as the synuclein toxicity inhibition by the compound in treated paraquat cells, relatively to the synuclein cytotoxicity in untreated paraquat cells, thus corresponding to the following equation:

$$\frac{(\text{LDH release of treated paraquat cells at non-effective concentration of test cmpd}) - (\text{LDH release of treated paraquat cells at most effective concentration of test cmpd})}{(\text{LDH release of untreated paraquat cells}) - (\text{LDH release control cells})} \times 100\%.$$

Compounds **19** (N-(2,6-dimethylphenyl)-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine-1-carboxamide) and **111** (2-phenyl-N-{2-[4-[3-(4-fluoro-benzyl)-1,2,4-thiadiazol-5-yl]piperazin-1-yl]ethyl}butanamide) were tested using the  $\alpha$ -synuclein cytotoxicity assay as described above. Figure 2 shows that these two compounds

(compound **19** = squares; compound **111** = triangles) were able, in a dose-dependent manner, to reduce LDH activity in the medium demonstrating that the respective compounds alleviate  $\alpha$ -synuclein-mediated cytotoxicity.

Dose responses were carried out on all exemplary compounds found to be  
5 active (10-point curves performed in duplicate) based on the above activity definition. Although the pharmacological properties of the compounds disclosed in this invention vary with structural changes in various parts of the molecules – including the linker X, the substituting pattern on the aryl rings, and the type of cyclic or non-cyclic diamino moiety between the linker X and the 1,2,4-thiazolyl moiety – as expected, active  
10 exemplary compounds more particularly possess  $EC_{50}$  in a cell-based assay of synuclein cytotoxicity in the range from about 0.0001  $\mu$ M to about 6  $\mu$ M.  $EC_{50}$  data obtained for compounds from Table 1 are presented in Table 2.

Example 215 - *in vivo* inhibition of synuclein-mediated instigated loss of substantia  
15 nigra neurons

In order to model neuronal loss in the substantia nigra region of the brain, mice are treated with paraquat at a dose not higher than 8 mg/kg/day for a continuous period of 15-100 days. These mice are also chronically co-treated during that period with:

- either exemplary compound **60** (1-[4-methoxyphenylsulfonyl]-4-[3-(4-methylbenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine), or  
20
- exemplary compound **74** (1-[4-methoxyphenylsulfonyl]-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]piperazine), or
- exemplary compound **53** (1-[4-methoxyphenylsulfonyl]-4-[3-(3-methoxybenzyl)-1,2,4-thiadiazol-5-yl]piperazine),

25 each being administered at a dose not higher than 20 mg/kg body weight/day), or by vehicle only (no active compound).

Mice treatment by means of vehicle or a compound of the invention is started preferably 1 or 2 days before administration of paraquat.

At the end of the treatment period, mice are sacrificed and the corresponding  
30 brains are used for immunohistochemical analysis. The substantia nigra brain region has a relatively high percentage of cells with high levels of tyrosine hydroxylase. Using antibodies raised against tyrosin hydroxylase (anti-tyrosin hydroxylase), tyrosine hydroxylase containing neurons in the brains are detected. The area of tyrosin hydroxylase staining in the substantia nigra regions are then quantified. Subsequently,  
35 the quantified tyrosin hydroxylase positive areas of mice treated with a compound of this invention versus mice treated with vehicle are compared. This analysis revealed that the substantia nigra area in mice treated with compound is significantly larger than

in vehicle treated mice, indicating that the corresponding compound is able to inhibit paraquat-triggered degeneration of substantia nigra cells *in vivo*.

Example 216 – *in vivo* inhibition of 6-hydroxydopamine (6-OHDA) instigated loss of substantia nigra neurons

Unilateral substantia nigra lesions by 6-OHDA are obtained by stereotactic striatal injections in brains of living rats as described by Vercammen et al. in *Molecular Therapy* (2006) 14(5):716-723. These rats are also chronically co-treated with the same exemplary compounds and at the same dose as mentioned in example 215, or by vehicle only (no active compound).







Daily treatment of compound or vehicle is started preferably 1 or 2 days before administration of 6-OHDA and lasted between 7 to 30 days after the 6-OHDA injection.







At the end of the treatment period, rats are sacrificed and the corresponding brains were used for immunohistochemical analysis. The substantia nigra brain region has a relatively high percentage of cells with high levels of tyrosine hydroxylase. Using antibodies raised against tyrosin hydroxylase (anti-tyrosine hydroxylase) tyrosine hydroxylase containing neurons in the brains were detected. The nigral lesion volumes and/or the tyrosine hydroxylase positive cell numbers were quantified as described in Vercammen et al. (cited *supra*).

This analysis reveals that the nigral lesion volumes are significantly reduced in rats treated with a compound according to this invention, as compared to vehicle treated rats, thus indicating that the compound is able to inhibit 6-OHDA triggered degeneration of substantia nigra cells *in vivo*.







This analysis also reveals that tyrosine hydroxylase positive cell numbers are higher in rats treated with a compound according to this invention as compared to vehicle treated rats, thus providing confirmation that the compound is able to inhibit 6-OHDA triggered degeneration of substantia nigra cells *in vivo*.







Table 1







No.	Compound name	Compound structure
1	4-phenylacetyl-1-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]piperazine	
2	4-(4-fluorophenylacetyl)-1-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]piperazine	
3	1-(4-fluorophenylacetyl)-4-[3-(4-methylbenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	
4	1-(4-methoxyphenylacetyl)-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	
5	1-phenylacetyl-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	
6	1-(4-fluorophenylacetyl)-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	






No.	Compound name	Compound structure
7	1-[chloro(phenyl)acetyl]-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	
8	1-(2-phenylbutanoyl)-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	
9	N-(3-fluorophenyl)-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]piperazine-1-carboxamide	
10	N-(2-methylphenyl)-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine-1-carboxamide	
11	N-(4-ethylphenyl)-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine-1-carboxamide	
12	N-(2-ethylphenyl)-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine-1-carboxamide	













No.	Compound name	Compound structure
13	N-phenyl-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]piperazine-1-carboxamide	
14	N-(4-ethoxyphenyl)-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine-1-carboxamide	
15	N-(2-methylphenyl)-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]piperazine-1-carboxamide	
16	N-(2-fluorophenyl)-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]piperazine-1-carboxamide	
17	N-(2-trifluoromethylphenyl)-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]piperazine-1-carboxamide	
18	N-(2-trifluoromethylphenyl)-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine-1-carboxamide	






No.	Compound name	Compound structure
19	N-(2,6-dimethylphenyl)-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine-1-carboxamide	
20	N-(2,4-dimethylphenyl)-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine-1-carboxamide	
21	N-(2,6-dichlorophenyl)-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine-1-carboxamide	
22	N-(3-cyanophenyl)-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine-1-carboxamide	
23	N-(2,4-difluorophenyl)-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine-1-carboxamide	
24	N-(2,6-dimethylphenyl)-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]piperazine-1-carboxamide	






No.	Compound name	Compound structure
25	N-1-naphtyl-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine-1-carboxamide	
26	N-(3,4-difluorophenyl)-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine-1-carboxamide	
27	N-(2,4-dimethoxyphenyl)-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]piperazine-1-carboxamide	
28	N-(3,4-difluorophenyl)-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]piperazine-1-carboxamide	
29	N-(3,5-dimethoxyphenyl)-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine-1-carboxamide	
30	1-[4-tert-butylphenylsulfonyl]-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]piperazine	

No.	Compound name	Compound structure
31	1-[4-methoxyphenylsulfonyl]-4-[3-(4-chlorobenzyl)-1,2,4-thiadiazol-5-yl]piperazine	
32	1-[4-methoxyphenylsulfonyl]-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]piperazine	
33	1-[4-fluorophenylsulfonyl]-4-[3-(4-chlorobenzyl)-1,2,4-thiadiazol-5-yl]piperazine	
34	1-[4-chlorophenylsulfonyl]-4-[3-(4-methylbenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	
35	1-[1-naphthylsulfonyl]-4-[3-(4-methylbenzyl)-1,2,4-thiadiazol-5-yl]piperazine	






No.	Compound name	Compound structure
36	1-[2,5-dichlorophenylsulfonyl]-4-[3-(4-methylbenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	
37	1-[2,4,6-trimethylphenylsulfonyl]-4-[3-(4-methylbenzyl)-1,2,4-thiadiazol-5-yl]piperazine	
38	1-[2-naphthylsulfonyl]-4-[3-(4-methylbenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	
39	1-[2,5-dichlorophenylsulfonyl]-4-[3-(4-chlorobenzyl)-1,2,4-thiadiazol-5-yl]piperazine	
40	1-[4-bromophenylsulfonyl]-4-[3-(4-methylbenzyl)-1,2,4-thiadiazol-5-yl]-3-methylpiperazine	






No.	Compound name	Compound structure
41	1-[1-naphtylsulfonyl]-4-[3-(4-methylbenzyl)-1,2,4-thiadiazol-5-yl]-3-methylpiperazine	
42	1-[4-tert-butylphenylsulfonyl]-4-[3-(4-methylbenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	
43	1-[1-naphtylsulfonyl]-4-[3-(4-chlorobenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	
44	1-[3-methoxyphenylsulfonyl]-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]piperazine	
45	1-[2,4,6-trimethylphenylsulfonyl]-4-[3-(4-methylbenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	






No.	Compound name	Compound structure
46	1-[3-(trifluorophenylsulfonyl)-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	
47	1-phenylsulfonyl-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	
48	1-[4-(acetamidophenylsulfonyl)-4-[3-(4-methylbenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	
49	1-[4-(acetamidophenylsulfonyl)-4-[3-(4-methylbenzyl)-1,2,4-thiadiazol-5-yl]piperazine	
50	1-[4-(methylphenylsulfonyl)-4-[3-(4-methylbenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	






No.	Compound name	Compound structure
51	1-[4-methoxyphenylsulfonyl]-4-[3-(4-chlorobenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	
52	1-[2-naphtylsulfonyl]-4-[3-(4-chlorobenzyl)-1,2,4-thiadiazol-5-yl]piperazine	
53	1-[4-methoxyphenylsulfonyl]-4-[3-(3-methoxybenzyl)-1,2,4-thiadiazol-5-yl]piperazine	
54	1-[4-tert-butylphenylsulfonyl]-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	
55	1-[4-acetamidophenylsulfonyl]-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	














No.	Compound name	Compound structure
56	1-[3-(trifluoromethylphenylsulfonyl)-4-[3-(4-methylbenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	
57	1-[4-fluorophenylsulfonyl]-4-[3-(4-methylbenzyl)-1,2,4-thiadiazol-5-yl]piperazine	
58	1-[4-fluorophenylsulfonyl]-4-[3-(4-methylbenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	
59	1-[4-fluorophenylsulfonyl]-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	
60	1-[4-methoxyphenylsulfonyl]-4-[3-(4-methylbenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	






No.	Compound name	Compound structure
61	1-[4-ter-butylphenylsulfonyl]-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]piperazine	
62	1-[3-trifluoromethylphenylsulfonyl]-4-[3-(4-methylbenzyl)-1,2,4-thiadiazol-5-yl]piperazine	
63	1-[4-methylphenylsulfonyl]-4-[3-(4-chlorobenzyl)-1,2,4-thiadiazol-5-yl]piperazine	
64	1-[4-bromophenylsulfonyl]-4-[3-(4-methylbenzyl)-1,2,4-thiadiazol-5-yl]piperazine	
65	1-[2-naphthylsulfonyl]-4-[3-(4-methylbenzyl)-1,2,4-thiadiazol-5-yl]piperazine	





No.	Compound name	Compound structure
66	1-[4-chlorophenylsulfonyl]-4-[3-(4-methylbenzyl)-1,2,4-thiadiazol-5-yl]piperazine	
67	1-[4-tert-butylphenylsulfonyl]-4-[3-(4-methylbenzyl)-1,2,4-thiadiazol-5-yl]piperazine	
68	1-[4-methoxyphenylsulfonyl]-4-[3-(4-methylbenzyl)-1,2,4-thiadiazol-5-yl]piperazine	
69	1-[4-tert-butylphenylsulfonyl]-4-[3-(4-chlorobenzyl)-1,2,4-thiadiazol-5-yl]piperazine	
70	1-[quinoline-8-sulfonyl]-4-[3-(4-methylbenzyl)-1,2,4-thiadiazol-5-yl]piperazine	

No.	Compound name	Compound structure
71	1-[4-nitrophenylsulfonyl]-4-[3-(4-methylbenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	
72	1-[3-nitro-4-chlorophenylsulfonyl]-4-[3-(4-methylbenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	
73	1-[4-nitrophenylsulfonyl]-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	
74	1-[4-methoxyphenylsulfonyl]-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]piperazine	
75	1-[3-nitro-4-chlorophenylsulfonyl]-4-[3-(4-methylbenzyl)-1,2,4-thiadiazol-5-yl]piperazine	





No.	Compound name	Compound structure
76	1-(benzylsulfonyl)-4-[3-(4-chlorobenzyl)-1,2,4-thiadiazol-5-yl]piperazine	
77	1-(benzylsulfonyl)-4-[3-(4-methylbenzyl)-1,2,4-thiadiazol-5-yl]piperazine	
78	1-(phenylprop-2-ensulfonyl)-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]piperazine	
79	1-(phenylprop-2-ensulfonyl)-4-[3-(4-methylbenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	
80	1-(phenylprop-2-ensulfonyl)-4-[3-(4-methylbenzyl)-1,2,4-thiadiazol-5-yl]piperazine	
81	1-(butylsulfonyl)-4-[3-(4-chlorobenzyl)-1,2,4-thiadiazol-5-yl]piperazine	





No.	Compound name	Compound structure
82	1-(octylsulfonyl)-4-[3-(4-methylbenzyl)-1,2,4-thiadiazol-5-yl]piperazine	
83	1-(butylsulfonyl)-4-[3-(4-methylbenzyl)-1,2,4-thiadiazol-5-yl]piperazine	
84	1-(ethylsulfonyl)-4-[3-(4-chlorobenzyl)-1,2,4-thiadiazol-5-yl]piperazine	
85	1-(isopropylsulfonyl)-4-[3-(4-methylbenzyl)-1,2,4-thiadiazol-5-yl]piperazine	
86	1-[(2E)-3-phenylprop-2-enoyl]-4-[3-(4-chlorobenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	





No.	Compound name	Compound structure
87	1-[(2E)-3-phenylprop-2-enoyl]-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	
88	1-[(2E)-3-phenylprop-2-enoyl]-4-[3-(4-chlorobenzyl)-1,2,4-thiadiazol-5-yl]piperazine	
89	1-(3-phenylpropanoyl)-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	
90	1-(3-phenylpropanoyl)-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]piperazine	
91	1-[3-phenylprop-2-enyl]-4-[3-(4-methylbenzyl)-1,2,4-thiadiazol-5-yl]piperazine	





No.	Compound name	Compound structure
92	1-[3-phenylprop-2-enyl]-4-[3-(4-chlorobenzyl)-1,2,4-thiadiazol-5-yl]piperazine	
93	1-[3-phenylprop-2-enyl]-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]piperazine	
94	4-pentyl-N-{2-[4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]piperazin-1-yl]ethyl}benzamide	
95	4-butyl-N-{2-[4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]piperazin-1-yl]ethyl}benzamide	








No.	Compound name	Compound structure
96	4-hexyl-N-{2-[4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]piperazin-1-yl]ethyl}benzamide	
97	4-chloro-N-{2-[4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]piperazin-1-yl]ethyl}benzamide	
98	3,5-dichloro-N-{2-[4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]piperazin-1-yl]ethyl}benzamide	
99	2-methyl-N-{2-[4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]piperazin-1-yl]ethyl}benzamide	







No.	Compound name	Compound structure
100	3-fluoro-N-{2-[4-[3-(4-chlorobenzyl)-1,2,4-thiadiazol-5-yl]piperazin-1-yl]ethyl}benzamide	
101	4-methyl-N-{2-[4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]piperazin-1-yl]ethyl}benzamide	
102	4-fluoro-N-{2-[4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]piperazin-1-yl]ethyl}benzamide	
103	4-ethyl-N-{2-[4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]piperazin-1-yl]ethyl}benzamide	







No.	Compound name	Compound structure
104	N-{2-[4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]piperazin-1-yl]ethyl}benzamide	
105	3-fluoro-N-{2-[4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]piperazin-1-yl]ethyl}benzamide	
106	3-fluoro-N-{2-[4-[3-benzyl-1,2,4-thiadiazol-5-yl]piperazin-1-yl]ethyl}benzamide	
107	2-(4-fluorophenyl)-N-{2-[4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]piperazin-1-yl]ethyl}acetamide	

No.	Compound name	Compound structure
108	2-phenyl-N-{2-[4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]piperazin-1-yl]ethyl}acetamide	
109	2-(4-fluorophenyl)-N-{2-[4-[3-(4-methylbenzyl)-1,2,4-thiadiazol-5-yl]piperazin-1-yl]ethyl}acetamide	
110	N-benzyl-N'-(2-[4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]piperazin-1-yl]ethyl)urea	
111	2-phenyl-N-{2-[4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]piperazin-1-yl]ethyl}butanamide	







No.	Compound name	Compound structure
112	3-phenyl-N-{2-[4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]piperazin-1-yl]ethyl}propanamide	
113	1-benzyl-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]piperazine	
114	1-(1,3-benzodioxol-5-ylmethyl)-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]piperazine	
115	1-(2-fluorobenzoyl)-4-[3-(3-methoxybenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	
116	1-(4-ethylbenzoyl)-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	
117	1-(4-butylbenzoyl)-4-[3-(4-methylbenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	







No.	Compound name	Compound structure
118	1-(4-methoxybenzoyl)-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	
119	1-(1,3-benzodioxol-5-ylcarbonyl)-4-[3-(3-methoxybenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	
120	1-(4-butylbenzoyl)-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	
121	1-(4-hexylbenzoyl)-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]piperazine	
122	1-(3-chlorobenzoyl)-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	







No.	Compound name	Compound structure
123	1-(4-fluorobenzoyl)-4-[3-(3-methoxybenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	
124	1-(4-methylbenzoyl)-4-[3-(3-methoxybenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	
125	1-(3-fluorobenzoyl)-4-[3-(4-chlorobenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	
126	1-benzoyl-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	
127	1-(4-fluorobenzoyl)-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	
128	1-(4-tert-butylbenzoyl)-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	








No.	Compound name	Compound structure
129	1-(1,1'-biphenyl-4-ylcarbonyl)-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	
130	1-(4-methoxybenzoyl)-4-[3-(4-methylbenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	
131	1-(4-ethylbenzoyl)-4-[3-(4-methylbenzyl)-1,2,4-thiadiazol-5-yl]piperazine	
132	1-(2-naphthoyl)-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	
133	1-(2-methoxybenzoyl)-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	
134	1-(4-pentylbenzoyl)-4-[3-(4-methylbenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	
















No.	Compound name	Compound structure
135	1-(4-bromobenzoyl)-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	
136	1-(2,4-dimethoxybenzoyl)-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	
137	1-(3,5-dichlorobenzoyl)-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]piperazine	
138	1-(3-chlorobenzoyl)-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]piperazine	
139	1-(4-methylbenzoyl)-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	
140	1-(2-methylbenzoyl)-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	







No.	Compound name	Compound structure
141	1-(4-methylbenzoyl)-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]piperazine	
142	1-(3-bromobenzoyl)-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	
143	1-(4-ethylbenzoyl)-4-[3-(3-methoxybenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	
144	1-(3-methylbenzoyl)-4-[3-(4-methylbenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	
145	1-(3-trifluoromethylbenzoyl)-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	
146	1-(4-tert-butylbenzoyl)-4-[3-(3-methoxybenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	







No.	Compound name	Compound structure
147	1-(4-ethylbenzoyl)-4-[3-(4-methylbenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	
148	1-(2-bromobenzoyl)-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	
149	1-(2-fluorobenzoyl)-4-[3-(4-methylbenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	
150	1-(3-fluorobenzoyl)-4-[3-benzyl-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	
151	1-(4-fluorobenzoyl)-4-[3-(4-methylbenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	
152	1-(2-methylbenzoyl)-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]piperazine	

No.	Compound name	Compound structure
153	1-(4-fluorobenzoyl)-4-[3-(4-chlorobenzyl)-1,2,4-thiadiazol-5-yl]piperazine	
154	1-(4-fluorobenzoyl)-4-[3-benzyl-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	
155	1-(4-chlorobenzoyl)-4-[3-(4-methylbenzyl)-1,2,4-thiadiazol-5-yl]piperazine	
156	1-(3-fluorobenzoyl)-4-[3-(4-methylbenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	
157	1-(3-fluorobenzoyl)-4-[3-(4-chlorobenzyl)-1,2,4-thiadiazol-5-yl]piperazine	
158	1-benzoyl-4-[3-(4-methylbenzyl)-1,2,4-thiadiazol-5-yl]piperazine	
159	1-(2-fluorobenzoyl)-4-[3-(4-chlorobenzyl)-1,2,4-thiadiazol-5-yl]piperazine	







No.	Compound name	Compound structure
160	1-(4-fluorobenzoyl)-4-[3-(4-methylbenzyl)-1,2,4-thiadiazol-5-yl]piperazine	
161	1-(1,3-benzodioxol-5-ylcarbonyl)-4-[3-(4-methylbenzyl)-1,2,4-thiadiazol-5-yl]-2-methyl+B176piperazine	
162	1-(3-fluorobenzoyl)-4-[3-(4-methylbenzyl)-1,2,4-thiadiazol-5-yl]piperazine	
163	1-(4-fluorobenzoyl)-4-[3-benzyl-1,2,4-thiadiazol-5-yl]piperazine	
164	1-(4-bromobenzoyl)-4-[3-(4-methylbenzyl)-1,2,4-thiadiazol-5-yl]piperazine	
165	1-(4-ethylbenzoyl)-4-[3-(4-chlorobenzyl)-1,2,4-thiadiazol-5-yl]piperazine	
166	1-(2-chlorobenzoyl)-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	







No.	Compound name	Compound structure
167	1-(2-fluorobenzoyl)-4-[3-(4-chlorobenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	
168	1-(4-trifluoromethylbenzoyl)-4-[3-(3-methoxybenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	
169	1-benzoyl-4-[3-(4-methylbenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	
170	1-(4-bromobenzoyl)-4-[3-(3-methoxybenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	
171	1-(4-trifluoromethylbenzoyl)-4-[3-(4-methylbenzyl)-1,2,4-thiadiazol-5-yl]piperazine	
172	1-(3-nitro-4-methylbenzoyl)-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	








No.	Compound name	Compound structure
173	1-benzoyl-4-[3-(3-methoxybenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	
174	1-(4-chlorobenzoyl)-4-[3-(3-methoxybenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	
175	1-(2-fluorobenzoyl)-4-[3-(4-methylbenzyl)-1,2,4-thiadiazol-5-yl]piperazine	
176	1-(4-hexylbenzoyl)-4-[3-(4-methylbenzyl)-1,2,4-thiadiazol-5-yl]piperazine	
177	1-(2-chloro-4-nitrobenzoyl)-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	
178	1-(1,3-benzodioxol-5-ylcarbonyl)-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	

No.	Compound name	Compound structure
179	1-(3-fluorobenzoyl)-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	
180	1-(4-tert-butylbenzoyl)-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]piperazine	
181	1-benzoyl-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]piperazine	
182	1-(4-butylbenzoyl)-4-[3-(4-methylbenzyl)-1,2,4-thiadiazol-5-yl]piperazine	
183	1-(4-tert-butylbenzoyl)-4-[3-(4-methylbenzyl)-1,2,4-thiadiazol-5-yl]piperazine	
184	1-(4-nitrobenzoyl)-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	



No.	Compound name	Compound structure
185	1-(2-methylphenyl)-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]piperazine	
186	1-(2-ethoxyphenyl)-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]piperazine	
187	1-(2-fluorophenyl)-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]piperazine	
188	1-(3-trifluoromethylphenyl)-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]piperazine	
189	1-(4-chlorobenzoyl)-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-1,4-diazepane	
190	1-(4-methylbenzoyl)-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-1,4-diazepane	

No.	Compound name	Compound structure
191	1-(1,3-benzodioxol-5-ylcarbonyl)-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-1,4-diazepane	
193	1-[4-methoxyphenylsulfonyl]-4-[3-(3-fluoro-benzyl)-1,2,4-thiadiazol-5-yl]piperazine	
194	1-[4-methoxyphenylsulfonyl]-4-[3-(2-fluoro-benzyl)-1,2,4-thiadiazol-5-yl]piperazine	
195	1-[2-methoxyphenylsulfonyl]-4-[3-(4-fluoro-benzyl)-1,2,4-thiadiazol-5-yl]piperazine	
196	1-[4-ethoxyphenylsulfonyl]-4-[3-(4-fluoro-benzyl)-1,2,4-thiadiazol-5-yl]piperazine	
197	1-[4-ethylphenylsulfonyl]-4-[3-(4-fluoro-benzyl)-1,2,4-thiadiazol-5-yl]piperazine	

No.	Compound name	Compound structure
198	1-phenylsulfonyl-4-[3-(4-fluoro-benzyl)-1,2,4-thiadiazol-5-yl]piperazine	
199	1-[4-methoxyphenylsulfonyl]-4-[3-benzyl-1,2,4-thiadiazol-5-yl]piperazine	
200	1-(4-propionyloxy)benzene-sulfonyl-4-[3-(4-fluoro-benzyl)-1,2,4-thiadiazol-5-yl]piperazine	
201	1-[4-methoxyphenylsulfonyl]-4-[3-(3-methyl-benzyl)-1,2,4-thiadiazol-5-yl]piperazine	
202	1-[4-methoxyphenylsulfonyl]-4-[3-(2-methyl-benzyl)-1,2,4-thiadiazol-5-yl]piperazine	
203	1-[4-methoxyphenylsulfonyl]-4-[3-(2-methoxy-benzyl)-1,2,4-thiadiazol-5-yl]piperazine	
204	1-[4-methoxyphenylsulfonyl]-4-[3-(3-methyl-4-fluoro-benzyl)-1,2,4-thiadiazol-5-yl]piperazine	

No.	Compound name	Compound structure
205	1-[4-methoxyphenylsulfonyl]-4-[3-(4-methoxy-benzyl-1,2,4-thiadiazol-5-yl)]piperazine	
206	1-[2-thienylsulfonyl]-4-[3-(2-methyl-benzyl-1,2,4-thiadiazol-5-yl)]piperazine	
207	1-[4-bromophenylsulfonyl]-4-[3-(3-methoxy-benzyl-1,2,4-thiadiazol-5-yl)]piperazine	
208	1-[4-methoxyphenylsulfonyl]-4-[3-(3-methoxybenzyl)-1,2,4-thiadiazol-5-yl]-2-methyl-piperazine	
209	<i>N</i> -[4-methoxyphenylsulfonyl]- <i>N'</i> -[3-(3-methoxybenzyl)-1,2,4-thiadiazol-5-yl]-ethane-1,2-diamine	
210	<i>N</i> -[4-methoxyphenylsulfonyl]- <i>N'</i> -[3-(3-methoxybenzyl)-1,2,4-thiadiazol-5-yl]-propane-1,2-diamine	

No.	Compound name	Compound structure
211	<i>N</i> -[4-methoxyphenylsulfonyl]- <i>N'</i> -[3-(3-methoxybenzyl)-1,2,4-thiadiazol-5-yl]-propane-1,3-diamine	
212	1-[4-methoxyphenylsulfonyl]-4-[3-(3-methoxybenzyl)-1,2,4-thiadiazol-5-yl]diazepane	
213	<i>N'</i> -[4-methoxyphenylsulfonyl]- <i>N</i> -[3-(3-methoxybenzyl)-1,2,4-thiadiazol-5-yl]- <i>N</i> -methylethane-1,2-diamine	
214	<i>N'</i> -[4-methoxyphenylsulfonyl]- <i>N</i> -[3-(3-methoxybenzyl)-1,2,4-thiadiazol-5-yl]- <i>N'</i> -methylethane-1,2-diamine	
215	<i>N'</i> -[4-methoxyphenylsulfonyl]- <i>N</i> -[3-(3-methoxybenzyl)-1,2,4-thiadiazol-5-yl]- <i>N,N'</i> -dimethylethane-1,2-diamine	
217	1-(4-hydroxybenzenesulfonyl)-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]piperazine	

(end of Table 1)

Table 2 - biological activity of exemplary compounds

No.	Name	% Inhib.	EC50 (µM)
60	1-[4-methoxyphenylsulfonyl]-4-[3-(4-methylbenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	93	0,000033
74	1-[4-methoxyphenylsulfonyl]-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]piperazine	44	0,000105
49	1-[4-acetamidophenylsulfonyl]-4-[3-(4-methylbenzyl)-1,2,4-thiadiazol-5-yl]piperazine	77	0,000106
31	1-[4-methoxyphenylsulfonyl]-4-[3-(4-chlorobenzyl)-1,2,4-thiadiazol-5-yl]piperazine	59	0,000169
68	1-[4-methoxyphenylsulfonyl]-4-[3-(4-methylbenzyl)-1,2,4-thiadiazol-5-yl]piperazine	53	0,000255
51	1-[4-methoxyphenylsulfonyl]-4-[3-(4-chlorobenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	94	0,001346
33	1-[4-fluorophenylsulfonyl]-4-[3-(4-chlorobenzyl)-1,2,4-thiadiazol-5-yl]piperazine	53	0,002818
48	1-[4-acetamidophenylsulfonyl]-4-[3-(4-methylbenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	91	0,008439
57	1-[4-fluorophenylsulfonyl]-4-[3-(4-methylbenzyl)-1,2,4-thiadiazol-5-yl]piperazine	88	0,010360
115	1-(2-fluorobenzoyl)-4-[3-(3-methoxybenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	75	0,036080
65	1-[2-naphtylsulfonyl]-4-[3-(4-methylbenzyl)-1,2,4-thiadiazol-5-yl]piperazine	78	0,039270
35	1-[1-naphtylsulfonyl]-4-[3-(4-methylbenzyl)-1,2,4-thiadiazol-5-yl]piperazine	47	0,047235
116	1-(4-ethylbenzoyl)-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	71	0,052160
80	1-(phenylprop-2-ensulfonyl)-4-[3-(4-methylbenzyl)-1,2,4-thiadiazol-5-yl]piperazine	70	0,056880
58	1-[4-fluorophenylsulfonyl]-4-[3-(4-methylbenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	58	0,061030
34	1-[4-chlorophenylsulfonyl]-4-[3-(4-methylbenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	66	0,065695
37	1-[2,4,6-trimethylphenylsulfonyl]-4-[3-(4-methylbenzyl)-1,2,4-thiadiazol-5-yl]piperazine	48	0,073110
55	1-[4-acetamidophenylsulfonyl]-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	114	0,078150
63	1-[4-methylphenylsulfonyl]-4-[3-(4-chlorobenzyl)-1,2,4-thiadiazol-5-yl]piperazine	83	0,080740
117	1-(4-butylbenzoyl)-4-[3-(4-methylbenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	82	0,084110
118	1-(4-methoxybenzoyl)-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	64	0,091145
119	1-(1,3-benzodioxol-5-ylcarbonyl)-4-[3-(3-methoxybenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	72	0,095050
120	1-(4-butylbenzoyl)-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	120	0,098730
40	1-[4-bromophenylsulfonyl]-4-[3-(4-methylbenzyl)-	77	0,099855

No.	Name	% Inhib.	EC50 ( $\mu$ M)
	1,2,4-thiadiazol-5-yl]-3-methylpiperazine		
36	1-[2,5-dichlorophenylsulfonyl]-4-[3-(4-methylbenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	52	0,10
52	1-[2-naphtylsulfonyl]-4-[3-(4-chlorobenzyl)-1,2,4-thiadiazol-5-yl]piperazine	104	0,10
121	1-(4-hexylbenzoyl)-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]piperazine	64	0,12
78	1-(phenylprop-2-ensulfonyl)-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]piperazine	75	0,13
38	1-[2-naphtylsulfonyl]-4-[3-(4-methylbenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	78	0,13
122	1-(3-chlorobenzoyl)-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	92	0,14
123	1-(4-fluorobenzoyl)-4-[3-(3-methoxybenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	95	0,14
124	1-(4-methylbenzoyl)-4-[3-(3-methoxybenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	57	0,14
1	4-phenylacetyl-1-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]piperazine	75	0,15
39	1-[2,5-dichlorophenylsulfonyl]-4-[3-(4-chlorobenzyl)-1,2,4-thiadiazol-5-yl]piperazine	25	0,16
125	1-(3-fluorobenzoyl)-4-[3-(4-chlorobenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	68	0,16
189	1-(4-chlorobenzoyl)-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-1,4-diazepane	85	0,17
79	1-(phenylprop-2-ensulfonyl)-4-[3-(4-methylbenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	53	0,17
19	N-(2,6-dimethylphenyl)-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine-1-carboxamide	95	0,20
126	1-benzoyl-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	63	0,21
127	1-(4-fluorobenzoyl)-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	108	0,23
128	1-(4-tert-butylbenzoyl)-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	95	0,24
129	1-(1,1'-biphenyl-4-ylcarbonyl)-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	61	0,24
2	4-(4-fluorophenylacetyl)-1-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]piperazine	54	0,25
130	1-(4-methoxybenzoyl)-4-[3-(4-methylbenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	118	0,25
131	1-(4-ethylbenzoyl)-4-[3-(4-methylbenzyl)-1,2,4-thiadiazol-5-yl]piperazine	91	0,25
107	2-(4-fluorophenyl)-N-(2-[4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]piperazin-1-yl]ethyl)acetamide	80	0,26
132	1-(2-naphthoyl)-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	74	0,26
133	1-(2-methoxybenzoyl)-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	118	0,29
134	1-(4-pentylbenzoyl)-4-[3-(4-methylbenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	75	0,30

No.	Name	% Inhib.	EC50 (μM)
135	1-(4-bromobenzoyl)-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	73	0,31
136	1-(2,4-dimethoxybenzoyl)-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	83	0,34
137	1-(3,5-dichlorobenzoyl)-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]piperazine	68	0,35
94	4-pentyl-N-{2-[4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]piperazin-1-yl]ethyl}benzamide	90	0,35
81	1-(butylsulfonyl)-4-[3-(4-chlorobenzyl)-1,2,4-thiadiazol-5-yl]piperazine	80	0,35
138	1-(3-chlorobenzoyl)-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]piperazine	81	0,36
185	1-(2-methylphenyl)-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]piperazine	114	0,38
95	4-butyl-N-{2-[4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]piperazin-1-yl]ethyl}benzamide	78	0,38
139	1-(4-methylbenzoyl)-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	87	0,40
140	1-(2-methylbenzoyl)-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	56	0,45
141	1-(4-methylbenzoyl)-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]piperazine	75	0,49
142	1-(3-bromobenzoyl)-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	72	0,50
9	N-(3-fluorophenyl)-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]piperazine-1-carboxamide	53	0,52
41	1-[1-naphtylsulfonyl]-4-[3-(4-methylbenzyl)-1,2,4-thiadiazol-5-yl]-3-methylpiperazine	54	0,53
112	3-phenyl-N-{2-[4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]piperazin-1-yl]ethyl}propanamide	91	0,55
143	1-(4-ethylbenzoyl)-4-[3-(3-methoxybenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	89	0,56
144	1-(3-methylbenzoyl)-4-[3-(4-methylbenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	64	0,56
89	1-(3-phenylpropanoyl)-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	86	0,60
10	N-(2-methylphenyl)-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine-1-carboxamide	72	0,60
145	1-(3-trifluoromethylbenzoyl)-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	60	0,62
11	N-(4-ethylphenyl)-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine-1-carboxamide	73	0,69
91	1-[3-phenylprop-2-enyl]-4-[3-(4-methylbenzyl)-1,2,4-thiadiazol-5-yl]piperazine	90	0,71
146	1-(4-tert-butylbenzoyl)-4-[3-(3-methoxybenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	94	0,72
92	1-[3-phenylprop-2-enyl]-4-[3-(4-chlorobenzyl)-1,2,4-thiadiazol-5-yl]piperazine	69	0,75
20	N-(2,4-dimethylphenyl)-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine-1-carboxamide	106	0,76



No.	Name	% Inhib.	EC50 (μM)
21	N-(2,6-dichlorophenyl)-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine-1-carboxamide	70	0,79
96	4-hexyl-N-{2-[4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]piperazin-1-yl]ethyl}benzamide	72	0,80
4	1-(4-methoxyphenylacetyl)-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	56	0,82
147	1-(4-ethylbenzoyl)-4-[3-(4-methylbenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	88	0,84
148	1-(2-bromobenzoyl)-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	56	0,86
42	1-[4-tert-butylphenylsulfonyl]-4-[3-(4-methylbenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	33	0,87
22	N-(3-cyanophenyl)-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine-1-carboxamide	59	0,88
43	1-[1-naphtylsulfonyl]-4-[3-(4-chlorobenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	35	0,89
12	N-(2-ethylphenyl)-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine-1-carboxamide	92	0,89
23	N-(2,4-difluorophenyl)-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine-1-carboxamide	66	0,94
149	1-(2-fluorobenzoyl)-4-[3-(4-methylbenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	105	0,98
86	1-[(2E)-3-phenylprop-2-enoyl]-4-[3-(4-chlorobenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	81	1,13
150	1-(3-fluorobenzoyl)-4-[3-benzyl-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	99	1,14
151	1-(4-fluorobenzoyl)-4-[3-(4-methylbenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	73	1,14
152	1-(2-methylbenzoyl)-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]piperazine	66	1,15
45	1-[2,4,6-trimethylphenylsulfonyl]-4-[3-(4-methylbenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	56	1,20
24	N-(2,6-dimethylphenyl)-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]piperazine-1-carboxamide	124	1,20
13	N-phenyl-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]piperazine-1-carboxamide	71	1,23
97	4-chloro-N-{2-[4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]piperazin-1-yl]ethyl}benzamide	68	1,29
46	1-[3-trifluorophenylsulfonyl]-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	64	1,34
90	1-(3-phenylpropanoyl)-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]piperazine	73	1,41
98	3,5-dichloro-N-{2-[4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]piperazin-1-yl]ethyl}benzamide	102	1,42
153	1-(4-fluorobenzoyl)-4-[3-(4-chlorobenzyl)-1,2,4-thiadiazol-5-yl]piperazine	53	1,44
8	1-(2-phenylbutanoyl)-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	71	1,49

No.	Name	% Inhib.	EC50 (µM)
113	1-benzyl-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]piperazine	65	1,54
99	2-methyl-N-{2-[4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]piperazin-1-yl]ethyl}benzamide	97	1,58
154	1-(4-fluorobenzoyl)-4-[3-benzyl-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	75	1,58
82	1-(octylsulfonyl)-4-[3-(4-methylbenzyl)-1,2,4-thiadiazol-5-yl]piperazine	50	1,58
155	1-(4-chlorobenzoyl)-4-[3-(4-methylbenzyl)-1,2,4-thiadiazol-5-yl]piperazine	76	1,64
156	1-(3-fluorobenzoyl)-4-[3-(4-methylbenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	86	1,67
25	N-1-naphthyl-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine-1-carboxamide	97	1,69
157	1-(3-fluorobenzoyl)-4-[3-(4-chlorobenzyl)-1,2,4-thiadiazol-5-yl]piperazine	70	1,70
14	N-(4-ethoxyphenyl)-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine-1-carboxamide	70	1,73
111	2-phenyl-N-{2-[4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]piperazin-1-yl]ethyl}butanamide	79	1,79
100	3-fluoro-N-{2-[4-[3-(4-chlorobenzyl)-1,2,4-thiadiazol-5-yl]piperazin-1-yl]ethyl}benzamide	75	1,79
101	4-methyl-N-{2-[4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]piperazin-1-yl]ethyl}benzamide	68	1,94
102	4-fluoro-N-{2-[4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]piperazin-1-yl]ethyl}benzamide	80	1,99
93	1-[3-phenylprop-2-enyl]-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]piperazine	91	1,99
186	1-(2-ethoxyphenyl)-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]piperazine	94	2,05
108	2-phenyl-N-{2-[4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]piperazin-1-yl]ethyl}acetamide	63	2,06
158	1-benzoyl-4-[3-(4-methylbenzyl)-1,2,4-thiadiazol-5-yl]piperazine	57	2,10
3	1-(4-fluorophenylacetyl)-4-[3-(4-methylbenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	76	2,20
103	4-ethyl-N-{2-[4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]piperazin-1-yl]ethyl}benzamide	139	2,32
87	1-[(2E)-3-phenylprop-2-enoyl]-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	94	2,49
83	1-(butylsulfonyl)-4-[3-(4-methylbenzyl)-1,2,4-thiadiazol-5-yl]piperazine	36	2,64
190	1-(4-methylbenzoyl)-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-1,4-diazepane	87	2,77
187	1-(2-fluorophenyl)-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]piperazine	83	2,81
159	1-(2-fluorobenzoyl)-4-[3-(4-chlorobenzyl)-1,2,4-thiadiazol-5-yl]piperazine	48	2,85
160	1-(4-fluorobenzoyl)-4-[3-(4-methylbenzyl)-1,2,4-thiadiazol-5-yl]piperazine	88	2,87
161	1-(1,3-benzodioxol-5-ylcarbonyl)-4-[3-(4-methylbenzyl)-1,2,4-thiadiazol-5-yl]-2-	101	3,36

No.	Name	% Inhib.	EC50 (μM)
	methyl+B176piperazine		
162	1-(3-fluorobenzoyl)-4-[3-(4-methylbenzyl)-1,2,4-thiadiazol-5-yl]piperazine	101	3,40
84	1-(ethylsulfonyl)-4-[3-(4-chlorobenzyl)-1,2,4-thiadiazol-5-yl]piperazine	53	3,48
109	2-(4-fluorophenyl)-N-{2-[4-[3-(4-methylbenzyl)-1,2,4-thiadiazol-5-yl]piperazin-1-yl]ethyl}acetamide	93	3,52
163	1-(4-fluorobenzoyl)-4-[3-benzyl-1,2,4-thiadiazol-5-yl]piperazine	67	3,61
85	1-(isopropylsulfonyl)-4-[3-(4-methylbenzyl)-1,2,4-thiadiazol-5-yl]piperazine	69	3,65
104	N-{2-[4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]piperazin-1-yl]ethyl}benzamide	65	3,82
164	1-(4-bromobenzoyl)-4-[3-(4-methylbenzyl)-1,2,4-thiadiazol-5-yl]piperazine	60	3,86
15	N-(2-methylphenyl)-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]piperazine-1-carboxamide	65	5,01
16	N-(2-fluorophenyl)-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]piperazine-1-carboxamide	72	5,68
30	1-[4-tert-butylphenylsulfonyl]-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]piperazine	51	
77	1-(benzylsulfonyl)-4-[3-(4-methylbenzyl)-1,2,4-thiadiazol-5-yl]piperazine	81	
5	1-phenylacetyl-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	83	
6	1-(4-fluorophenylacetyl)-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	75	
7	1-[chloro(phenyl)acetyl]-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	69	
17	N-(2-trifluoromethylphenyl)-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]piperazine-1-carboxamide	46	
18	N-(2-trifluoromethylphenyl)-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine-1-carboxamide	41	
26	N-(3,4-difluorophenyl)-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine-1-carboxamide	70	
27	N-(2,4-dimethoxyphenyl)-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]piperazine-1-carboxamide	67	
28	N-(3,4-difluorophenyl)-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]piperazine-1-carboxamide	64	
29	N-(3,5-dimethoxyphenyl)-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine-1-carboxamide	51	
47	1-phenylsulfonyl-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	129	
50	1-[4-methylphenylsulfonyl]-4-[3-(4-methylbenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	105	
54	1-[4-tert-butylphenylsulfonyl]-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	60	
56	1-[3-trifluoromethylphenylsulfonyl]-4-[3-(4-	87	

No.	Name	% Inhib.	EC50 (μM)
	methylbenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine		
59	1-[4-fluorophenylsulfonyl]-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	42	
61	1-[4-ter-butylphenylsulfonyl]-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]piperazine	47	
62	1-[3-trifluoromethylphenylsulfonyl]-4-[3-(4-methylbenzyl)-1,2,4-thiadiazol-5-yl]piperazine	45	
64	1-[4-bromophenylsulfonyl]-4-[3-(4-methylbenzyl)-1,2,4-thiadiazol-5-yl]piperazine	58	
66	1-[4-chlorophenylsulfonyl]-4-[3-(4-methylbenzyl)-1,2,4-thiadiazol-5-yl]piperazine	81	
67	1-[4-tert-butylphenylsulfonyl]-4-[3-(4-methylbenzyl)-1,2,4-thiadiazol-5-yl]piperazine	41	
69	1-[4-tert-butylphenylsulfonyl]-4-[3-(4-chlorobenzyl)-1,2,4-thiadiazol-5-yl]piperazine	31	
70	1-[quinoline-8-sulfonyl]-4-[3-(4-methylbenzyl)-1,2,4-thiadiazol-5-yl]piperazine	44	
71	1-[4-nitrophenylsulfonyl]-4-[3-(4-methylbenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	33	
73	1-[4-nitrophenylsulfonyl]-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	33	
76	1-(benzylsulfonyl)-4-[3-(4-chlorobenzyl)-1,2,4-thiadiazol-5-yl]piperazine	40	
88	1-[(2E)-3-phenylprop-2-enoyl]-4-[3-(4-chlorobenzyl)-1,2,4-thiadiazol-5-yl]piperazine	72	
105	3-fluoro-N-{2-[4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]piperazin-1-yl]ethyl}benzamide	115	
106	3-fluoro-N-{2-[4-[3-benzyl-1,2,4-thiadiazol-5-yl]piperazin-1-yl]ethyl}benzamide	49	
110	N-benzyl-N'-(2-[4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]piperazin-1-yl]ethyl)urea	77	
114	1-(1,3-benzodioxol-5-ylmethyl)-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]piperazine	86	
165	1-(4-ethylbenzoyl)-4-[3-(4-chlorobenzyl)-1,2,4-thiadiazol-5-yl]piperazine	133	
166	1-(2-chlorobenzoyl)-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	123	
167	1-(2-fluorobenzoyl)-4-[3-(4-chlorobenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	117	
168	1-(4-trifluoromethylbenzoyl)-4-[3-(3-methoxybenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	91	
169	1-benzoyl-4-[3-(4-methylbenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	91	
170	1-(4-bromobenzoyl)-4-[3-(3-methoxybenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	89	
171	1-(4-trifluoromethylbenzoyl)-4-[3-(4-methylbenzyl)-1,2,4-thiadiazol-5-yl]piperazine	86	
172	1-(3-nitro-4-methylbenzoyl)-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	86	
173	1-benzoyl-4-[3-(3-methoxybenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	85	
174	1-(4-chlorobenzoyl)-4-[3-(3-methoxybenzyl)-	83	

No.	Name	% Inhib.	EC50 (μM)
	1,2,4-thiadiazol-5-yl]-2-methylpiperazine		
175	1-(2-fluorobenzoyl)-4-[3-(4-methylbenzyl)-1,2,4-thiadiazol-5-yl]piperazine	78	
176	1-(4-hexylbenzoyl)-4-[3-(4-methylbenzyl)-1,2,4-thiadiazol-5-yl]piperazine	77	
177	1-(2-chloro-4-nitrobenzoyl)-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	77	
178	1-(1,3-benzodioxol-5-ylcarbonyl)-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	68	
179	1-(3-fluorobenzoyl)-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	68	
180	1-(4-tert-butylbenzoyl)-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]piperazine	62	
181	1-benzoyl-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]piperazine	60	
182	1-(4-butylbenzoyl)-4-[3-(4-methylbenzyl)-1,2,4-thiadiazol-5-yl]piperazine	57	
183	1-(4-tert-butylbenzoyl)-4-[3-(4-methylbenzyl)-1,2,4-thiadiazol-5-yl]piperazine	52	
184	1-(4-nitrobenzoyl)-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-2-methylpiperazine	52	
188	1-(3-trifluoromethylphenyl)-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]piperazine	96	
191	1-(1,3-benzodioxol-5-ylcarbonyl)-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-1,4-diazepane	63	
193	1-[4-methoxyphenylsulfonyl]-4-[3-(3-fluorobenzyl)-1,2,4-thiadiazol-5-yl]piperazine	68	0.0107
194	1-[4-methoxyphenylsulfonyl]-4-[3-(2-fluorobenzyl)-1,2,4-thiadiazol-5-yl]piperazine	102	0.0027
195	1-[2-methoxyphenylsulfonyl]-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]piperazine	99	0.0567
196	1-[4-ethoxyphenylsulfonyl]-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]piperazine	42	0.0176
197	1-[4-ethylphenylsulfonyl]-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]piperazine	84	0.535
198	1-phenylsulfonyl-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]piperazine	25	0.349
199	1-[4-methoxyphenylsulfonyl]-4-[3-benzyl-1,2,4-thiadiazol-5-yl]piperazine	38	0.0038
200	1-(4-propionyloxy)benzene-sulfonyl-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]piperazine	80	0.103
201	1-[4-methoxyphenylsulfonyl]-4-[3-(3-methylbenzyl)-1,2,4-thiadiazol-5-yl]piperazine	97	0.0047
202	1-[4-methoxyphenylsulfonyl]-4-[3-(2-methylbenzyl)-1,2,4-thiadiazol-5-yl]piperazine	63	0.0168
203	1-[4-methoxyphenylsulfonyl]-4-[3-(2-methoxybenzyl)-1,2,4-thiadiazol-5-yl]piperazine	61	0.0134
204	1-[4-methoxyphenylsulfonyl]-4-[3-(3-methyl-4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]piperazine	90	0.0022
205	1-[4-methoxyphenylsulfonyl]-4-[3-(4-methoxybenzyl)-1,2,4-thiadiazol-5-yl]piperazine	53	0.0024
206	1-[2-thienylsulfonyl]-4-[3-(2-methylbenzyl)-1,2,4-thiadiazol-5-yl]piperazine	106	0.468

No.	Name	% Inhib.	EC50 (μM)
207	1-[4-bromophenylsulfonyl]-4-[3-(3-methoxybenzyl)-1,2,4-thiadiazol-5-yl]piperazine	83	0.055
208	1-[4-methoxyphenylsulfonyl]-4-[3-(3-methoxybenzyl)-1,2,4-thia-diazol-5-yl]-2-methyl-piperazine	92	0.0073
209	<i>N</i> -[4-methoxyphenylsulfonyl]- <i>N'</i> -[3-(3-methoxybenzyl)-1,2,4-thia-diazol-5-yl]-ethane-1,2-diamine	100	0.317
210	<i>N</i> -[4-methoxyphenylsulfonyl]- <i>N'</i> -[3-(3-methoxybenzyl)-1,2,4-thia-diazol-5-yl]-propane-1,2-diamine	107	0.289
211	<i>N</i> -[4-methoxyphenylsulfonyl]- <i>N'</i> -[3-(3-methoxybenzyl)-1,2,4-thia-diazol-5-yl]-propane-1,3-diamine	100	0.367
212	1-[4-methoxyphenylsulfonyl]-4-[3-(3-methoxybenzyl)-1,2,4-thiadiazol-5-yl]diazepane	99	0.109
213	<i>N'</i> -[4-methoxyphenylsulfonyl]- <i>N</i> -[3-(3-methoxybenzyl)-1,2,4-thia-diazol-5-yl]- <i>N</i> -methylethane-1,2-diamine	94	0.361
214	<i>N'</i> -[4-methoxyphenylsulfonyl]- <i>N</i> -[3-(3-methoxybenzyl)-1,2,4-thia-diazol-5-yl]- <i>N'</i> -methylethane-1,2-diamine	95	0.498
215	<i>N'</i> -[4-methoxyphenylsulfonyl]- <i>N</i> -[3-(3-methoxybenzyl)-1,2,4-thia-diazol-5-yl]- <i>N,N'</i> -dimethylethane-1,2-diamine	105	0.301
217	1-(4-hydroxybenzenesulfonyl)-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]piperazine	77	0.077
44	1-[3-methoxyphenylsulfonyl]-4-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]piperazine	99	0.128
53	1-[4-methoxyphenylsulfonyl]-4-[3-(3-methoxybenzyl)-1,2,4-thiadiazol-5-yl]piperazine	83	0.0014

(end of Table 2)

Examples 217 to 294 - N-arylsulfonylation of 1,2,4-thiadiazole intermediates represented by the structural formula (VI) into 1,2,4-thiadiazole compounds represented by the structural formula (C)

By analogy with example 207 (especially compound **209**), the following compounds are also synthesised from 4-methoxyphenylsulfonyl chloride and the relevant intermediates from examples 81 to 91:

- 10        - *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(4-methylbenzyl)-1,2,4-thiadiazol-5-yl]-ethane-1,2-diamine,
- *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-ethane-1,2-diamine,
- *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(3-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-ethane-1,2-diamine,
- 15        - *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(3-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-ethane-1,2-diamine,

- *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(2-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-ethane-1,2-diamine,
- *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(3-benzyl)-1,2,4-thiadiazol-5-yl]-ethane-1,2-diamine,
- 5     - *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(3-methylbenzyl)-1,2,4-thiadiazol-5-yl]-ethane-1,2-diamine,
- *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(2-methylbenzyl)-1,2,4-thiadiazol-5-yl]-ethane-1,2-diamine,
- *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(2-methoxybenzyl)-1,2,4-thiadiazol-5-yl]-ethane-1,2-diamine,
- 10     - *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(4-methoxybenzyl)-1,2,4-thiadiazol-5-yl]-ethane-1,2-diamine,
- *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(3-methyl-4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-ethane-1,2-diamine, and
- 15     - *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(4-chlorobenzyl)-1,2,4-thiadiazol-5-yl]-ethane-1,2-diamine.

By analogy with example 207 (especially compound **211**), the following compounds are also synthesised from 4-methoxyphenylsulfonyl chloride and the relevant intermediates from examples 92 to 102:

- 20     - *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(4-methylbenzyl)-1,2,4-thiadiazol-5-yl]-propane-1,3-diamine,
- *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-propane-1,3-diamine,
- *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(3-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-propane-1,3-diamine,
- 25     - *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(2-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-propane-1,3-diamine,
- *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(3-benzyl)-1,2,4-thiadiazol-5-yl]-propane-1,3-diamine,
- 30     - *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(3-methylbenzyl)-1,2,4-thiadiazol-5-yl]-propane-1,3-diamine,
- *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(2-methylbenzyl)-1,2,4-thiadiazol-5-yl]-propane-1,3-diamine,
- *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(2-methoxybenzyl)-1,2,4-thiadiazol-5-yl]-propane-1,3-diamine,
- 35     - *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(4-methoxybenzyl)-1,2,4-thiadiazol-5-yl]-propane-1,3-diamine,

- *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(3-methyl-4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-propane-1,3-diamine, and
- *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(4-chlorobenzyl)-1,2,4-thiadiazol-5-yl]-propane-1,3-diamine.

5 By analogy with example 207 (especially compound **210**), the following compounds are also synthesised from 4-methoxyphenylsulfonyl chloride and the relevant intermediates from examples 125 to 135:

- *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(4-methylbenzyl)-1,2,4-thiadiazol-5-yl]-propane-1,2-diamine,
- 10 - *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-propane-1,2-diamine,
- *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(3-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-propane-1,2-diamine,
- *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(2-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-propane-1,2-diamine,
- 15 - *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(3-benzyl)-1,2,4-thiadiazol-5-yl]-propane-1,2-diamine,
- *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(3-methylbenzyl)-1,2,4-thiadiazol-5-yl]-propane-1,2-diamine,
- 20 - *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(2-methylbenzyl)-1,2,4-thiadiazol-5-yl]-propane-1,2-diamine,
- *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(2-methoxybenzyl)-1,2,4-thiadiazol-5-yl]-propane-1,2-diamine,
- *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(4-methoxybenzyl)-1,2,4-thiadiazol-5-yl]-propane-1,2-diamine,
- 25 - *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(3-methyl-4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-propane-1,2-diamine, and
- *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(4-chlorobenzyl)-1,2,4-thiadiazol-5-yl]-propane-1,2-diamine.

30 By analogy with example 207 (especially compound **213**), the following compounds are also synthesised from 4-methoxyphenylsulfonyl chloride and the relevant intermediates from examples 103 to 113:

- *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(4-methylbenzyl)-1,2,4-thiadiazol-5-yl]-*N*-methyl-ethane-1,2-diamine,
- 35 - *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-*N*-methyl-ethane-1,2-diamine,



- *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(3-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-*N*-methyl-ethane-1,2-diamine,
- *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(2-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-*N*-methyl-ethane-1,2-diamine,
- 5     - *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(3-benzyl)-1,2,4-thiadiazol-5-yl]-*N*-methyl-ethane-1,2-diamine,
- *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(3-methylbenzyl)-1,2,4-thiadiazol-5-yl]-*N*-methyl-ethane-1,2-diamine,
- *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(2-methylbenzyl)-1,2,4-thiadiazol-5-yl]-*N*-methyl-ethane-1,2-diamine,
- 10     - *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(2-methoxybenzyl)-1,2,4-thiadiazol-5-yl]-*N*-methyl-ethane-1,2-diamine,
- *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(4-methoxybenzyl)-1,2,4-thiadiazol-5-yl]-*N*-methyl-ethane-1,2-diamine,
- 15     - *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(3-methyl-4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-*N*-methyl-ethane-1,2-diamine, and
- *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(4-chlorobenzyl)-1,2,4-thiadiazol-5-yl]-*N*-methyl-ethane-1,2-diamine.

By analogy with example 207 (especially compound **214**), the following  
20 compounds are also synthesised from 4-methoxyphenylsulfonyl chloride and the relevant intermediates from examples 114 to 124:

- *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(4-methylbenzyl)-1,2,4-thiadiazol-5-yl]-*N'*-methyl-ethane-1,2-diamine,
- *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-*N'*-methyl-ethane-1,2-diamine,
- 25     - *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(3-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-*N'*-methyl-ethane-1,2-diamine,
- *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(2-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-*N'*-methyl-ethane-1,2-diamine,
- 30     - *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(3-benzyl)-1,2,4-thiadiazol-5-yl]-*N'*-methyl-ethane-1,2-diamine,
- *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(3-methylbenzyl)-1,2,4-thiadiazol-5-yl]-*N'*-methyl-ethane-1,2-diamine,
- *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(2-methylbenzyl)-1,2,4-thiadiazol-5-yl]-*N'*-methyl-ethane-1,2-diamine,
- 35     - *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(2-methoxybenzyl)-1,2,4-thiadiazol-5-yl]-*N'*-methyl-ethane-1,2-diamine,

- *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(4-methoxybenzyl)-1,2,4-thiadiazol-5-yl]-*N'*-methyl-ethane-1,2-diamine,
- *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(3-methyl-4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-*N'*-methyl-ethane-1,2-diamine, and
- 5     - *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(4-chlorobenzyl)-1,2,4-thiadiazol-5-yl]-*N'*-methyl-ethane-1,2-diamine.

By analogy with example 207 (especially compound **215**), the following compounds are also synthesised from 4-methoxyphenylsulfonyl chloride and the relevant intermediates from examples 136 to 146:

- 10     - *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(4-methylbenzyl)-1,2,4-thiadiazol-5-yl]-*N*,  
*N'*-dimethyl-ethane-1,2-diamine,
- *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-*N*,  
*N'*-dimethyl-ethane-1,2-diamine,
- *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(3-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-*N*,  
15     *N'*-dimethyl-ethane-1,2-diamine,
- *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(2-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-*N*,  
*N'*-dimethyl-ethane-1,2-diamine,
- *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(3-benzyl)-1,2,4-thiadiazol-5-yl]-*N,N'*-  
dimethyl-ethane-1,2-diamine,
- 20     - *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(3-methylbenzyl)-1,2,4-thiadiazol-5-yl]-*N*,  
*N'*-dimethyl-ethane-1,2-diamine,
- *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(2-methylbenzyl)-1,2,4-thiadiazol-5-yl]-*N*,  
*N'*-dimethyl-ethane-1,2-diamine,
- *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(2-methoxybenzyl)-1,2,4-thiadiazol-5-yl]-  
25     *N,N'*-dimethyl-ethane-1,2-diamine,
- *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(4-methoxybenzyl)-1,2,4-thiadiazol-5-yl]-  
*N,N'*-dimethyl-ethane-1,2-diamine,
- *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(3-methyl-4-fluorobenzyl)-1,2,4-thia-  
diazol-5-yl]-*N,N'*-dimethyl-ethane-1,2-diamine, and
- 30     - *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(4-chlorobenzyl)-1,2,4-thiadiazol-5-yl]-*N*,  
*N'*-dimethyl-ethane-1,2-diamine.

By analogy with example 207, the following compounds are also synthesised from 4-methoxyphenylsulfonyl chloride and the relevant intermediates from examples 147 to 158:

- 35     - *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(4-methylbenzyl)-1,2,4-thiadiazol-5-yl]-*N*,  
*N'*-diethyl-ethane-1,2-diamine,

- *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-*N*,  
*N'*-diethyl-ethane-1,2-diamine,
- *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(3-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-*N*,  
*N'*-diethyl-ethane-1,2-diamine,
- 5 - *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(2-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-*N*,  
*N'*-diethyl-ethane-1,2-diamine,
- *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(3-benzyl)-1,2,4-thiadiazol-5-yl]-*N*,*N'*-  
diethyl-ethane-1,2-diamine,
- *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(3-methylbenzyl)-1,2,4-thiadiazol-5-yl]-*N*,  
10 *N'*-diethyl-ethane-1,2-diamine,
- *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(2-methylbenzyl)-1,2,4-thiadiazol-5-yl]- *N*,  
*N'*-diethyl-ethane-1,2-diamine,
- *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(2-methoxybenzyl)-1,2,4-thiadiazol-5-yl]-  
*N*,*N'*-diethyl-ethane-1,2-diamine,
- 15 - *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(4-methoxybenzyl)-1,2,4-thiadiazol-5-yl]-  
*N*,*N'*-diethyl-ethane-1,2-diamine,
- *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(3-methyl-4-fluorobenzyl)-1,2,4-thia-  
diazol-5-yl]-*N*,*N'*-diethyl-ethane-1,2-diamine, and
- *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(4-chlorobenzyl)-1,2,4-thiadiazol-5-yl]-  
20 *N*,*N'*-diethyl-ethane-1,2-diamine.

It should be understood that in the foregoing examples 217 to 294, 4-methoxyphenylsulfonyl chloride was only used to illustrate the feasibility of arylsulfonylation of 1,2,4-thiadiazole intermediates represented by the structural formula (VI). Similar compounds can also be synthesised from any arylsulfonyl chloride  
25 represented by the structural formula (VB) according to the list provided herein-before in the detailed description of the invention.

Examples 295 to 378 - N-heteroarylsulfonylation of 1,2,4-thiadiazole intermediates represented by the structural formula (VI) into 1,2,4-thiadiazole compounds represented by the structural formula (F)  
30

By analogy with example 207 (especially compound 206), the following compounds are also synthesised from 2-thienylsulfonyl chloride and the relevant intermediates from examples 75 to 158:

- *N*-[2-thienylsulfonyl]-*N'*-[3-(3-methoxybenzyl)-1,2,4-thiadiazol-5-yl]-  
35 ethane-1,2-diamine,
- *N*-[2-thienylsulfonyl]-*N'*-[3-(3-methoxybenzyl)-1,2,4-thiadiazol-5-yl]-  
propane-1,2-diamine,

- *N*-[2-thienylsulfonyl]-*N'*-[3-(3-methoxybenzyl)-1,2,4-thiadiazol-5-yl]-propane-1,3-diamine,
- *N'*-[2-thienylsulfonyl]-*N*-[3-(3-methoxybenzyl)-1,2,4-thiadiazol-5-yl]-*N*-methylethane-1,2-diamine,
- 5       - *N'*-[2-thienylsulfonyl]-*N*-[3-(3-methoxybenzyl)-1,2,4-thiadiazol-5-yl]-*N'*-methylethane-1,2-diamine,
- - *N'*-[2-thienylsulfonyl]-*N*-[3-(3-methoxybenzyl)-1,2,4-thiadiazol-5-yl]-*N,N'*-dimethylethane-1,2-diamine,
- *N*-[2-thienylsulfonyl]-*N'*-[3-(4-methylbenzyl)-1,2,4-thiadiazol-5-yl]-ethane-1,2-
- 10       diamine,
- *N*-[2-thienylsulfonyl]-*N'*-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-ethane-1,2-
- diamine,
- *N*-[2-thienylsulfonyl]-*N'*-[3-(3-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-ethane-1,2-
- diamine,
- 15       - *N*-[2-thienylsulfonyl]-*N'*-[3-(2-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-ethane-1,2-
- diamine,
- *N*-[2-thienylsulfonyl]-*N'*-[3-(3-benzyl)-1,2,4-thiadiazol-5-yl]-ethane-1,2-
- diamine,
- *N*-[2-thienylsulfonyl]-*N'*-[3-(3-methylbenzyl)-1,2,4-thiadiazol-5-yl]-ethane-1,2-
- 20       diamine,
- *N*-[2-thienylsulfonyl]-*N'*-[3-(2-methylbenzyl)-1,2,4-thiadiazol-5-yl]-ethane-1,2-
- diamine,
- *N*-[2-thienylsulfonyl]-*N'*-[3-(2-methoxybenzyl)-1,2,4-thiadiazol-5-yl]-ethane-
- 1,2-diamine,
- 25       - *N*-[2-thienylsulfonyl]-*N'*-[3-(4-methoxybenzyl)-1,2,4-thiadiazol-5-yl]-ethane-
- 1,2-diamine,
- *N*-[2-thienylsulfonyl]-*N'*-[3-(3-methyl-4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-
- ethane-1,2-diamine,
- *N*-[2-thienylsulfonyl]-*N'*-[3-(4-chlorobenzyl)-1,2,4-thiadiazol-5-yl]-ethane-1,2-
- 30       diamine,
- *N*-[2-thienylsulfonyl]-*N'*-[3-(4-methylbenzyl)-1,2,4-thiadiazol-5-yl]-propane-
- 1,3-diamine,
- *N*-[2-thienylsulfonyl]-*N'*-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-propane-
- 1,3-diamine,
- 35       - *N*-[2-thienylsulfonyl]-*N'*-[3-(3-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-propane-
- 1,3-diamine,

- *N*-[2-thienylsulfonyl]-*N'*-[3-(2-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-propane-1,3-diamine,
- *N*-[2-thienylsulfonyl]-*N'*-[3-(3-benzyl)-1,2,4-thiadiazol-5-yl]-propane-1,3-diamine,
- 5     - *N*-[2-thienylsulfonyl]-*N'*-[3-(3-methylbenzyl)-1,2,4-thiadiazol-5-yl]-propane-1,3-diamine,
- *N*-[2-thienylsulfonyl]-*N'*-[3-(2-methylbenzyl)-1,2,4-thiadiazol-5-yl]-propane-1,3-diamine,
- *N*-[2-thienylsulfonyl]-*N'*-[3-(2-methoxybenzyl)-1,2,4-thiadiazol-5-yl]-propane-1,3-diamine,
- 10     - *N*-[2-thienylsulfonyl]-*N'*-[3-(4-methoxybenzyl)-1,2,4-thiadiazol-5-yl]-propane-1,3-diamine,
- *N*-[2-thienylsulfonyl]-*N'*-[3-(3-methyl-4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-propane-1,3-diamine,
- 15     - *N*-[2-thienylsulfonyl]-*N'*-[3-(4-chlorobenzyl)-1,2,4-thiadiazol-5-yl]-propane-1,3-diamine,
- *N*-[2-thienylsulfonyl]-*N'*-[3-(4-methylbenzyl)-1,2,4-thiadiazol-5-yl]-propane-1,2-diamine,
- *N*-[2-thienylsulfonyl]-*N'*-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-propane-1,2-diamine,
- 20     - *N*-[2-thienylsulfonyl]-*N'*-[3-(3-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-propane-1,2-diamine,
- *N*-[2-thienylsulfonyl]-*N'*-[3-(2-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-propane-1,2-diamine,
- 25     - *N*-[2-thienylsulfonyl]-*N'*-[3-(3-benzyl)-1,2,4-thiadiazol-5-yl]-propane-1,2-diamine,
- *N*-[2-thienylsulfonyl]-*N'*-[3-(3-methylbenzyl)-1,2,4-thiadiazol-5-yl]-propane-1,2-diamine,
- *N*-[2-thienylsulfonyl]-*N'*-[3-(2-methylbenzyl)-1,2,4-thiadiazol-5-yl]-propane-1,2-diamine,
- 30     - *N*-[2-thienylsulfonyl]-*N'*-[3-(2-methoxybenzyl)-1,2,4-thiadiazol-5-yl]-propane-1,2-diamine,
- *N*-[2-thienylsulfonyl]-*N'*-[3-(4-methoxybenzyl)-1,2,4-thiadiazol-5-yl]-propane-1,2-diamine,
- 35     - *N*-[2-thienylsulfonyl]-*N'*-[3-(3-methyl-4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-propane-1,2-diamine,

- *N*-[2-thienylsulfonyl]-*N'*-[3-(4-chlorobenzyl)-1,2,4-thiadiazol-5-yl]-propane-1,2-diamine,
- *N*-[2-thienylsulfonyl]-*N'*-[3-(4-methylbenzyl)-1,2,4-thiadiazol-5-yl]-*N*-methyl-ethane-1,2-diamine,
- 5     - *N*-[2-thienylsulfonyl]-*N'*-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-*N*-methyl-ethane-1,2-diamine,
- *N*-[2-thienylsulfonyl]-*N'*-[3-(3-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-*N*-methyl-ethane-1,2-diamine,
- *N*-[2-thienylsulfonyl]-*N'*-[3-(2-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-*N*-methyl-ethane-1,2-diamine,
- 10     - *N*-[2-thienylsulfonyl]-*N'*-[3-(3-benzyl)-1,2,4-thiadiazol-5-yl]-*N*-methyl-ethane-1,2-diamine,
- *N*-[2-thienylsulfonyl]-*N'*-[3-(3-methylbenzyl)-1,2,4-thiadiazol-5-yl]-*N*-methyl-ethane-1,2-diamine,
- 15     - *N*-[2-thienylsulfonyl]-*N'*-[3-(2-methylbenzyl)-1,2,4-thiadiazol-5-yl]-*N*-methyl-ethane-1,2-diamine,
- *N*-[2-thienylsulfonyl]-*N'*-[3-(2-methoxybenzyl)-1,2,4-thiadiazol-5-yl]-*N*-methyl-ethane-1,2-diamine,
- *N*-[2-thienylsulfonyl]-*N'*-[3-(4-methoxybenzyl)-1,2,4-thiadiazol-5-yl]-*N*-methyl-ethane-1,2-diamine,
- 20     - *N*-[2-thienylsulfonyl]-*N'*-[3-(3-methyl-4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-*N*-methyl-ethane-1,2-diamine,
- *N*-[2-thienylsulfonyl]-*N'*-[3-(4-chlorobenzyl)-1,2,4-thiadiazol-5-yl]-*N*-methyl-ethane-1,2-diamine,
- 25     - *N*-[2-thienylsulfonyl]-*N'*-[3-(4-methylbenzyl)-1,2,4-thiadiazol-5-yl]-*N,N'*-dimethyl-ethane-1,2-diamine,
- *N*-[2-thienylsulfonyl]-*N'*-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-*N,N'*-dimethyl-ethane-1,2-diamine,
- *N*-[2-thienylsulfonyl]-*N'*-[3-(3-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-*N,N'*-dimethyl-ethane-1,2-diamine,
- 30     - *N*-[2-thienylsulfonyl]-*N'*-[3-(2-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-*N,N'*-dimethyl-ethane-1,2-diamine,
- *N*-[2-thienylsulfonyl]-*N'*-[3-(3-benzyl)-1,2,4-thiadiazol-5-yl]-*N,N'*-dimethyl-ethane-1,2-diamine,
- 35     - *N*-[2-thienylsulfonyl]-*N'*-[3-(3-methylbenzyl)-1,2,4-thiadiazol-5-yl]-*N,N'*-dimethyl-ethane-1,2-diamine,

- *N*-[2-thienylsulfonyl]-*N'*-[3-(2-methylbenzyl)-1,2,4-thiadiazol-5-yl]-*N,N'*-dimethyl-ethane-1,2-diamine,
- *N*-[2-thienylsulfonyl]-*N'*-[3-(2-methoxybenzyl)-1,2,4-thiadiazol-5-yl]-*N,N'*-dimethyl-ethane-1,2-diamine,
- 5 - *N*-[2-thienylsulfonyl]-*N'*-[3-(4-methoxybenzyl)-1,2,4-thiadiazol-5-yl]-*N,N'*-dimethyl-ethane-1,2-diamine,
- *N*-[2-thienylsulfonyl]-*N'*-[3-(3-methyl-4-fluorobenzyl)-1,2,4-thia-diazol-5-yl]-*N,N'*-dimethyl-ethane-1,2-diamine,
- *N*-[2-thienylsulfonyl]-*N'*-[3-(4-chlorobenzyl)-1,2,4-thiadiazol-5-yl]-*N,N'*-dimethyl-ethane-1,2-diamine,
- 10 - *N*-[2-thienylsulfonyl]-*N'*-[3-(4-methylbenzyl)-1,2,4-thiadiazol-5-yl]-*N,N'*-diethyl-ethane-1,2-diamine,
- *N*-[2-thienylsulfonyl]-*N'*-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-*N,N'*-diethyl-ethane-1,2-diamine,
- 15 - *N*-[2-thienylsulfonyl]-*N'*-[3-(3-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-*N,N'*-diethyl-ethane-1,2-diamine,
- *N*-[2-thienylsulfonyl]-*N'*-[3-(2-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-*N,N'*-diethyl-ethane-1,2-diamine,
- *N*-[2-thienylsulfonyl]-*N'*-[3-(3-benzyl)-1,2,4-thiadiazol-5-yl]-*N,N'*-diethyl-ethane-1,2-diamine,
- 20 - *N*-[2-thienylsulfonyl]-*N'*-[3-(3-methylbenzyl)-1,2,4-thiadiazol-5-yl]-*N,N'*-diethyl-ethane-1,2-diamine,
- *N*-[2-thienylsulfonyl]-*N'*-[3-(2-methylbenzyl)-1,2,4-thiadiazol-5-yl]-*N,N'*-diethyl-ethane-1,2-diamine,
- 25 - *N*-[2-thienylsulfonyl]-*N'*-[3-(2-methoxybenzyl)-1,2,4-thiadiazol-5-yl]-*N,N'*-diethyl-ethane-1,2-diamine,
- *N*-[2-thienylsulfonyl]-*N'*-[3-(4-methoxybenzyl)-1,2,4-thiadiazol-5-yl]-*N,N'*-diethyl-ethane-1,2-diamine,
- *N*-[2-thienylsulfonyl]-*N'*-[3-(3-methyl-4-fluorobenzyl)-1,2,4-thia-diazol-5-yl]-*N,N'*-diethyl-ethane-1,2-diamine, and
- 30 - *N*-[2-thienylsulfonyl]-*N'*-[3-(4-chlorobenzyl)-1,2,4-thiadiazol-5-yl]-*N,N'*-diethyl-ethane-1,2-diamine.

It should be understood that in the foregoing examples 295 to 378, 2-thienylsulfonyl chloride was only used to illustrate the feasibility of  
35 heteroarylsulfonylation of 1,2,4-thiadiazole intermediates represented by the structural formula (VI). Similar compounds can also be synthesised from any other heteroarylsulfonyl chloride.

Examples 379 to 438 - nucleophilic replacement with diaminoalkanes onto 5-chloro-3-(substituted benzyl)-1,2,4-thiadiazole derivatives

The following intermediate compounds are synthesised from 2,3-diamino butane and the relevant 3-(substituted benzyl)-5-chloro-1,2,4-thiadiazole derivative from examples 2 to 13, while using the experimental conditions of examples 75 to 80:

- $N^2$ -[3-(4-methyl-benzyl)-[1,2,4]thiadiazol-5-yl]-2,3-diamino butane (example 379),
- $N^2$ -[3-(4-fluoro-benzyl)-[1,2,4]thiadiazol-5-yl]-2,3-diamino butane (example 380),
- $N^2$ -[3-(3-methoxy-benzyl)-[1,2,4]thiadiazol-5-yl]-2,3-diamino butane (example 381),
- $N^2$ -[3-(3-fluoro-benzyl)-[1,2,4]thiadiazol-5-yl]-2,3-diamino butane (example 382),
- $N^2$ -[3-(2-fluoro-benzyl)-[1,2,4]thiadiazol-5-yl]-2,3-diamino butane (example 383),
- $N^2$ -[3-(3-benzyl)-[1,2,4]thiadiazol-5-yl]-2,3-diamino butane (example 384),
- $N^2$ -[3-(3-methyl-benzyl)-[1,2,4]thiadiazol-5-yl]-2,3-diamino butane (example 385),
- $N^2$ -[3-(2-methyl-benzyl)-[1,2,4]thiadiazol-5-yl]-2,3-diamino butane (example 386),
- $N^2$ -[3-(2-methoxy-benzyl)-[1,2,4]thiadiazol-5-yl]-2,3-diamino butane (example 387),
- $N^2$ -[3-(4-methoxy-benzyl)-[1,2,4]thiadiazol-5-yl]-2,3-diamino butane (example 388),
- $N^2$ -[3-(3-methyl-4-fluoro-benzyl)-[1,2,4]thiadiazol-5-yl]-2,3-diamino butane (example 389), and
- $N^2$ -[3-(4-chloro-benzyl)-[1,2,4]thiadiazol-5-yl]-2,3-diamino butane (example 390).

The following intermediate compounds are synthesised from 1,3-diamino butane and the relevant 3-(substituted benzyl)-5-chloro-1,2,4-thiadiazole derivative from examples 2 to 13, while using the experimental conditions of examples 75 to 80:

- $N$ -[3-(4-methyl-benzyl)-[1,2,4]thiadiazol-5-yl]-1,3-diamino butane (example 391),
- $N$ -[3-(4-fluoro-benzyl)-[1,2,4]thiadiazol-5-yl]-1,3-diamino butane (example 392),



- *N*-[3-(3-methoxy-benzyl)-[1,2,4]thiadiazol-5-yl]-1,3-diamino butane (example 393),
- *N*-[3-(3-fluoro-benzyl)-[1,2,4]thiadiazol-5-yl]-1,3-diamino butane (example 394),
- 5     - *N*-[3-(2-fluoro-benzyl)-[1,2,4]thiadiazol-5-yl]-1,3-diamino butane (example 395),
- *N*-[3-(3-benzyl)-[1,2,4]thiadiazol-5-yl]-1,3-diamino butane (example 396),
- *N*-[3-(3-methyl-benzyl)-[1,2,4]thiadiazol-5-yl]-1,3-diamino butane (example 397),
- 10     - *N*-[3-(2-methyl-benzyl)-[1,2,4]thiadiazol-5-yl]-1,3-diamino butane (example 398),
- *N*-[3-(2-methoxy-benzyl)-[1,2,4]thiadiazol-5-yl]-1,3-diamino butane (example 399),
- *N*-[3-(4-methoxy-benzyl)-[1,2,4]thiadiazol-5-yl]-1,3-diamino butane (example 400),
- 15     - *N*-[3-(3-methyl-4-fluoro-benzyl)-[1,2,4]thiadiazol-5-yl]-1,3-diamino butane (example 401), and
- *N*-[3-(4-chloro-benzyl)-[1,2,4]thiadiazol-5-yl]-1,3-diamino butane (example 402).
- 20     The following intermediate compounds are synthesised from 1,2-diamino butane and the relevant 3-(substituted benzyl)-5-chloro-1,2,4-thiadiazole derivative from examples 2 to 13, while using the experimental conditions of examples 75 to 80:
- *N*-[3-(4-methyl-benzyl)-[1,2,4]thiadiazol-5-yl]-1,2-diamino butane (example 403),
- 25     - *N*-[3-(4-fluoro-benzyl)-[1,2,4]thiadiazol-5-yl]-1,2-diamino butane (example 404),
- *N*-[3-(3-methoxy-benzyl)-[1,2,4]thiadiazol-5-yl]-1,2-diamino butane (example 405),
- *N*-[3-(3-fluoro-benzyl)-[1,2,4]thiadiazol-5-yl]-1,2-diamino butane (example 406),
- 30     - *N*-[3-(2-fluoro-benzyl)-[1,2,4]thiadiazol-5-yl]-1,2-diamino butane (example 407),
- *N*-[3-(3-benzyl)-[1,2,4]thiadiazol-5-yl]-1,2-diamino butane (example 408),
- *N*-[3-(3-methyl-benzyl)-[1,2,4]thiadiazol-5-yl]-1,2-diamino butane (example 409),
- 35     - *N*-[3-(2-methyl-benzyl)-[1,2,4]thiadiazol-5-yl]-1,2-diamino butane (example 410),

- *N*-[3-(2-methoxy-benzyl)-[1,2,4]thiadiazol-5-yl]-1,2-diamino butane (example 411),
- *N*-[3-(4-methoxy-benzyl)-[1,2,4]thiadiazol-5-yl]-1,2-diamino butane (example 412),
- 5     - *N*-[3-(3-methyl-4-fluoro-benzyl)-[1,2,4]thiadiazol-5-yl]-1,2-diamino butane (example 413), and
- *N*-[3-(4-chloro-benzyl)-[1,2,4]thiadiazol-5-yl]-1,2-diamino butane (example 414).

10     The following intermediate compounds are synthesised from 1,2-diamino pentane and the relevant 3-(substituted benzyl)-5-chloro-1,2,4-thiadiazole derivative from examples 2 to 13, while using the experimental conditions of examples 75 to 80:

- *N*-[3-(4-methyl-benzyl)-[1,2,4]thiadiazol-5-yl]-1,2-diamino pentane (example 415),
- *N*-[3-(4-fluoro-benzyl)-[1,2,4]thiadiazol-5-yl]-1,2-diamino pentane (example 416),
- 15     - *N*-[3-(3-methoxy-benzyl)-[1,2,4]thiadiazol-5-yl]-1,2-diamino pentane (example 417),
- *N*-[3-(3-fluoro-benzyl)-[1,2,4]thiadiazol-5-yl]-1,2-diamino pentane (example 418),
- 20     - *N*-[3-(2-fluoro-benzyl)-[1,2,4]thiadiazol-5-yl]-1,2-diamino pentane (example 419),
- *N*-[3-(3-benzyl)-[1,2,4]thiadiazol-5-yl]-1,2-diamino pentane (example 420),
- *N*-[3-(3-methyl-benzyl)-[1,2,4]thiadiazol-5-yl]-1,2-diamino pentane (example 421),
- 25     - *N*-[3-(2-methyl-benzyl)-[1,2,4]thiadiazol-5-yl]-1,2-diamino pentane (example 422),
- *N*-[3-(2-methoxy-benzyl)-[1,2,4]thiadiazol-5-yl]-1,2-diamino pentane (example 423),
- *N*-[3-(4-methoxy-benzyl)-[1,2,4]thiadiazol-5-yl]-1,2-diamino pentane (example 424),
- 30     - *N*-[3-(3-methyl-4-fluoro-benzyl)-[1,2,4]thiadiazol-5-yl]-1,2-diamino pentane (example 425), and
- *N*-[3-(4-chloro-benzyl)-[1,2,4]thiadiazol-5-yl]-1,2-diamino pentane (example 426).

35     The following intermediate compounds are synthesised from 1,3-diamino pentane and the relevant 3-(substituted benzyl)-5-chloro-1,2,4-thiadiazole derivative from examples 2 to 13, while using the experimental conditions of examples 75 to 80:

- *N*-[3-(4-methyl-benzyl)-[1,2,4]thiadiazol-5-yl]-1,3-diamino pentane (example 427),
- *N*-[3-(4-fluoro-benzyl)-[1,2,4]thiadiazol-5-yl]-1,3-diamino pentane (example 428),
- 5     - *N*-[3-(3-methoxy-benzyl)-[1,2,4]thiadiazol-5-yl]-1,3-diamino pentane (example 429),
- *N*-[3-(3-fluoro-benzyl)-[1,2,4]thiadiazol-5-yl]-1,3-diamino pentane (example 430),
- *N*-[3-(2-fluoro-benzyl)-[1,2,4]thiadiazol-5-yl]-1,3-diamino pentane (example 431),
- 10     - *N*-[3-(3-benzyl)-[1,2,4]thiadiazol-5-yl]-1,3-diamino pentane (example 432),
- *N*-[3-(3-methyl-benzyl)-[1,2,4]thiadiazol-5-yl]-1,3-diamino pentane (example 433),
- *N*-[3-(2-methyl-benzyl)-[1,2,4]thiadiazol-5-yl]-1,3-diamino pentane (example 434),
- 15     - *N*-[3-(2-methoxy-benzyl)-[1,2,4]thiadiazol-5-yl]-1,3-diamino pentane (example 435),
- *N*-[3-(4-methoxy-benzyl)-[1,2,4]thiadiazol-5-yl]-1,3-diamino pentane (example 436),
- 20     - *N*-[3-(3-methyl-4-fluoro-benzyl)-[1,2,4]thiadiazol-5-yl]-1,3-diamino pentane (example 437), and
- *N*-[3-(4-chloro-benzyl)-[1,2,4]thiadiazol-5-yl]-1,3-diamino pentane (example 438).

Examples 439 to 498 – N-sulfonylation of 1,2,4-thiadiazole intermediate compounds

25     379 to 438

By analogy with example 207, the following compounds are synthesised from 4-methoxyphenyl-sulfonyl chloride and the relevant intermediate compounds 379 to 438:

- *N*<sup>3</sup>-(4-methoxy-phenyl sulfonyl)-*N*<sup>2</sup>-[3-(4-methyl-benzyl)-[1,2,4]thiadiazol-5-yl]-2,3-diamino butane (example 439),
- 30     - *N*<sup>3</sup>-(4-methoxy-phenyl sulfonyl)-*N*<sup>2</sup>-[3-(4-fluoro-benzyl)-[1,2,4]thiadiazol-5-yl]-2,3-diamino butane (example 440),
- *N*<sup>3</sup>-(4-methoxy-phenyl sulfonyl)-*N*<sup>2</sup>-[3-(3-methoxy-benzyl)-[1,2,4]thiadiazol-5-yl]-2,3-diamino butane (example 441),
- *N*<sup>3</sup>-(4-methoxy-phenyl sulfonyl)-*N*<sup>2</sup>-[3-(3-fluoro-benzyl)-[1,2,4]thiadiazol-5-yl]-2,3-diamino butane (example 442),
- 35     - *N*<sup>3</sup>-(4-methoxy-phenyl sulfonyl)-*N*<sup>2</sup>-[3-(2-fluoro-benzyl)-[1,2,4]thiadiazol-5-yl]-2,3-diamino butane (example 443),

- $N^3$ -(4-methoxy-phenyl sulfonyl)- $N^2$ -[3-(3-benzyl)-[1,2,4]thiadiazol-5-yl]-2,3-diamino butane (example 444),
- $N^3$ -(4-methoxy-phenyl sulfonyl)- $N^2$ -[3-(3-methyl-benzyl)-[1,2,4]thiadiazol-5-yl]-2,3-diamino butane (example 445),
- 5 -  $N^3$ -(4-methoxy-phenyl sulfonyl)- $N^2$ -[3-(2-methyl-benzyl)-[1,2,4]thiadiazol-5-yl]-2,3-diamino butane (example 446),
- $N^3$ -(4-methoxy-phenyl sulfonyl)- $N^2$ -[3-(2-methoxy-benzyl)-[1,2,4]thiadiazol-5-yl]-2,3-diamino butane (example 447),
- $N^3$ -(4-methoxy-phenyl sulfonyl)- $N^2$ -[3-(4-methoxy-benzyl)-[1,2,4]thiadiazol-5-yl]-2,3-diamino butane (example 448),
- 10 -  $N^3$ -(4-methoxy-phenyl sulfonyl)- $N^2$ -[3-(3-methyl-4-fluoro-benzyl)-[1,2,4]thiadiazol-5-yl]-2,3-diamino butane (example 449), and
- $N^3$ -(4-methoxy-phenyl sulfonyl)- $N^2$ -[3-(4-chloro-benzyl)-[1,2,4]thiadiazol-5-yl]-2,3-diamino butane (example 450).
- 15 -  $N^3$ -(4-methoxy-phenyl sulfonyl)- $N^1$ -[3-(4-methyl-benzyl)-[1,2,4]thiadiazol-5-yl]-1,3-diamino butane (example 451),
- $N^3$ -(4-methoxy-phenyl sulfonyl)- $N^1$ -[3-(4-fluoro-benzyl)-[1,2,4]thiadiazol-5-yl]-1,3-diamino butane (example 452),
- $N^3$ -(4-methoxy-phenyl sulfonyl)- $N^1$ -[3-(3-methoxy-benzyl)-[1,2,4]thiadiazol-5-yl]-1,3-diamino butane (example 453),
- 20 -  $N^3$ -(4-methoxy-phenyl sulfonyl)- $N^1$ -[3-(3-fluoro-benzyl)-[1,2,4]thiadiazol-5-yl]-1,3-diamino butane (example 454),
- $N^3$ -(4-methoxy-phenyl sulfonyl)- $N^1$ -[3-(2-fluoro-benzyl)-[1,2,4]thiadiazol-5-yl]-1,3-diamino butane (example 455),
- 25 -  $N^3$ -(4-methoxy-phenyl sulfonyl)- $N^1$ -[3-(3-benzyl)-[1,2,4]thiadiazol-5-yl]-1,3-diamino butane (example 456),
- $N^3$ -(4-methoxy-phenyl sulfonyl)- $N^1$ -[3-(3-methyl-benzyl)-[1,2,4]thiadiazol-5-yl]-1,3-diamino butane (example 457),
- $N^3$ -(4-methoxy-phenyl sulfonyl)- $N^1$ -[3-(2-methyl-benzyl)-[1,2,4]thiadiazol-5-yl]-1,3-diamino butane (example 458),
- 30 -  $N^3$ -(4-methoxy-phenyl sulfonyl)- $N^1$ -[3-(2-methoxy-benzyl)-[1,2,4]thiadiazol-5-yl]-1,3-diamino butane (example 459),
- $N^3$ -(4-methoxy-phenyl sulfonyl)- $N^1$ -[3-(4-methoxy-benzyl)-[1,2,4]thiadiazol-5-yl]-1,3-diamino butane (example 460),
- 35 -  $N^3$ -(4-methoxy-phenyl sulfonyl)- $N^1$ -[3-(3-methyl-4-fluoro-benzyl)-[1,2,4]thiadiazol-5-yl]-1,3-diamino butane (example 461),

- $N^3$ -(4-methoxy-phenyl sulfonyl)- $N^1$ -[3-(4-chloro-benzyl)-[1,2,4]thiadiazol-5-yl]-1,3-diamino butane (example 462),
- $N^2$ -(4-methoxy-phenyl sulfonyl)- $N^1$ -[3-(4-methyl-benzyl)-[1,2,4]thiadiazol-5-yl]-1,2-diamino butane (example 463),
- 5 -  $N^2$ -(4-methoxy-phenyl sulfonyl)- $N^1$ -[3-(4-fluoro-benzyl)-[1,2,4]thiadiazol-5-yl]-1,2-diamino butane (example 464),
- $N^2$ -(4-methoxy-phenyl sulfonyl)- $N^1$ -[3-(3-methoxy-benzyl)-[1,2,4]thiadiazol-5-yl]-1,2-diamino butane (example 465),
- $N^2$ -(4-methoxy-phenyl sulfonyl)- $N^1$ -[3-(3-fluoro-benzyl)-[1,2,4]thiadiazol-5-yl]-1,2-diamino butane (example 466),
- 10 -  $N^2$ -(4-methoxy-phenyl sulfonyl)- $N^1$ -[3-(2-fluoro-benzyl)-[1,2,4]thiadiazol-5-yl]-1,2-diamino butane (example 467),
- $N^2$ -(4-methoxy-phenyl sulfonyl)- $N^1$ -[3-(3-benzyl)-[1,2,4]thiadiazol-5-yl]-1,2-diamino butane (example 468),
- 15 -  $N^2$ -(4-methoxy-phenyl sulfonyl)- $N^1$ -[3-(3-methyl-benzyl)-[1,2,4]thiadiazol-5-yl]-1,2-diamino butane (example 469),
- $N^2$ -(4-methoxy-phenyl sulfonyl)- $N^1$ -[3-(2-methyl-benzyl)-[1,2,4]thiadiazol-5-yl]-1,2-diamino butane (example 470),
- $N^2$ -(4-methoxy-phenyl sulfonyl)- $N^1$ -[3-(2-methoxy-benzyl)-[1,2,4]thiadiazol-5-yl]-1,2-diamino butane (example 471),
- 20 -  $N^2$ -(4-methoxy-phenyl sulfonyl)- $N^1$ -[3-(4-methoxy-benzyl)-[1,2,4]thiadiazol-5-yl]-1,2-diamino butane (example 472),
- $N^2$ -(4-methoxy-phenyl sulfonyl)- $N^1$ -[3-(3-methyl-4-fluoro-benzyl)-[1,2,4]thiadiazol-5-yl]-1,2-diamino butane (example 473),
- 25 -  $N^2$ -(4-methoxy-phenyl sulfonyl)- $N^1$ -[3-(4-chloro-benzyl)-[1,2,4]thiadiazol-5-yl]-1,2-diamino butane (example 474),
- $N^2$ -(4-methoxy-phenyl sulfonyl)- $N^1$ -[3-(4-methyl-benzyl)-[1,2,4]thiadiazol-5-yl]-1,2-diamino pentane (example 475),
- $N^2$ -(4-methoxy-phenyl sulfonyl)- $N^1$ -[3-(4-fluoro-benzyl)-[1,2,4]thiadiazol-5-yl]-1,2-diamino pentane (example 476),
- 30 -  $N^2$ -(4-methoxy-phenyl sulfonyl)- $N^1$ -[3-(3-methoxy-benzyl)-[1,2,4]thiadiazol-5-yl]-1,2-diamino pentane (example 477),
- $N^2$ -(4-methoxy-phenyl sulfonyl)- $N^1$ -[3-(3-fluoro-benzyl)-[1,2,4]thiadiazol-5-yl]-1,2-diamino pentane (example 478),
- 35 -  $N^2$ -(4-methoxy-phenyl sulfonyl)- $N^1$ -[3-(2-fluoro-benzyl)-[1,2,4]thiadiazol-5-yl]-1,2-diamino pentane (example 479),

- $N^2$ -(4-methoxy-phenyl sulfonyl)- $N^1$ -[3-(3-benzyl)-[1,2,4]thiadiazol-5-yl]-1,2-diamino pentane (example 480),
- $N^2$ -(4-methoxy-phenyl sulfonyl)- $N^1$ -[3-(3-methyl-benzyl)-[1,2,4]thiadiazol-5-yl]-1,2-diamino pentane (example 481),
- 5 -  $N^2$ -(4-methoxy-phenyl sulfonyl)- $N^1$ -[3-(2-methyl-benzyl)-[1,2,4]thiadiazol-5-yl]-1,2-diamino pentane (example 482),
- $N^2$ -(4-methoxy-phenyl sulfonyl)- $N^1$ -[3-(2-methoxy-benzyl)-[1,2,4]thiadiazol-5-yl]-1,2-diamino pentane (example 483),
- $N^2$ -(4-methoxy-phenyl sulfonyl)- $N^1$ -[3-(4-methoxy-benzyl)-[1,2,4]thiadiazol-5-yl]-1,2-diamino pentane (example 484),
- 10 -  $N^2$ -(4-methoxy-phenyl sulfonyl)- $N^1$ -[3-(3-methyl-4-fluoro-benzyl)-[1,2,4]thiadiazol-5-yl]-1,2-diamino pentane (example 485),
- $N^2$ -(4-methoxy-phenyl sulfonyl)- $N^1$ -[3-(4-chloro-benzyl)-[1,2,4]thiadiazol-5-yl]-1,2-diamino pentane (example 486),
- 15 -  $N^3$ -(4-methoxy-phenyl sulfonyl)- $N^1$ -[3-(4-methyl-benzyl)-[1,2,4]thiadiazol-5-yl]-1,3-diamino pentane (example 487),
- $N^3$ -(4-methoxy-phenyl sulfonyl)- $N^1$ -[3-(4-fluoro-benzyl)-[1,2,4]thiadiazol-5-yl]-1,3-diamino pentane (example 488),
- $N^3$ -(4-methoxy-phenyl sulfonyl)- $N^1$ -[3-(3-methoxy-benzyl)-[1,2,4]thiadiazol-5-yl]-1,3-diamino pentane (example 489),
- 20 -  $N^3$ -(4-methoxy-phenyl sulfonyl)- $N^1$ -[3-(3-fluoro-benzyl)-[1,2,4]thiadiazol-5-yl]-1,3-diamino pentane (example 490),
- $N^3$ -(4-methoxy-phenyl sulfonyl)- $N^1$ -[3-(2-fluoro-benzyl)-[1,2,4]thiadiazol-5-yl]-1,3-diamino pentane (example 491),
- 25 -  $N^3$ -(4-methoxy-phenyl sulfonyl)- $N^1$ -[3-(3-benzyl)-[1,2,4]thiadiazol-5-yl]-1,3-diamino pentane (example 492),
- $N^3$ -(4-methoxy-phenyl sulfonyl)- $N^1$ -[3-(3-methyl-benzyl)-[1,2,4]thiadiazol-5-yl]-1,3-diamino pentane (example 493),
- $N^3$ -(4-methoxy-phenyl sulfonyl)- $N^1$ -[3-(2-methyl-benzyl)-[1,2,4]thiadiazol-5-yl]-1,3-diamino pentane (example 494),
- 30 -  $N^3$ -(4-methoxy-phenyl sulfonyl)- $N^1$ -[3-(2-methoxy-benzyl)-[1,2,4]thiadiazol-5-yl]-1,3-diamino pentane (example 495),
- $N^3$ -(4-methoxy-phenyl sulfonyl)- $N^1$ -[3-(4-methoxy-benzyl)-[1,2,4]thiadiazol-5-yl]-1,3-diamino pentane (example 496),
- 35 -  $N^3$ -(4-methoxy-phenyl sulfonyl)- $N^1$ -[3-(3-methyl-4-fluoro-benzyl)-[1,2,4]thiadiazol-5-yl]-1,3-diamino pentane (example 497), and

- $N^3$ -(4-methoxy-phenyl sulfonyl)- $N^1$ -[3-(4-chloro-benzyl)-[1,2,4]thiadiazol-5-yl]-1,3-diamino pentane (example 498).

It should be understood that in the foregoing examples 439 to 498, 4-methoxyphenylsulfonyl chloride was only used to illustrate the feasibility of arylsulfonylation of 1,2,4-thiadiazole intermediates that are diaminoalkane derivatised. Similar compounds can also be synthesised from any arylsulfonyl chloride or heteroarylsulfonyl chloride according to the lists provided herein-before in the detailed description of the invention.

10 Examples 499 to 558 – N-acylation of 1,2,4-thiadiazole intermediate compounds 379 to 438

By analogy with example 208, the following compounds are synthesised from 4-methoxybenzoyl chloride and the relevant intermediate compounds 379 to 438:

- 15 -  $N^3$ -(4-methoxy-benzoyl)- $N^2$ -[3-(4-methyl-benzyl)-[1,2,4]thiadiazol-5-yl]-2,3-diamino butane (example 499),
- $N^3$ -(4-methoxy-benzoyl)- $N^2$ -[3-(4-fluoro-benzyl)-[1,2,4]thiadiazol-5-yl]-2,3-diamino butane (example 500),
- $N^3$ -(4-methoxy-benzoyl)- $N^2$ -[3-(3-methoxy-benzyl)-[1,2,4]thiadiazol-5-yl]-2,3-diamino butane (example 501),
- 20 -  $N^3$ -(4-methoxy-benzoyl)- $N^2$ -[3-(3-fluoro-benzyl)-[1,2,4]thiadiazol-5-yl]-2,3-diamino butane (example 502),
- $N^3$ -(4-methoxy-benzoyl)- $N^2$ -[3-(2-fluoro-benzyl)-[1,2,4]thiadiazol-5-yl]-2,3-diamino butane (example 503),
- $N^3$ -(4-methoxy-benzoyl)- $N^2$ -[3-(3-benzyl)-[1,2,4]thiadiazol-5-yl]-2,3-diamino butane (example 504),
- 25 -  $N^3$ -(4-methoxy-benzoyl)- $N^2$ -[3-(3-methyl-benzyl)-[1,2,4]thiadiazol-5-yl]-2,3-diamino butane (example 505),
- $N^3$ -(4-methoxy-benzoyl)- $N^2$ -[3-(2-methyl-benzyl)-[1,2,4]thiadiazol-5-yl]-2,3-diamino butane (example 506),
- 30 -  $N^3$ -(4-methoxy-benzoyl)- $N^2$ -[3-(2-methoxy-benzyl)-[1,2,4]thiadiazol-5-yl]-2,3-diamino butane (example 507),
- $N^3$ -(4-methoxy-benzoyl)- $N^2$ -[3-(4-methoxy-benzyl)-[1,2,4]thiadiazol-5-yl]-2,3-diamino butane (example 508),
- $N^3$ -(4-methoxy-benzoyl)- $N^2$ -[3-(3-methyl-4-fluoro-benzyl)-[1,2,4]thiadiazol-5-yl]-2,3-diamino butane (example 509),
- 35 -  $N^3$ -(4-methoxy-benzoyl)- $N^2$ -[3-(4-chloro-benzyl)-[1,2,4]thiadiazol-5-yl]-2,3-diamino butane (example 510),

- $N^3$ -(4-methoxy-benzoyl)- $N^1$ -[3-(4-methyl-benzyl)-[1,2,4]thiadiazol-5-yl]-1,3-diamino butane (example 511),
- $N^3$ -(4-methoxy-benzoyl)- $N^1$ -[3-(4-fluoro-benzyl)-[1,2,4]thiadiazol-5-yl]-1,3-diamino butane (example 512),
- 5 -  $N^3$ -(4-methoxy-benzoyl)- $N^1$ -[3-(3-methoxy-benzyl)-[1,2,4]thiadiazol-5-yl]-1,3-diamino butane (example 513),
- $N^3$ -(4-methoxy-benzoyl)- $N^1$ -[3-(3-fluoro-benzyl)-[1,2,4]thiadiazol-5-yl]-1,3-diamino butane (example 514),
- $N^3$ -(4-methoxy-benzoyl)- $N^1$ -[3-(2-fluoro-benzyl)-[1,2,4]thiadiazol-5-yl]-1,3-diamino butane (example 515),
- 10 -  $N^3$ -(4-methoxy-benzoyl)- $N^1$ -[3-(3-benzyl)-[1,2,4]thiadiazol-5-yl]-1,3-diamino butane (example 516),
- $N^3$ -(4-methoxy-benzoyl)- $N^1$ -[3-(3-methyl-benzyl)-[1,2,4]thiadiazol-5-yl]-1,3-diamino butane (example 517),
- 15 -  $N^3$ -(4-methoxy-benzoyl)- $N^1$ -[3-(2-methyl-benzyl)-[1,2,4]thiadiazol-5-yl]-1,3-diamino butane (example 518),
- $N^3$ -(4-methoxy-benzoyl)- $N^1$ -[3-(2-methoxy-benzyl)-[1,2,4]thiadiazol-5-yl]-1,3-diamino butane (example 519),
- $N^3$ -(4-methoxy-benzoyl)- $N^1$ -[3-(4-methoxy-benzyl)-[1,2,4]thiadiazol-5-yl]-1,3-diamino butane (example 520),
- 20 -  $N^3$ -(4-methoxy-benzoyl)- $N^1$ -[3-(3-methyl-4-fluoro-benzyl)-[1,2,4]thiadiazol-5-yl]-1,3-diamino butane (example 521),
- $N^3$ -(4-methoxy-benzoyl)- $N^1$ -[3-(4-chloro-benzyl)-[1,2,4]thiadiazol-5-yl]-1,3-diamino butane (example 522),
- 25 -  $N^2$ -(4-methoxy-benzoyl)- $N^1$ -[3-(4-methyl-benzyl)-[1,2,4]thiadiazol-5-yl]-1,2-diamino butane (example 523),
- $N^2$ -(4-methoxy-benzoyl)- $N^1$ -[3-(4-fluoro-benzyl)-[1,2,4]thiadiazol-5-yl]-1,2-diamino butane (example 524),
- $N^2$ -(4-methoxy-benzoyl)- $N^1$ -[3-(3-methoxy-benzyl)-[1,2,4]thiadiazol-5-yl]-1,2-diamino butane (example 525),
- 30 -  $N^2$ -(4-methoxy-benzoyl)- $N^1$ -[3-(3-fluoro-benzyl)-[1,2,4]thiadiazol-5-yl]-1,2-diamino butane (example 526),
- $N^2$ -(4-methoxy-benzoyl)- $N^1$ -[3-(2-fluoro-benzyl)-[1,2,4]thiadiazol-5-yl]-1,2-diamino butane (example 527),
- 35 -  $N^2$ -(4-methoxy-benzoyl)- $N^1$ -[3-(3-benzyl)-[1,2,4]thiadiazol-5-yl]-1,2-diamino butane (example 528),



- $N^2$ -(4-methoxy-benzoyl)- $N^1$ -[3-(3-methyl-benzyl)-[1,2,4]thiadiazol-5-yl]-1,2-diamino butane (example 529),
- $N^2$ -(4-methoxy-benzoyl)- $N^1$ -[3-(2-methyl-benzyl)-[1,2,4]thiadiazol-5-yl]-1,2-diamino butane (example 530),
- 5 -  $N^2$ -(4-methoxy-benzoyl)- $N^1$ -[3-(2-methoxy-benzyl)-[1,2,4]thiadiazol-5-yl]-1,2-diamino butane (example 531),
- $N^2$ -(4-methoxy-benzoyl)- $N^1$ -[3-(4-methoxy-benzyl)-[1,2,4]thiadiazol-5-yl]-1,2-diamino butane (example 532),
- $N^2$ -(4-methoxy-benzoyl)- $N^1$ -[3-(3-methyl-4-fluoro-benzyl)-[1,2,4]thiadiazol-5-yl]-1,2-diamino butane (example 533),
- 10 -  $N^2$ -(4-methoxy-benzoyl)- $N^1$ -[3-(4-chloro-benzyl)-[1,2,4]thiadiazol-5-yl]-1,2-diamino butane (example 534),
- $N^2$ -(4-methoxy-benzoyl)- $N^1$ -[3-(4-methyl-benzyl)-[1,2,4]thiadiazol-5-yl]-1,2-diamino pentane (example 535),
- 15 -  $N^2$ -(4-methoxy-benzoyl)- $N^1$ -[3-(4-fluoro-benzyl)-[1,2,4]thiadiazol-5-yl]-1,2-diamino pentane (example 536),
- $N^2$ -(4-methoxy-benzoyl)- $N^1$ -[3-(3-methoxy-benzyl)-[1,2,4]thiadiazol-5-yl]-1,2-diamino pentane (example 537),
- $N^2$ -(4-methoxy-benzoyl)- $N^1$ -[3-(3-fluoro-benzyl)-[1,2,4]thiadiazol-5-yl]-1,2-diamino pentane (example 538),
- 20 -  $N^2$ -(4-methoxy-benzoyl)- $N^1$ -[3-(2-fluoro-benzyl)-[1,2,4]thiadiazol-5-yl]-1,2-diamino pentane (example 539),
- $N^2$ -(4-methoxy-benzoyl)- $N^1$ -[3-(3-benzyl)-[1,2,4]thiadiazol-5-yl]-1,2-diamino pentane (example 540),
- 25 -  $N^2$ -(4-methoxy-benzoyl)- $N^1$ -[3-(3-methyl-benzyl)-[1,2,4]thiadiazol-5-yl]-1,2-diamino pentane (example 541),
- $N^2$ -(4-methoxy-benzoyl)- $N^1$ -[3-(2-methyl-benzyl)-[1,2,4]thiadiazol-5-yl]-1,2-diamino pentane (example 542),
- $N^2$ -(4-methoxy-benzoyl)- $N^1$ -[3-(2-methoxy-benzyl)-[1,2,4]thiadiazol-5-yl]-1,2-diamino pentane (example 543),
- 30 -  $N^2$ -(4-methoxy-benzoyl)- $N^1$ -[3-(4-methoxy-benzyl)-[1,2,4]thiadiazol-5-yl]-1,2-diamino pentane (example 544),
- $N^2$ -(4-methoxy-benzoyl)- $N^1$ -[3-(3-methyl-4-fluoro-benzyl)-[1,2,4]thiadiazol-5-yl]-1,2-diamino pentane (example 545),
- 35 -  $N^2$ -(4-methoxy-benzoyl)- $N^1$ -[3-(4-chloro-benzyl)-[1,2,4]thiadiazol-5-yl]-1,2-diamino pentane (example 546),

- $N^3$ -(4-methoxy-benzoyl)- $N^1$ -[3-(4-methyl-benzyl)-[1,2,4]thiadiazol-5-yl]-1,3-diamino pentane (example 547),
- $N^3$ -(4-methoxy-benzoyl)- $N^1$ -[3-(4-fluoro-benzyl)-[1,2,4]thiadiazol-5-yl]-1,3-diamino pentane (example 548),
- 5 -  $N^3$ -(4-methoxy-benzoyl)- $N^1$ -[3-(3-methoxy-benzyl)-[1,2,4]thiadiazol-5-yl]-1,3-diamino pentane (example 549),
- $N^3$ -(4-methoxy-benzoyl)- $N^1$ -[3-(3-fluoro-benzyl)-[1,2,4]thiadiazol-5-yl]-1,3-diamino pentane (example 550),
- $N^3$ -(4-methoxy-benzoyl)- $N^1$ -[3-(2-fluoro-benzyl)-[1,2,4]thiadiazol-5-yl]-1,3-diamino pentane (example 551),
- 10 -  $N^3$ -(4-methoxy-benzoyl)- $N^1$ -[3-(3-benzyl)-[1,2,4]thiadiazol-5-yl]-1,3-diamino pentane (example 552),
- $N^3$ -(4-methoxy-benzoyl)- $N^1$ -[3-(3-methyl-benzyl)-[1,2,4]thiadiazol-5-yl]-1,3-diamino pentane (example 553),
- 15 -  $N^3$ -(4-methoxy-benzoyl)- $N^1$ -[3-(2-methyl-benzyl)-[1,2,4]thiadiazol-5-yl]-1,3-diamino pentane (example 554),
- $N^3$ -(4-methoxy-benzoyl)- $N^1$ -[3-(2-methoxy-benzyl)-[1,2,4]thiadiazol-5-yl]-1,3-diamino pentane (example 555),
- $N^3$ -(4-methoxy-benzoyl)- $N^1$ -[3-(4-methoxy-benzyl)-[1,2,4]thiadiazol-5-yl]-1,3-diamino pentane (example 556),
- 20 -  $N^3$ -(4-methoxy-benzoyl)- $N^1$ -[3-(3-methyl-4-fluoro-benzyl)-[1,2,4]thiadiazol-5-yl]-1,3-diamino pentane (example 557), and
- $N^3$ -(4-methoxy-benzoyl)- $N^1$ -[3-(4-chloro-benzyl)-[1,2,4]thiadiazol-5-yl]-1,3-diamino pentane (example 558).


25 It should be understood that in the foregoing examples 499 to 558, 4-methoxybenzoyl chloride was only used to illustrate the feasibility of acylation of 1,2,4-thiadiazole intermediates represented by the structural formula (VI). Similar compounds can also be synthesised from any acyl chloride according to the list provided herein-before in the detailed description of the invention.

30

35

CLAIMS

1. A 1,2,4-thiadiazole derivative according to the structural formula (C):




5 wherein

- R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub> and R<sub>5</sub> are each independently selected from the group consisting of hydrogen, C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkoxy, aryl, aryloxy, aryl-C<sub>1-4</sub> alkyloxy, heteroaryloxy, benzenesulfonate, amino, hydroxy, nitro, trifluoromethyl, trifluoromethoxy and halogen, or any two adjacent substituents selected from the group consisting of R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub> and R<sub>5</sub> form, together with the phenyl ring carbon atoms to which they are attached, a saturated or unsaturated ring fused to said phenyl ring and having from 5 to 7 ring members, said saturated or unsaturated ring optionally comprising one or two oxygen atoms and being optionally substituted with one or more halogen atoms;
- R<sub>7</sub>, R<sub>8</sub>, R<sub>9</sub>, R<sub>10</sub> and R<sub>11</sub> are each independently selected from the group consisting of hydrogen, C<sub>1-10</sub> alkyl, C<sub>1-6</sub> alkoxy, aryl, hydroxy, acetyl, nitro, trifluoromethyl, trifluoromethoxy, mono-C<sub>1-6</sub>alkylamino, di-C<sub>1-6</sub>alkylamino, C<sub>1-6</sub> alkylcarbonyloxy, C<sub>1-6</sub> alkylthio, cyano, heterocyclic, benzyloxy, dialkylaminosulfonyl and halogen; or any two adjacent substituents selected from the group consisting of R<sub>7</sub>, R<sub>8</sub>, R<sub>9</sub>, R<sub>10</sub> and R<sub>11</sub> form, together with the phenyl ring carbon atoms to which they are attached, a saturated or unsaturated ring fused to said phenyl ring and having from 5 to 7 ring members, said saturated or unsaturated ring optionally comprising one or two heteroatoms independently selected from the group consisting of oxygen, sulfur and nitrogen; and each of said C<sub>1-6</sub> alkyl, C<sub>1-6</sub> alkoxy, aryl or fused ring is optionally substituted with one or more halogen atoms;
- R<sub>12</sub> and R<sub>13</sub> are each independently selected from the group consisting of hydrogen, C<sub>1-6</sub> alkyl, aryl-C<sub>1-4</sub> alkyl, aryl and N-containing heterocyclic

rings, or  $R_{12}$  and  $R_{13}$  together form a  $C_{3-6}$  cycloalkyl or heterocyclic group;

- X is a linking moiety selected from the group consisting of a single bond; -C(=O)-; -S(=O)<sub>2</sub>-; divalent saturated, ethylenically unsaturated or acetylenically unsaturated non-cyclic hydrocarbon groups comprising from 1 to 8 atoms in the main chain, each of said atoms in the main chain being independently selected from the group consisting of carbon, nitrogen and sulfur, and each of said carbon atoms in the main chain being optionally substituted with one or more substituents independently selected from the group consisting of oxo, thioxo,  $C_{1-4}$  alkyl and halogen, provided that the number of heteroatoms in the main chain of said divalent saturated or unsaturated non-cyclic hydrocarbon group is 0, 1 or 2; and divalent saturated or unsaturated heterocyclic groups comprising from 2 to 6 carbon atoms and from 1 to 3 heteroatoms independently selected from the group consisting of oxygen, sulfur and nitrogen in the said heterocyclic group; or X together with one of  $R_7$  and  $R_{11}$  forms a saturated or unsaturated ring having from 5 to 7 ring members and being fused to the phenyl ring bearing said one of  $R_7$  and  $R_{11}$ , said saturated or unsaturated ring optionally comprising one or two heteroatoms independently selected from the group consisting of oxygen, sulfur and nitrogen, and said saturated or unsaturated ring optionally comprising one or more substituents independently selected from the group consisting of  $C_{1-4}$  alkyl and trifluoromethyl;
- n is an integer from 0 to 11;
- R and R' are each independently selected from hydrogen and  $C_{1-4}$  alkyl; and
- $R_{14}$  and  $R_{15}$  are each independently selected from hydrogen and  $C_{1-4}$  alkyl,

or according to the structural formula (F):



wherein X, R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub>, R<sub>6</sub>, R<sub>12</sub>, R<sub>13</sub>, R, R', R<sub>14</sub>, R<sub>15</sub> and n are as defined with respect to formula (C), and further wherein Het<sup>1</sup> is a heteroaryl group optionally substituted with one or more substituents independently selected from the group consisting of halogen, trifluoromethyl, nitro, cyano and C<sub>1-10</sub> alkyl,

5 or a stereoisomer or solvate thereof, or a pharmaceutically acceptable salt thereof.

2. A 1,2,4-thiadiazole derivative according to claim 1, wherein Het<sup>1</sup> is selected from the group consisting of furyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, cyanoimidazolyl, dicyanoimidazolyl, isoxazolyl, isothiazolyl, 1,2,3-triazolyl, 10 1,2,4-triazolyl, pyranyl, pyridinyl, ethylpyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, 1,2,3-triazinyl, 1,2,4-triazinyl, 1,3,5-triazinyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, tetrazolyl, thiadiazinyl, indolyl, isoindolyl, benzofuryl, benzothienyl, benzothiophenyl, indazolyl, benzimidazolyl, 15 benzthiazolyl, benzisothiazolyl, benzisoxazolyl, purinyl, quinazolinyl, quinoliziny, quinoliny, isoquinoliny, ethylquinoliny, quinoxaliny, naphthyridiny, pteridiny carbazolyl, azepiny, diazepiny, acridiny, pyrroliny, pyrazoliny, indoliny, pyrrolidiny, piperidiny, piperaziny, azepiny, diazepiny, morpholiny, thiomorpholiny, oxazolidiny, oxazoliny, oxazepiny, aziridiny and 20 tetrahydrofuranyl.


3. A 1,2,4-thiadiazole derivative according to claim 1 or claim 2, wherein the linking moiety X is SO<sub>2</sub>.

25 4. A 1,2,4-thiadiazole derivative according to claim 1 or claim 2, wherein the linking moiety X is selected from the group consisting of -CO-CH<sub>2</sub>-, -CO-(CH<sub>2</sub>)<sub>2</sub>-, -CO-CH=CH-, -CO-CHR<sub>14</sub>- and -CO-CHX'-, wherein R<sub>14</sub> is C<sub>1-4</sub> alkyl and X' is halogen, and wherein the carbonyl group of said linking moiety X is neither adjacent to Het<sup>1</sup> in a derivative according to the structural formula (F) nor 30 adjacent to the phenyl ring bearing substituents R<sub>7</sub>, R<sub>8</sub>, R<sub>9</sub>, R<sub>10</sub> and R<sub>11</sub> in a derivative according to the structural formula (C).


5. A 1,2,4-thiadiazole derivative according to claim 1 or claim 2, wherein X is a 35 divalent saturated group comprising a carbon atom and a nitrogen atom in the main chain, the said carbon atom being substituted with oxo or thioxo.

6. A 1,2,4-thiadiazole derivative according to any of claims 1 to 5, wherein at least one of R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub> and R<sub>5</sub> is fluoro or chloro.
- 5 7. A 1,2,4-thiadiazole derivative according to any of claims 1 to 6, wherein at least two of R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub> and R<sub>5</sub> are hydrogen.
8. A 1,2,4-thiadiazole derivative according to any of claims 1 to 7, wherein at least one of R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub> and R<sub>5</sub> is methoxy.
- 10 9. A 1,2,4-thiadiazole derivative according to any of claims 1 to 8, wherein n is 1 or 2.
10. A 1,2,4-thiadiazole derivative according to any of claims 1 to 9, wherein R and R' are both hydrogen.
- 15 11. A 1,2,4-thiadiazole derivative according to any of claims 1 to 9, wherein at least one of R and R' is methyl.
12. A 1,2,4-thiadiazole derivative according to any of claims 1 to 11, wherein R<sub>14</sub> and R<sub>15</sub> are both hydrogen.
- 20 13. A 1,2,4-thiadiazole derivative according to any of claims 1 to 11, wherein at least one of R<sub>14</sub> and R<sub>15</sub> is a C<sub>1-4</sub> alkyl.
- 25 14. A 1,2,4-thiadiazole derivative according to any of claims 1 to 13, wherein R<sub>12</sub> and R<sub>13</sub> together form a ring selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and piperidinyl.
- 30 15. A 1,2,4-thiadiazole derivative according to any of claims 1 to 13, wherein R<sub>12</sub> is hydrogen and R<sub>13</sub> is selected from the group consisting of piperidinyl and morpholinyl.
- 35 16. A 1,2,4-thiadiazole derivative according to any of claims 1 to 15, wherein two adjacent substituents selected from the group consisting of R<sub>7</sub>, R<sub>8</sub>, R<sub>9</sub>, R<sub>10</sub> and R<sub>11</sub> form, together with the phenyl ring carbon atoms to which they are attached, a homocyclic or heterocyclic group fused to said phenyl ring.

17. A 1,2,4-thiadiazole derivative according to any of claims 1 to 16, wherein at least three of  $R_7$ ,  $R_8$ ,  $R_9$ ,  $R_{10}$  and  $R_{11}$  are hydrogen, and wherein at most two of  $R_7$ ,  $R_8$ ,  $R_9$ ,  $R_{10}$  and  $R_{11}$  are independently selected from the group consisting of  $C_{1-6}$  alkyl,  $C_{1-6}$  alkoxy, phenyl, hydroxy, acetyl, nitro, trifluoromethyl, trifluoromethoxy, mono- $C_{1-6}$ alkylamino, di- $C_{1-6}$ alkylamino,  $C_{1-6}$  alkylcarbonyloxy,  $C_{1-6}$  alkylthio, cyano, heterocyclic, benzyloxy, dialkylaminosulfonyl and halogen.
18. A 1,2,4-thiadiazole derivative selected from the group consisting of *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(3-methoxybenzyl)-1,2,4-thiadiazol-5-yl]-propane-1,2-diamine and 1-[2-thienylsulfonyl]-4-[3-(2-methyl-benzyl-1,2,4-thiadiazol-5-yl)piperazine].
19. A process for producing a 1,2,4-thiadiazole derivative according to any of claims 1 to 17, comprising the steps of:
- (a) reacting ammonia with a substituted benzonitrile compound represented by the structural formula (I)




wherein  $R_1$ ,  $R_2$ ,  $R_3$ ,  $R_4$ ,  $R_5$ ,  $R_{12}$  and  $R_{13}$  are as defined in claim 1, to form an amidine intermediate represented by the structural formula (II),



- (b) reacting the amidine intermediate represented by the structural formula (II) with  $\text{CCl}_3\text{SCl}$  to form a 3-substituted-5-chloro-1,2,4-thiadiazole derivative represented by the structural formula (III)

5

10



and

- (c) reacting the 3-substituted-5-chloro-1,2,4-thiadiazole derivative represented by the structural formula (III) with a non-cyclic diamine represented by the structural formula  $\text{R}'\text{NH}-(\text{CHR}_{15})_n-\text{CHR}_{14}-\text{NHR}$ , wherein  $n$ ,  $\text{R}$ ,  $\text{R}'$ ,  $\text{R}_{14}$  and  $\text{R}_{15}$  are as defined in claim 1.


15

20. A method according to claim 19, further comprising a step (d) of reacting the derivative resulting from step (c) with an aryl derivative represented by the structural formula

20



156



for producing a derivative according to the structural formula (C) or a heteroaryl derivative having the structural formula  $X'-Het^1$ , wherein  $R_7$ ,  $R_8$ ,  $R_9$ ,  $R_{10}$ ,  $R_{11}$  and  $Het^1$  are as defined in claim 1, and wherein  $X'$  is an activated derivative of  $X$  as defined in claim 1 which upon reaction with an amino group of said non-cyclic diamine results into the linking moiety  $X$  as defined in claim 1, for producing a derivative according to the structural formula (F).

21. A method according to claim 20, wherein  $X$  is  $SO_2$  and wherein said aryl or heteroaryl derivative is an aryl or heteroaryl sulfonyl chloride.
22. A method according to claim 20, wherein  $X$  is selected from the group consisting of  $-CO-CH_2-$ ,  $-CO-(CH_2)_2-$ ,  $-CO-CH=CH-$ ,  $-CO-CHR_{14}-$  and  $-CO-CHX'-$ , wherein  $R_{14}$  is  $C_{1-4}$  alkyl and  $X'$  is halogen, and wherein said aryl or heteroaryl derivative is an aryl or heteroaryl carbonyl chloride.
23. A method according to claim 20, wherein  $X$  is a divalent saturated group comprising a carbon atom and a nitrogen atom in the main chain, the said carbon atom being substituted with oxo or thioxo, and wherein said aryl or heteroaryl derivative is an aryl or heteroaryl isocyanate or isothiocyanate.
24. A pharmaceutical composition comprising a therapeutic effective amount of a 1,2,4-thiadiazole derivative according to any of claims 1 to 18, and optionally one or more pharmaceutically acceptable carriers.
25. A pharmaceutical composition according to claim 24, further comprising a therapeutic amount of one or more drugs selected from the group consisting of neuro-protective agents and  $\alpha$ -synuclein deposition inhibitors.
26. A method of preventing or treating an  $\alpha$ -synucleopathy, comprising the administration of a therapeutic effective amount of a 1,2,4-thiadiazole derivative according to any of claims 1 to 18 to a patient in need thereof, optionally in

combination with one or more pharmaceutically acceptable carriers, and optionally in combination with a therapeutic amount of one or more drugs selected from the group consisting of neuro-protective agents and  $\alpha$ -synuclein deposition inhibitors.

5

27. A method of prevention or treatment according to claim 26, wherein said  $\alpha$ -synucleopathy is selected from the group consisting of Parkinson's disease, diffuse Lewy body disease, traumatic brain injury, amyotrophic lateral sclerosis, Niemann-Pick disease, Hallervorden-Spatz syndrome, Down syndrome, neuroaxonal dystrophy, multiple system atrophy and Alzheimer's disease.

10

28. A 1,2,4-thiadiazole derivative according to claim 1, being selected from the group consisting of:

15

- *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(3-methoxybenzyl)-1,2,4-thiadiazol-5-yl]-ethane-1,2-diamine,

- *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(3-methoxybenzyl)-1,2,4-thiadiazol-5-yl]-propane-1,2-diamine,

- *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(3-methoxybenzyl)-1,2,4-thiadiazol-5-yl]-propane-1,3-diamine,

20

- *N'*-[4-methoxyphenylsulfonyl]-*N*-[3-(3-methoxybenzyl)-1,2,4-thiadiazol-5-yl]-*N*-methylethane-1,2-diamine,

- *N'*-[4-methoxyphenylsulfonyl]-*N*-[3-(3-methoxybenzyl)-1,2,4-thiadiazol-5-yl]-*N'*-methylethane-1,2-diamine,

25

- *N'*-[4-methoxyphenylsulfonyl]-*N*-[3-(3-methoxybenzyl)-1,2,4-thiadiazol-5-yl]-*N,N'*-dimethylethane-1,2-diamine,

- *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(4-methylbenzyl)-1,2,4-thiadiazol-5-yl]-ethane-1,2-diamine,

- *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-ethane-1,2-diamine,

30

- *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(3-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-ethane-1,2-diamine,

- *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(2-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-ethane-1,2-diamine,

- *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(3-benzyl)-1,2,4-thiadiazol-5-yl]-ethane-1,2-diamine,

35

- *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(3-methylbenzyl)-1,2,4-thiadiazol-5-yl]-ethane-1,2-diamine,

- *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(2-methylbenzyl)-1,2,4-thiadiazol-5-yl]-ethane-1,2-diamine,
- *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(2-methoxybenzyl)-1,2,4-thiadiazol-5-yl]-ethane-1,2-diamine,
- 5 - *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(4-methoxybenzyl)-1,2,4-thiadiazol-5-yl]-ethane-1,2-diamine,
- *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(3-methyl-4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-ethane-1,2-diamine,
- *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(4-chlorobenzyl)-1,2,4-thiadiazol-5-yl]-ethane-1,2-diamine,
- 10 - *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(4-methylbenzyl)-1,2,4-thiadiazol-5-yl]-propane-1,3-diamine,
- *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-propane-1,3-diamine,
- 15 - *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(3-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-propane-1,3-diamine,
- *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(2-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-propane-1,3-diamine,
- *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(3-benzyl)-1,2,4-thiadiazol-5-yl]-propane-1,3-diamine,
- 20 - *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(3-methylbenzyl)-1,2,4-thiadiazol-5-yl]-propane-1,3-diamine,
- *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(2-methylbenzyl)-1,2,4-thiadiazol-5-yl]-propane-1,3-diamine,
- 25 - *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(2-methoxybenzyl)-1,2,4-thiadiazol-5-yl]-propane-1,3-diamine,
- *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(4-methoxybenzyl)-1,2,4-thiadiazol-5-yl]-propane-1,3-diamine,
- *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(3-methyl-4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-propane-1,3-diamine,
- 30 - *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(4-chlorobenzyl)-1,2,4-thiadiazol-5-yl]-propane-1,3-diamine,
- *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(4-methylbenzyl)-1,2,4-thiadiazol-5-yl]-propane-1,2-diamine,
- 35 - *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-propane-1,2-diamine,

- *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(3-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-propane-1,2-diamine,
- *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(2-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-propane-1,2-diamine,
- 5    - *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(3-benzyl)-1,2,4-thiadiazol-5-yl]-propane-1,2-diamine,
- *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(3-methylbenzyl)-1,2,4-thiadiazol-5-yl]-propane-1,2-diamine,
- *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(2-methylbenzyl)-1,2,4-thiadiazol-5-yl]-propane-1,2-diamine,
- 10   - *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(2-methoxybenzyl)-1,2,4-thiadiazol-5-yl]-propane-1,2-diamine,
- *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(4-methoxybenzyl)-1,2,4-thiadiazol-5-yl]-propane-1,2-diamine,
- 15   - *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(3-methyl-4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-propane-1,2-diamine,
- *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(4-chlorobenzyl)-1,2,4-thiadiazol-5-yl]-propane-1,2-diamine,
- *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(4-methylbenzyl)-1,2,4-thiadiazol-5-yl]-*N*-methyl-ethane-1,2-diamine,
- 20   - *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-*N*-methyl-ethane-1,2-diamine,
- *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(3-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-*N*-methyl-ethane-1,2-diamine,
- 25   - *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(2-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-*N*-methyl-ethane-1,2-diamine,
- *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(3-benzyl)-1,2,4-thiadiazol-5-yl]-*N*-methyl-ethane-1,2-diamine,
- *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(3-methylbenzyl)-1,2,4-thiadiazol-5-yl]-*N*-methyl-ethane-1,2-diamine,
- 30   - *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(2-methylbenzyl)-1,2,4-thiadiazol-5-yl]-*N*-methyl-ethane-1,2-diamine,
- *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(2-methoxybenzyl)-1,2,4-thiadiazol-5-yl]-*N*-methyl-ethane-1,2-diamine,
- 35   - *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(4-methoxybenzyl)-1,2,4-thiadiazol-5-yl]-*N*-methyl-ethane-1,2-diamine,

- *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(3-methyl-4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]- *N*-methyl-ethane-1,2-diamine,
- *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(4-chlorobenzyl)-1,2,4-thiadiazol-5-yl]-*N*-methyl-ethane-1,2-diamine,
- 5 - *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(4-methylbenzyl)-1,2,4-thiadiazol-5-yl]-*N*, *N'*-dimethyl-ethane-1,2-diamine,
- *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-*N*, *N'*-dimethyl-ethane-1,2-diamine,
- *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(3-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-*N*, *N'*-dimethyl-ethane-1,2-diamine,
- 10 - *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(2-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-*N*, *N'*-dimethyl-ethane-1,2-diamine,
- *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(3-benzyl)-1,2,4-thiadiazol-5-yl]-*N*, *N'*-dimethyl-ethane-1,2-diamine,
- 15 - *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(3-methylbenzyl)-1,2,4-thiadiazol-5-yl]-*N*, *N'*-dimethyl-ethane-1,2-diamine,
- *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(2-methylbenzyl)-1,2,4-thiadiazol-5-yl]- *N*, *N'*-dimethyl-ethane-1,2-diamine,
- *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(2-methoxybenzyl)-1,2,4-thiadiazol-5-yl]-*N*, *N'*-dimethyl-ethane-1,2-diamine,
- 20 - *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(4-methoxybenzyl)-1,2,4-thiadiazol-5-yl]-*N*, *N'*-dimethyl-ethane-1,2-diamine,
- *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(3-methyl-4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-*N*, *N'*-dimethyl-ethane-1,2-diamine,
- 25 - *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(4-chlorobenzyl)-1,2,4-thiadiazol-5-yl]-*N*, *N'*-dimethyl-ethane-1,2-diamine,
- *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(4-methylbenzyl)-1,2,4-thiadiazol-5-yl]-*N*, *N'*-diethyl-ethane-1,2-diamine,
- *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-*N*, *N'*-diethyl-ethane-1,2-diamine,
- 30 - *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(3-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-*N*, *N'*-diethyl-ethane-1,2-diamine,
- *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(2-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-*N*, *N'*-diethyl-ethane-1,2-diamine,
- 35 - *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(3-benzyl)-1,2,4-thiadiazol-5-yl]-*N*, *N'*-diethyl-ethane-1,2-diamine,

- *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(3-methylbenzyl)-1,2,4-thiadiazol-5-yl]-*N*,  
*N'*-diethyl-ethane-1,2-diamine,
- *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(2-methylbenzyl)-1,2,4-thiadiazol-5-yl]- *N*,  
*N'*-diethyl-ethane-1,2-diamine,
- 5     - *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(2-methoxybenzyl)-1,2,4-thiadiazol-5-yl]-  
*N,N'*-diethyl-ethane-1,2-diamine,
- *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(4-methoxybenzyl)-1,2,4-thiadiazol-5-yl]-  
*N,N'*-diethyl-ethane-1,2-diamine,
- *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(3-methyl-4-fluorobenzyl)-1,2,4-thia-  
10     diazol-5-yl]-*N,N'*-diethyl-ethane-1,2-diamine,
- *N*-[4-methoxyphenylsulfonyl]-*N'*-[3-(4-chlorobenzyl)-1,2,4-thiadiazol-5-yl]-  
*N,N'*-diethyl-ethane-1,2-diamine,
- *N*-[2-thienylsulfonyl]-*N'*-[3-(3-methoxybenzyl)-1,2,4-thiadiazol-5-yl]-  
ethane-1,2-diamine,
- 15     - *N*-[2-thienylsulfonyl]-*N'*-[3-(3-methoxybenzyl)-1,2,4-thiadiazol-5-yl]-  
propane-1,2-diamine,
- *N*-[2-thienylsulfonyl]-*N'*-[3-(3-methoxybenzyl)-1,2,4-thiadiazol-5-yl]-  
propane-1,3-diamine,
- *N'*-[2-thienylsulfonyl]-*N*-[3-(3-methoxybenzyl)-1,2,4-thiadiazol-5-yl]-*N*-  
20     methylethane-1,2-diamine,
- *N'*-[2-thienylsulfonyl]-*N*-[3-(3-methoxybenzyl)-1,2,4-thiadiazol-5-yl]-*N'*-  
methylethane-1,2-diamine,
- *N'*-[2-thienylsulfonyl]-*N*-[3-(3-methoxybenzyl)-1,2,4-thiadiazol-5-yl]-*N,N'*-  
dimethylethane-1,2-diamine,
- 25     - *N*-[2-thienylsulfonyl]-*N'*-[3-(4-methylbenzyl)-1,2,4-thiadiazol-5-yl]-ethane-1,2-  
diamine,
- *N*-[2-thienylsulfonyl]-*N'*-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-ethane-1,2-  
diamine,
- *N*-[2-thienylsulfonyl]-*N'*-[3-(3-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-ethane-1,2-  
30     diamine,
- *N*-[2-thienylsulfonyl]-*N'*-[3-(2-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-ethane-1,2-  
diamine,
- *N*-[2-thienylsulfonyl]-*N'*-[3-(3-benzyl)-1,2,4-thiadiazol-5-yl]-ethane-1,2-  
diamine,
- 35     - *N*-[2-thienylsulfonyl]-*N'*-[3-(3-methylbenzyl)-1,2,4-thiadiazol-5-yl]-ethane-1,2-  
diamine,

- *N*-[2-thienylsulfonyl]-*N'*-[3-(2-methylbenzyl)-1,2,4-thiadiazol-5-yl]-ethane-1,2-diamine,
- *N*-[2-thienylsulfonyl]-*N'*-[3-(2-methoxybenzyl)-1,2,4-thiadiazol-5-yl]-ethane-1,2-diamine,
- 5 - *N*-[2-thienylsulfonyl]-*N'*-[3-(4-methoxybenzyl)-1,2,4-thiadiazol-5-yl]-ethane-1,2-diamine,
- *N*-[2-thienylsulfonyl]-*N'*-[3-(3-methyl-4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-ethane-1,2-diamine,
- *N*-[2-thienylsulfonyl]-*N'*-[3-(4-chlorobenzyl)-1,2,4-thiadiazol-5-yl]-ethane-1,2-diamine,
- 10 - *N*-[2-thienylsulfonyl]-*N'*-[3-(4-methylbenzyl)-1,2,4-thiadiazol-5-yl]-propane-1,3-diamine,
- *N*-[2-thienylsulfonyl]-*N'*-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-propane-1,3-diamine,
- 15 - *N*-[2-thienylsulfonyl]-*N'*-[3-(3-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-propane-1,3-diamine,
- *N*-[2-thienylsulfonyl]-*N'*-[3-(2-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-propane-1,3-diamine,
- *N*-[2-thienylsulfonyl]-*N'*-[3-(3-benzyl)-1,2,4-thiadiazol-5-yl]-propane-1,3-diamine,
- 20 - *N*-[2-thienylsulfonyl]-*N'*-[3-(3-methylbenzyl)-1,2,4-thiadiazol-5-yl]-propane-1,3-diamine,
- *N*-[2-thienylsulfonyl]-*N'*-[3-(2-methylbenzyl)-1,2,4-thiadiazol-5-yl]-propane-1,3-diamine,
- 25 - *N*-[2-thienylsulfonyl]-*N'*-[3-(2-methoxybenzyl)-1,2,4-thiadiazol-5-yl]-propane-1,3-diamine,
- *N*-[2-thienylsulfonyl]-*N'*-[3-(4-methoxybenzyl)-1,2,4-thiadiazol-5-yl]-propane-1,3-diamine,
- *N*-[2-thienylsulfonyl]-*N'*-[3-(3-methyl-4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-propane-1,3-diamine,
- 30 - *N*-[2-thienylsulfonyl]-*N'*-[3-(4-chlorobenzyl)-1,2,4-thiadiazol-5-yl]-propane-1,3-diamine,
- *N*-[2-thienylsulfonyl]-*N'*-[3-(4-methylbenzyl)-1,2,4-thiadiazol-5-yl]-propane-1,2-diamine,
- 35 - *N*-[2-thienylsulfonyl]-*N'*-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-propane-1,2-diamine,

- *N*-[2-thienylsulfonyl]-*N'*-[3-(3-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-propane-1,2-diamine,
- *N*-[2-thienylsulfonyl]-*N'*-[3-(2-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-propane-1,2-diamine,
- 5     - *N*-[2-thienylsulfonyl]-*N'*-[3-(3-benzyl)-1,2,4-thiadiazol-5-yl]-propane-1,2-diamine,
- *N*-[2-thienylsulfonyl]-*N'*-[3-(3-methylbenzyl)-1,2,4-thiadiazol-5-yl]-propane-1,2-diamine,
- *N*-[2-thienylsulfonyl]-*N'*-[3-(2-methylbenzyl)-1,2,4-thiadiazol-5-yl]-propane-1,2-diamine,
- 10     - *N*-[2-thienylsulfonyl]-*N'*-[3-(2-methoxybenzyl)-1,2,4-thiadiazol-5-yl]-propane-1,2-diamine,
- *N*-[2-thienylsulfonyl]-*N'*-[3-(4-methoxybenzyl)-1,2,4-thiadiazol-5-yl]-propane-1,2-diamine,
- 15     - *N*-[2-thienylsulfonyl]-*N'*-[3-(3-methyl-4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-propane-1,2-diamine,
- *N*-[2-thienylsulfonyl]-*N'*-[3-(4-chlorobenzyl)-1,2,4-thiadiazol-5-yl]-propane-1,2-diamine,
- *N*-[2-thienylsulfonyl]-*N'*-[3-(4-methylbenzyl)-1,2,4-thiadiazol-5-yl]-*N*-methyl-ethane-1,2-diamine,
- 20     - *N*-[2-thienylsulfonyl]-*N'*-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-*N*-methyl-ethane-1,2-diamine,
- *N*-[2-thienylsulfonyl]-*N'*-[3-(3-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-*N*-methyl-ethane-1,2-diamine,
- 25     - *N*-[2-thienylsulfonyl]-*N'*-[3-(2-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-*N*-methyl-ethane-1,2-diamine,
- *N*-[2-thienylsulfonyl]-*N'*-[3-(3-benzyl)-1,2,4-thiadiazol-5-yl]-*N*-methyl-ethane-1,2-diamine,
- *N*-[2-thienylsulfonyl]-*N'*-[3-(3-methylbenzyl)-1,2,4-thiadiazol-5-yl]-*N*-methyl-ethane-1,2-diamine,
- 30     - *N*-[2-thienylsulfonyl]-*N'*-[3-(2-methylbenzyl)-1,2,4-thiadiazol-5-yl]-*N*-methyl-ethane-1,2-diamine,
- *N*-[2-thienylsulfonyl]-*N'*-[3-(2-methoxybenzyl)-1,2,4-thiadiazol-5-yl]-*N*-methyl-ethane-1,2-diamine,
- 35     - *N*-[2-thienylsulfonyl]-*N'*-[3-(4-methoxybenzyl)-1,2,4-thiadiazol-5-yl]-*N*-methyl-ethane-1,2-diamine,



- *N*-[2-thienylsulfonyl]-*N'*-[3-(3-methyl-4-fluorobenzyl)-1,2,4-thia-diazol-5-yl]-*N*-methyl-ethane-1,2-diamine,
- *N*-[2-thienylsulfonyl]-*N'*-[3-(4-chlorobenzyl)-1,2,4-thiadiazol-5-yl]-*N*-methyl-ethane-1,2-diamine,
- 5     - *N*-[2-thienylsulfonyl]-*N'*-[3-(4-methylbenzyl)-1,2,4-thiadiazol-5-yl]-*N,N'*-dimethyl-ethane-1,2-diamine,
- *N*-[2-thienylsulfonyl]-*N'*-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-*N,N'*-dimethyl-ethane-1,2-diamine,
- *N*-[2-thienylsulfonyl]-*N'*-[3-(3-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-*N,N'*-dimethyl-ethane-1,2-diamine,
- 10     - *N*-[2-thienylsulfonyl]-*N'*-[3-(2-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-*N,N'*-dimethyl-ethane-1,2-diamine,
- *N*-[2-thienylsulfonyl]-*N'*-[3-(3-benzyl)-1,2,4-thiadiazol-5-yl]-*N,N'*-dimethyl-ethane-1,2-diamine,
- 15     - *N*-[2-thienylsulfonyl]-*N'*-[3-(3-methylbenzyl)-1,2,4-thiadiazol-5-yl]-*N,N'*-dimethyl-ethane-1,2-diamine,
- *N*-[2-thienylsulfonyl]-*N'*-[3-(2-methylbenzyl)-1,2,4-thiadiazol-5-yl]-*N,N'*-dimethyl-ethane-1,2-diamine,
- *N*-[2-thienylsulfonyl]-*N'*-[3-(2-methoxybenzyl)-1,2,4-thiadiazol-5-yl]-*N,N'*-dimethyl-ethane-1,2-diamine,
- 20     - *N*-[2-thienylsulfonyl]-*N'*-[3-(4-methoxybenzyl)-1,2,4-thiadiazol-5-yl]-*N,N'*-dimethyl-ethane-1,2-diamine,
- *N*-[2-thienylsulfonyl]-*N'*-[3-(3-methyl-4-fluorobenzyl)-1,2,4-thia-diazol-5-yl]-*N,N'*-dimethyl-ethane-1,2-diamine,
- 25     - *N*-[2-thienylsulfonyl]-*N'*-[3-(4-chlorobenzyl)-1,2,4-thiadiazol-5-yl]-*N,N'*-dimethyl-ethane-1,2-diamine,
- *N*-[2-thienylsulfonyl]-*N'*-[3-(4-methylbenzyl)-1,2,4-thiadiazol-5-yl]-*N,N'*-diethyl-ethane-1,2-diamine,
- *N*-[2-thienylsulfonyl]-*N'*-[3-(4-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-*N,N'*-diethyl-ethane-1,2-diamine,
- 30     - *N*-[2-thienylsulfonyl]-*N'*-[3-(3-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-*N,N'*-diethyl-ethane-1,2-diamine,
- *N*-[2-thienylsulfonyl]-*N'*-[3-(2-fluorobenzyl)-1,2,4-thiadiazol-5-yl]-*N,N'*-diethyl-ethane-1,2-diamine,
- 35     - *N*-[2-thienylsulfonyl]-*N'*-[3-(3-benzyl)-1,2,4-thiadiazol-5-yl]-*N,N'*-diethyl-ethane-1,2-diamine,

- *N*-[2-thienylsulfonyl]-*N'*-[3-(3-methylbenzyl)-1,2,4-thiadiazol-5-yl]-*N,N'*-diethyl-ethane-1,2-diamine,
- *N*-[2-thienylsulfonyl]-*N'*-[3-(2-methylbenzyl)-1,2,4-thiadiazol-5-yl]-*N,N'*-diethyl-ethane-1,2-diamine,
- 5     - *N*-[2-thienylsulfonyl]-*N'*-[3-(2-methoxybenzyl)-1,2,4-thiadiazol-5-yl]-*N,N'*-diethyl-ethane-1,2-diamine,
- *N*-[2-thienylsulfonyl]-*N'*-[3-(4-methoxybenzyl)-1,2,4-thiadiazol-5-yl]-*N,N'*-diethyl-ethane-1,2-diamine,
- *N*-[2-thienylsulfonyl]-*N'*-[3-(3-methyl-4-fluorobenzyl)-1,2,4-thia-diazol-5-yl]-*N,N'*-diethyl-ethane-1,2-diamine, and
- 10     - *N*-[2-thienylsulfonyl]-*N'*-[3-(4-chlorobenzyl)-1,2,4-thiadiazol-5-yl]-*N,N'*-diethyl-ethane-1,2-diamine.

15

20

25

30

35

1/4




Figure 1




Figure 2




Figure 3




Figure 4

## INTERNATIONAL SEARCH REPORT

International application No  
PCT/EP2007/010192

## A. CLASSIFICATION OF SUBJECT MATTER

INV. C07D285/08 A61K31/433 A61P25/16 A61P25/28

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, CHEM ABS Data, BEILSTEIN Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 2006/002981 A (GRUENENTHAL GMBH [DE]; KUEHNERT SVEN [DE]; OBERBOERSCH STEFAN [DE]; HA) 12 January 2006 (2006-01-12) abstract; claim 1	1-28
A	WO 2005/095368 A (PFIZER PROD INC [US]; CHEN YUHPYNG LIANG [US]) 13 October 2005 (2005-10-13) abstract; claim 1	1-28
A	WO 2005/020991 A (PFIZER PROD INC [US]; CHEN YUHPYNG L [US]) 10 March 2005 (2005-03-10) abstract; claim 1	1-28



Further documents are listed in the continuation of Box C.



See patent family annex.

## \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \* & \* document member of the same patent family

Date of the actual completion of the international search

8 April 2008

Date of mailing of the international search report

16/04/2008

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Bérillon, Laurent

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/EP2007/010192

## Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 26, 27  
because they relate to subject matter not required to be searched by this Authority, namely:  
Although claims 26 and 27 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fees, this Authority did not invite payment of additional fees.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- ☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- ☐ No protest accompanied the payment of additional search fees.



# INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/EP2007/010192

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 2006002981	A	12-01-2006	CA 2572685 A1	12-01-2006
			DE 102004032567 A1	02-03-2006
			EP 1765816 A1	28-03-2007
			JP 2008505149 T	21-02-2008
			US 2007112011 A1	17-05-2007
WO 2005095368	A	13-10-2005	BR PI0509504 A	11-09-2007
			CA 2561596 A1	13-10-2005
			EP 1735294 A1	27-12-2006
			JP 2007530661 T	01-11-2007
WO 2005020991	A	10-03-2005	BR PI0413709 A	17-10-2006
			CA 2534532 A1	10-03-2005
			EP 1658072 A1	24-05-2006
			JP 2007502828 T	15-02-2007
			MX PA06001845 A	04-05-2006
			UY 28484 A1	31-03-2005